Glucagon receptor agonists, conjugated to glucose-dependent insulinotropic polypeptide antibodies

Abstract

Disclosed herein are polypeptides having activity as agonists of a glucagon receptor ("GCGR"), molecules comprising such polypeptides and molecules comprising an antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor ("GIPR"), pharmaceutical compositions comprising such polypeptides and molecules, and methods of using such polypeptides, molecules, and pharmaceutical compositions in weight management and the treatment of certain disorders such as obesity.

Description

GLUCAGON RECEPTOR AGONISTS AND CONJUGATES TO Glucose-dependent insulinotropic polypeptide ANTAGONISTS FIELD[1] The present disclosure provides polypeptides that agonize a glucagon receptor (“GCGR”), molecules comprising such polypeptides and a half-life extending domain (e.g., an Fc-containing polypeptide), including molecules comprising a polypeptide that agonizes a GCGR and an antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), pharmaceutical compositions comprising such polypeptides and molecules, and methods of using such polypeptides, molecules, and pharmaceutical compositions in weight management and the treatment of obesity.BACKGROUND[2] Obesity is a chronic, heterogeneous, neurometabolic disease that has grown into an extremely prevalent public health problem. Obesity is projected to affect nearly a quarter of the world’s population by 2035 (World Obesity Federation’s World Obesity Atlas 2023), and obesityassociated morbidity has exerted a tremendous burden on patients and the healthcare system globally. [3] Incretin-based therapeutics have transformed type 2 diabetes management, with some recently developed agents, such as the glucagon-like peptide-1 (GLP-1) agonist semaglutide and the GLP-1 / glucose-dependent insulinotropic polypeptide (GIP) dual agonist tirzepatide, also promoting notable weight reductions in diabetic and nondiabetic patients. GLP-1 and GIP are endogenous, gut-derived incretin hormones that regulate weight through their receptors. These incretins augment glucose-stimulated insulin secretion and play important roles in weight regulation. For example, GIP promotes fat storage in adipocytes, as well as pancreatic islet β-cell function and glucose-dependent insulin secretion, while GLP-1 promotes satiety.[4] GIP, formerly known as gastric inhibitory polypeptide, is a single 42-amino acid peptide secreted from K-cells in the small intestine (duodenum and jejunum). Food ingestion induces GIP secretion. Human GIP is derived from the processing of proGIP, a 153-amino acid precursor that is encoded by a gene localized to chromosome 17q. (Inagaki et al., Mol Endocrinol 1989, 3:1014-1021; Fehmann et al. Endocr Rev. 1995; 16:390-410.)[5] The GIP receptor (GIPR) is a member of the secretin-glucagon family of G-protein coupled receptors (GPCRs). GIPR is expressed in a number of tissues, including the pancreas, gut, adipose tissue, heart, pituitary, adrenal cortex, and brain. (Usdin et al., Endocrinology, 1993, 133:2861-2870.) GIPR knockout mice (Gipr - / -) are resistant to high fat diet-induced weight gain and have improved insulin sensitivity and lipid profiles. (Yamada et al., Diabetes, 2006, 55:S86; Miyawaki et al., Nature Med., 2002, 8:738-742.) [6] GLP-1 is a 31-amino acid peptide derived from the proglucagon gene. It is secreted by intestinal L-cells and released in response to food ingestion to induce insulin secretion from pancreatic β–cells. (Baggio et al., Diabetes, 2004, 53(S3):S205-S214.) In addition to its incretin effects, GLP-1 also decreases glucagon secretion, delays gastric emptying, and reduces caloric intake. (Drucker, Diabetes Care, 2003, 26(10): 2929-2940.) GLP-1 exerts its effects by activating the GLP-1 receptor, which belongs to a class B G-protein-coupled receptor. GLP-1 is rapidly degraded by the DPP-IV enzyme, resulting in a physiological half-life of approximately two minutes. Recently, long-lasting GLP-1 receptor agonists (GLP-1 RAs) such as exenatide, liraglutide, dulaglutide, and semaglutide have been developed and are now being used clinically to improve glycemic control in patients with type 2 diabetes.[7] While incretin-based therapeutics have transformed the obesity treatment landscape, not all patients are able to tolerate GLP-1-based therapies, which have been associated with an increased risk of gastrointestinal adverse events (e.g., biliary disease, pancreatitis, bowel obstruction, and gastroparesis) in some patients. (Sodhi et al., JAMA, 2023, 330(18):17951797.) Moreover, some patients hit a weight loss plateau on GLP-1-based therapies but still need to further reduce their body weight. Accordingly, there remains a need for alternative therapeutic agents for use in weight management and the treatment or amelioration of obesity.SUMMARY[8] Glucagon is a 29-amino acid peptide hormone (SEQ ID NO: 1576) secreted by α-cells of the islet of Langerhans in the pancreas. Glucagon is involved in glucose homeostasis, lipolysis, and amino acid catabolism. Under normal physiological conditions, glucagon levels increase when blood glucose falls, which causes glycogen in the liver to be broken down into glucose for release into the bloodstream. Acute glucagon administration has been associated with increased energy expenditure and circulating insulin and glucose concentrations in adults without diabetes. (Frampton et al., IJO, 2022, 48:1948-1959.) [9] Provided herein are polypeptides having activity as agonists of a glucagon receptor (“GCGR”) and molecules comprising such polypeptides and a half-life extending domain (e.g., an Fc-containing polypeptide), including molecules comprising an antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”). These polypeptides and molecules, e.g., molecules comprising an anti-GIPR antibody and a GCGR agonist (“GIPRxGCG”), may reduce body weight, liver weight, and fat mass and improve plasma glucose and insulin levels and plasma lipid profiles in obese subjects, alone or in combination with GLP1 based therapies, e.g., semaglutide. Also provided herein are pharmaceutical compositions comprising these polypeptides and molecules, uses of the polypeptides and molecules, and pharmaceutical compositions in weight management and the treatment of, for example, obesity.

[10] One aspect of the disclosure provides a polypeptide that agonizes a glucagon receptor (“GCGR”), wherein: the polypeptide comprises at least 25 amino acids, wherein the polypeptide comprises 5bromo-tryptophan at position 25; andthe polypeptide has at least 79% (e.g., at least 82%, at least 86%, at least 93%, at least 96%, or 100%) sequence identity to the amino acid sequence of SEQ ID NO: 1587.

[11] Another aspect of the disclosure provides polypeptide that agonizes a GCGR, wherein: the polypeptide comprises at least 28 amino acids, wherein the polypeptide comprises 2aminoisobutyric acid at position 16 and lysine, serine, or aspartic acid at position 28; andthe polypeptide has at least 89% (e.g., at least 93%, at least 96%, or 100%) sequence identity to the amino acid sequence of SEQ ID NO: 1596.

[12] Still another aspect of the disclosure provides a polypeptide that agonizes a GCGR, wherein: the polypeptide comprises at least 28 amino acids, wherein the polypeptide comprises 2aminoisobutyric acid at position 16, leucine at position 27, and lysine at position 28; andthe polypeptide has at least 89% sequence identity to the amino acid sequence of SEQ ID NO: 1615.

[13] Yet another aspect of the disclosure provides a polypeptide that agonizes a GCGR, wherein: the polypeptide comprises at least 28 amino acids, wherein the polypeptide comprises 2aminoisobutyric acid at position 16, aspartic acid at position 24, and lysine at position 28; andthe polypeptide has at least 89% (e.g., at least 93%, at least 96%, or 100%) sequence identity to the amino acid sequence of SEQ ID NO: 1626.

[14] Still another aspect of the disclosure provides a polypeptide that agonizes a GCGR comprising the amino acid sequence of any one of SEQ ID NOs: 15871627.

[15] Yet another aspect of the disclosure provides a molecule comprising: a first polypeptide that agonizes a GCGR, wherein the first polypeptide is selected from those described herein; and a second polypeptide comprising the amino acid sequence of any one of SEQ ID NOs: 16281683,wherein the C-terminus of the second polypeptide is covalently linked to an εamino group of a lysine residue of the first polypeptide.

[16] Still another aspect of the disclosure provides a molecule comprising a polypeptide that agonizes a GCGR, wherein the polypeptide is selected from those described herein; and an antigen-binding protein.

[17] Yet another aspect of the disclosure provides a molecule comprising: a polypeptide that agonizes a GCGR, wherein the polypeptide is selected from those described herein; and a halflife extending domain (e.g., an Fc-containing polypeptide, such as, e.g., an antibody).

[18] Still another aspect of the disclosure provides a molecule comprising a polypeptide that agonizes a GCGR, wherein the polypeptide is selected from those described herein; and an antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”).

[19] Yet another aspect of the disclosure provides a molecule comprising: a polypeptide that agonizes a glucagon receptor (“GCGR”); a linker polypeptide; and an antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein:an εamino group of a lysine residue of the polypeptide is covalently linked to a Cterminus of the linker polypeptide; andan N-terminus of the linker polypeptide is conjugated to a cysteine residue of the antibody.

[20] Still another aspect of the disclosure provides a molecule comprising:a polypeptide that agonizes a glucagon receptor (“GCGR”) comprising the amino acid sequence of any one of SEQ ID NOs: 15871627 (e.g., SEQ ID NOs: 1587, 1592, 1596, 1615, or 1626);a linker polypeptide comprising the amino acid sequence of any one of SEQ ID NOs: 16281683 (e.g., SEQ ID NOs: 16281630); andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a light chain and a heavy chain, wherein the light chain comprises the amino acid sequence of SEQ ID NO: 388 and the heavy chain comprises the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 24 or position 28 of the polypeptide is covalently linked to a Cterminus of the linker polypeptide; andan N-terminus of the linker polypeptide is conjugated to a cysteine residue at position 275 of the heavy chain of the antibody.

[21] Yet another aspect of the disclosure provides a molecule comprising: a first polypeptide that agonizes a glucagon receptor (“GCGR”); a first linker polypeptide; an antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”); a second linker polypeptide; and a second polypeptide that agonizes a GCGR, wherein:an εamino group of a lysine residue of the first polypeptide is covalently linked to a Cterminus of the first linker polypeptide; an N-terminus of the first linker polypeptide is conjugated to a cysteine residue of the antibody;an εamino group of a lysine residue of the second polypeptide is covalently linked to a Cterminus of the second linker polypeptide; andan N-terminus of the second linker polypeptide is conjugated to a cysteine residue of the antibody.

[22] Still another aspect of the disclosure provides a molecule comprising:a polypeptide that agonizes a glucagon receptor (“GCGR”) comprising the amino acid sequence of SEQ ID NO: 1615;a linker polypeptide comprising the amino acid sequence of SEQ ID NO: 1629; andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a light chain and a heavy chain, wherein the light chain comprises the amino acid sequence of SEQ ID NO: 388 and the heavy chain comprises the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 28 of the polypeptide is covalently linked to a Cterminus of the linker polypeptide; andan N-terminus of the linker polypeptide is conjugated to a cysteine residue at position 275 of the heavy chain of the antibody.

[23] Yet another aspect of the disclosure provides a molecule comprising:a polypeptide that agonizes a glucagon receptor (“GCGR”) comprising the amino acid sequence of SEQ ID NO: 1626;a linker polypeptide comprising the amino acid sequence of SEQ ID NO: 1628; andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a light chain and a heavy chain, wherein the light chain comprises the amino acid sequence of SEQ ID NO: 388 and the heavy chain comprises the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 28 of the polypeptide is covalently linked to a Cterminus of the linker polypeptide; andan N-terminus of the linker polypeptide is conjugated to a cysteine residue at position 275 of the heavy chain of the antibody.

[24] Still another aspect of the disclosure provides a molecule comprising:a polypeptide that agonizes a glucagon receptor (“GCGR”) comprising the amino acid sequence of SEQ ID NO: 1592;a linker polypeptide comprising the amino acid sequence of SEQ ID NO: 1628; andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a light chain and a heavy chain, wherein the light chain comprises the amino acid sequence of SEQ ID NO: 388 and the heavy chain comprises the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 24 of the polypeptide is covalently linked to a Cterminus of the linker polypeptide; andan N-terminus of the linker polypeptide is conjugated to a cysteine residue at position 275 of the heavy chain of the antibody.

[25] Yet another aspect of the disclosure provides a molecule comprising:a polypeptide that agonizes a glucagon receptor (“GCGR”) comprising the amino acid sequence of SEQ ID NO: 1626;a linker polypeptide comprising the amino acid sequence of SEQ ID NO: 1629; andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a light chain and a heavy chain, wherein the light chain comprises the amino acid sequence of SEQ ID NO: 388 and the heavy chain comprises the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 28 of the polypeptide is covalently linked to a Cterminus of the linker polypeptide; andan N-terminus of the linker polypeptide is conjugated to a cysteine residue at position 275 of the heavy chain of the antibody.

[26] Still another aspect of the disclosure provides a molecule comprising:a polypeptide that agonizes a glucagon receptor (“GCGR”) comprising the amino acid sequence of SEQ ID NO: 1587;a linker polypeptide comprising the amino acid sequence of SEQ ID NO: 1628; andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a light chain and a heavy chain, wherein the light chain comprises the amino acid sequence of SEQ ID NO: 388 and the heavy chain comprises the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 28 of the polypeptide is covalently linked to a Cterminus of the linker polypeptide; andan N-terminus of the linker polypeptide is conjugated to a cysteine residue at position 275 of the heavy chain of the antibody.

[27] Yet another aspect of the disclosure provides a molecule comprising:a polypeptide that agonizes a glucagon receptor (“GCGR”) comprising the amino acid sequence of SEQ ID NO: 1587;a linker polypeptide comprising the amino acid sequence of SEQ ID NO: 1630; andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a light chain and a heavy chain, wherein the light chain comprises the amino acid sequence of SEQ ID NO: 388 and the heavy chain comprises the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 28 of the polypeptide is covalently linked to a Cterminus of the linker polypeptide; andan N-terminus of the linker polypeptide is conjugated to a cysteine residue at position 275 of the heavy chain of the antibody.

[28] Still another aspect of the disclosure provides a molecule comprising:a first polypeptide and a second polypeptide that agonize a glucagon receptor (“GCGR”), wherein each of the first polypeptide and the second polypeptide comprise an amino acid sequence independently selected from SEQ ID NOs: 15871627 (e.g., SEQ ID NOs: 1587, 1592, 1596, 1615, or 1626);a first linker polypeptide and a second linker polypeptide, wherein each of the first linker polypeptide and the second linker polypeptide comprise an amino acid sequence selected from SEQ ID NOs: 16281683 (e.g., SEQ ID NOs: 16281630); andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a first light chain and a second light chain, wherein the first light chain and the second light chain each comprise the amino acid sequence of SEQ ID NO: 388, and a first heavy chain and a second heavy chain, wherein the first heavy chain and the second heavy chain each comprise the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 24 or position 28 of the first polypeptide is covalently linked to a Cterminus of the first linker polypeptide; an N-terminus of the first linker polypeptide is conjugated to a cysteine residue at position 275 of the first heavy chain of the antibody;an εamino group of a lysine residue at position 24 or position 28 of the second polypeptide is covalently linked to a Cterminus of the second linker polypeptide; andan N-terminus of the second linker polypeptide is conjugated to a cysteine residue at position 275 of the second heavy chain of the antibody.

[29] In some embodiments, the first polypeptide and the second polypeptide have identical amino acid sequences. In some embodiments, the first linker polypeptide and the second linker polypeptide have identical amino acid sequences. In some embodiments, the first polypeptide and the second polypeptide have identical amino acid sequences, and the first linker polypeptide and the second linker polypeptide have identical amino acid sequences.

[30] Yet another aspect of the disclosure provides a molecule comprising:a first polypeptide and a second polypeptide that agonize a glucagon receptor (“GCGR”), wherein the first polypeptide and the second polypeptide each comprise the amino acid sequence of SEQ ID NO: 1615;a first linker polypeptide and a second linker polypeptide, wherein the first linker polypeptide and the second linker polypeptide each comprise the amino acid sequence of SEQ ID NO: 1629; andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a first light chain and a second light chain, wherein the first light chain and the second light chain each comprise the amino acid sequence of SEQ ID NO: 388, and a first heavy chain and a second heavy chain, wherein the first heavy chain and the second heavy chain each comprise the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 28 of the first polypeptide is covalently linked to a Cterminus of the first linker polypeptide; an N-terminus of the first linker polypeptide is conjugated to a cysteine residue at position 275 of the first heavy chain of the antibody;an εamino group of a lysine residue at position 28 of the second polypeptide is covalently linked to a Cterminus of the second linker polypeptide; andan N-terminus of the second linker polypeptide is conjugated to a cysteine residue at position 275 of the second heavy chain of the antibody.

[31] Still another aspect of the disclosure provides a molecule comprising:a first polypeptide and a second polypeptide that agonize a glucagon receptor (“GCGR”), wherein the first polypeptide and the second polypeptide each comprise the amino acid sequence of SEQ ID NO: 1626;a first linker polypeptide and a second linker polypeptide, wherein the first linker polypeptide and the second linker polypeptide each comprise the amino acid sequence of SEQ ID NO: 1628; andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a first light chain and a second light chain, wherein the first light chain and the second light chain each comprise the amino acid sequence of SEQ ID NO: 388, and a first heavy chain and a second heavy chain, wherein the first heavy chain and the second heavy chain each comprise the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 28 of the first polypeptide is covalently linked to a Cterminus of the first linker polypeptide; an N-terminus of the first linker polypeptide is conjugated to a cysteine residue at position 275 of the first heavy chain of the antibody;an εamino group of a lysine residue at position 28 of the second polypeptide is covalently linked to a Cterminus of the second linker polypeptide; andan N-terminus of the second linker polypeptide is conjugated to a cysteine residue at position 275 of the second heavy chain of the antibody.

[32] Yet another aspect of the disclosure provides a molecule comprising:a first polypeptide and a second polypeptide that agonize a glucagon receptor (“GCGR”), wherein the first polypeptide and the second polypeptide each comprise the amino acid sequence of SEQ ID NO: 1592;a first linker polypeptide and a second linker polypeptide, wherein the first linker polypeptide and the second linker polypeptide each comprise the amino acid sequence of SEQ ID NO: 1628; andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a first light chain and a second light chain, wherein the first light chain and the second light chain each comprise the amino acid sequence of SEQ ID NO: 388, and a first heavy chain and a second heavy chain, wherein the first heavy chain and the second heavy chain each comprise the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 24 of the first polypeptide is covalently linked to a Cterminus of the first linker polypeptide; an N-terminus of the first linker polypeptide is conjugated to a cysteine residue at position 275 of the first heavy chain of the antibody;an εamino group of a lysine residue at position 24 of the second polypeptide is covalently linked to a Cterminus of the second linker polypeptide; andan N-terminus of the second linker polypeptide is conjugated to a cysteine residue at position 275 of the second heavy chain of the antibody.

[33] Still another aspect of the disclosure provides a molecule comprising:a first polypeptide and a second polypeptide that agonize a glucagon receptor (“GCGR”), wherein the first polypeptide and the second polypeptide each comprise the amino acid sequence of SEQ ID NO: 1626;a first linker polypeptide and a second linker polypeptide, wherein the first linker polypeptide and the second linker polypeptide each comprise the amino acid sequence of SEQ ID NO: 1629; andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a first light chain and a second light chain, wherein the first light chain and the second light chain each comprise the amino acid sequence of SEQ ID NO: 388, and a first heavy chain and a second heavy chain, wherein the first heavy chain and the second heavy chain each comprise the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 28 of the first polypeptide is covalently linked to a Cterminus of the first linker polypeptide; an N-terminus of the first linker polypeptide is conjugated to a cysteine residue at position 275 of the first heavy chain of the antibody;an εamino group of a lysine residue at position 28 of the second polypeptide is covalently linked to a Cterminus of the second linker polypeptide; andan N-terminus of the second linker polypeptide is conjugated to a cysteine residue at position 275 of the second heavy chain of the antibody.

[34] Yet another aspect of the disclosure provides a molecule comprising:a first polypeptide and a second polypeptide that agonize a glucagon receptor (“GCGR”), wherein the first polypeptide and the second polypeptide each comprise the amino acid sequence of SEQ ID NO: 1587;a first linker polypeptide and a second linker polypeptide, wherein the first linker polypeptide and the second linker polypeptide each comprise the amino acid sequence of SEQ ID NO: 1628; andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a first light chain and a second light chain, wherein the first light chain and the second light chain each comprise the amino acid sequence of SEQ ID NO: 388, and a first heavy chain and a second heavy chain, wherein the first heavy chain and the second heavy chain each comprise the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 28 of the first polypeptide is covalently linked to a Cterminus of the first linker polypeptide; an N-terminus of the first linker polypeptide is conjugated to a cysteine residue at position 275 of the first heavy chain of the antibody;an εamino group of a lysine residue at position 28 of the second polypeptide is covalently linked to a Cterminus of the second linker polypeptide; andan N-terminus of the second linker polypeptide is conjugated to a cysteine residue at position 275 of the second heavy chain of the antibody.

[35] Still another aspect of the disclosure provides a molecule comprising:a first polypeptide and a second polypeptide that agonize a glucagon receptor (“GCGR”), wherein the first polypeptide and the second polypeptide each comprise the amino acid sequence of SEQ ID NO: 1587;a first linker polypeptide and a second linker polypeptide, wherein the first linker polypeptide and the second linker polypeptide each comprise the amino acid sequence of SEQ ID NO: 1630; andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a first light chain and a second light chain, wherein the first light chain and the second light chain each comprise the amino acid sequence of SEQ ID NO: 388, and a first heavy chain and a second heavy chain, wherein the first heavy chain and the second heavy chain each comprise the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 28 of the first polypeptide is covalently linked to a Cterminus of the first linker polypeptide; an N-terminus of the first linker polypeptide is conjugated to a cysteine residue at position 275 of the first heavy chain of the antibody;an εamino group of a lysine residue at position 28 of the second polypeptide is covalently linked to a Cterminus of the second linker polypeptide; andan N-terminus of the second linker polypeptide is conjugated to a cysteine residue at position 275 of the second heavy chain of the antibody.

[36] Yet another aspect of the disclosure provides a pharmaceutical composition comprising a polypeptide or molecule disclosed herein and a pharmaceutically acceptable excipient.

[37] Still another aspect of the disclosure provides a method of treating obesity in a subject in need of treatment, the method comprising administering a polypeptide, molecule, or a pharmaceutical composition to the subject.

[38] Another aspect of the disclosure provides a method of reducing body weight and / or food intake in a subject in need thereof (e.g., an overweight or obese subject), the method comprising administering a polypeptide, molecule, or a pharmaceutical composition to the subject.

[39] Yet another aspect of the disclosure provides a polypeptide or molecule disclosed herein for use as a medicament. Another aspect of the disclosure provides a polypeptide or molecule disclosed herein, or a pharmaceutical composition disclosed herein, for use in the treatment of obesity. Still another aspect of the disclosure provides a polypeptide or molecule disclosed herein, or a pharmaceutical composition disclosed herein, for use in a method of reducing body weight and / or food intake in a subject in need thereof (e.g., an overweight or obese subject).

[40] Yet another aspect of the disclosure provides a polypeptide or molecule disclosed herein for the manufacture of a medicament for the treatment of obesity. Another aspect of the disclosure provides a polypeptide or molecule disclosed herein for the manufacture of a medicament for reducing body weight and / or food intake in a subject in need thereof (e.g., an overweight or obese subject).

[41] Another aspect of the disclosure provides a GCGR agonist and a GIPR antagonist for use in therapy. Yet another aspect of the disclosure provides a GCGR agonist for use in therapy in combination with a GIPR antagonist. Still another aspect provides a GIPR antagonist for use in therapy in combination with a GCGR agonist. In some embodiments, the therapy is for use in weight management. In some embodiments, the therapy is for use in treating obesity. In some cases, the GCGR agonist and the GIPR antagonist may be used in acute therapy. In other cases, the GCGR agonist and the GIPR antagonist may be used in chronic therapy. The GCGR agonist and the GIPR antagonist may be present in the same or separate pharmaceutical compositions.

[42] Another aspect of the disclosure provides a use of a GCGR agonist and a GIPR antagonist in the preparation of a medicament. Yet another aspect of the disclosure provides a use of a GCGR agonist in the preparation of a medicament for use in combination therapy with a GIPR antagonist. Still another aspect of the disclosure provides a use of a GIPR antagonist in the preparation of a medicament for use in combination therapy with a GCGR agonist. In some embodiments, the medicament is for use in combination therapy for weight management. In some embodiments, the medicament is for use in combination therapy in treating obesity.

[43] Another aspect of the disclosure provides a method of treating obesity in a subject in need thereof, the method comprising administering a glucagon receptor (GCGR) agonist and a GIPR antagonist to the subject. Still another aspect of the disclosure provides a method of reducing body weight and / or food intake in a subject in need thereof, the method comprising administering a glucagon receptor (GCGR) agonist and a GIPR antagonist to the subject.

[44] Another aspect of the disclosure provides a GCGR agonist and a GIPR antagonist for use in treating obesity. Yet another aspect of the disclosure provides a GCGR agonist for use in treating obesity in combination with a GIPR antagonist. Still another aspect of the disclosure provides a GIPR antagonist for use in treating obesity in combination with a GCGR agonist.

[45] Another aspect of the disclosure provides a GCGR agonist and a GIPR antagonist for use in reducing body weight and / or food intake in a subject in need thereof. Yet another aspect of the disclosure provides a GCGR agonist for use in reducing body weight and / or food intake in a subject in need thereof in combination with a GIPR antagonist. Still another aspect of the disclosure provides a GIPR antagonist for use in reducing body weight and / or food intake in a subject in need thereof in combination with a GCGR agonist.

[46] Another aspect of the disclosure provides a use of a GCGR agonist and a GIPR antagonist in the manufacture of a medicament for treating obesity. Yet another aspect of the disclosure provides a use of a GCGR agonist in the manufacture of a medicament for treating obesity in combination with a GIPR antagonist. Still another aspect of the disclosure provides a use of a GIPR antagonist in the manufacture of a medicament for treating obesity in combination with a GCGR agonist.

[47] Another aspect of the disclosure provides a use of a GCGR agonist and a GIPR antagonist in the manufacture of a medicament for reducing body weight and / or food intake in a subject in need thereof. Yet another aspect of the disclosure provides a use of a GCGR agonist in the manufacture of a medicament for reducing body weight and / or food intake in a subject in need thereof in combination with a GIPR antagonist. Still another aspect of the disclosure provides a use of a GIPR antagonist in the manufacture of a medicament for reducing body weight and / or food intake in a subject in need thereof in combination with a GCGR agonist.

[48] Another aspect of the disclosure provides a combination therapy comprising a GLP1 agonist (e.g., semaglutide) and a polypeptide or molecule disclosed herein for use in weight management. Still another aspect of the disclosure provides a combination therapy comprising a GLP1 agonist (e.g., semaglutide) and a polypeptide or molecule disclosed herein for use in the treatment of obesity. Another aspect of the disclosure provides a combination therapy comprising a GLP1 agonist (e.g., semaglutide) and a polypeptide or molecule disclosed herein for use in a method of reducing body weight and / or food intake in a subject in need thereof (e.g., an overweight or obese subject). 

[49] Further aspects and advantages will be apparent to those of ordinary skill in the art from a review of the following detailed description. The description hereafter includes specific cases, embodiments, and examples with the understanding that the disclosure is illustrative and is not intended to limit the embodiments of the present disclosure to the specific cases, embodiments, and examples described herein. Illustratively, example embodiments of the present disclosure include, but are not limited to, the following embodiments E1E240.E1. A polypeptide that agonizes a glucagon receptor (“GCGR”), wherein: the polypeptide comprises at least 25 amino acids, wherein the polypeptide comprises 5bromo-tryptophan at position 25; andthe polypeptide has at least 79% sequence identity to the amino acid sequence of SEQ ID NO: 1587. E2. The polypeptide of E1, wherein the polypeptide has at least 82% sequence identity to the amino acid sequence of SEQ ID NO: 1587. E3. The polypeptide of E1 or E2, wherein the polypeptide has at least 86% sequence identity to the amino acid sequence of SEQ ID NO: 1587. E4. The polypeptide of any one of E1 to E3, wherein the polypeptide has at least 89% sequence identity to the amino acid sequence of SEQ ID NO: 1587. E5. The polypeptide of any one of E1 to E4, wherein the polypeptide has at least 93% sequence identity to the amino acid sequence of SEQ ID NO: 1587. E6. The polypeptide of any one of E1 to E5, wherein the polypeptide has at least 96% sequence identity to the amino acid sequence of SEQ ID NO: 1587. E7. The polypeptide of E1, wherein the polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 15871595. E8. The polypeptide of E1, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1587. E9. The polypeptide of E1, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 1587. E10. The polypeptide of E1, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1588. E11. The polypeptide of E1, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 1588. E12. The polypeptide of E1, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1589. E13. The polypeptide of E1, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 1589. E14. The polypeptide of E1, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1590. E15. The polypeptide of E1, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 1590. E16. The polypeptide of E1, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1591. E17. The polypeptide of E1, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 1591. E18. The polypeptide of E1, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1592. E19. The polypeptide of E1, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 1592. E20. The polypeptide of E1, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1593. E21. The polypeptide of E1, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 1593. E22. The polypeptide of E1, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1594. E23. The polypeptide of E1, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 1594. E24. The polypeptide of E1, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1595. E25. The polypeptide of E1, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 1595. E26. The polypeptide of E1, comprising at least 27 amino acids. E27. The polypeptide of E26, wherein the polypeptide further comprises one or more of:d-serine at position 2;2-aminoisobutyric acid at position 16;lysine at position 17;β-(2-naphthyl)-L-alanine at position 18;aspartic acid, lysine, alanine, or glutamic acid at position 24; andleucine at position 27. E28. The polypeptide of any one of E1, E26, or E27, wherein the polypeptide further comprises dserine at position 2. E29. The polypeptide of any one of E1 or E26E28, wherein the polypeptide further comprises 2aminoisobutyric acid at position 16.  E30. The polypeptide of any one of E1 or E26-E29, wherein the polypeptide further comprises lysine at position 17. E31. The polypeptide of any one of E1 or E26-E30, wherein the polypeptide further comprises β-(2-naphthyl)-L-alanine at position 18. E32. The polypeptide of any one of E1 or E26E31, wherein the polypeptide further comprises aspartic acid at position 24. E33. The polypeptide of any one of E1 or E26E31, wherein the polypeptide further comprises lysine at position 24. E34. The polypeptide of any one of E1 or E26E31, wherein the polypeptide further comprises alanine at position 24. E35. The polypeptide of any one of E1 or E26E31, wherein the polypeptide further comprises glutamic acid at position 24. E36. The polypeptide of any one of E1 or E26E35, wherein the polypeptide further comprises leucine at position 27. E37. The polypeptide of any one of E1 or E26E36, wherein the polypeptide comprises d-serine at position 2 and 2aminoisobutyric acid at position 16. E38. The polypeptide of any one of E1 or E26E37, wherein the polypeptide comprises dserine at position 2, 2aminoisobutyric acid at position 16, and leucine at position 27. E39. The polypeptide of any one of E1 or E26E38, comprising at least 28 amino acids. E40. The polypeptide of E36, wherein the polypeptide further comprises lysine or aspartic acid at position 28. E41. The polypeptide of E36 or E37, wherein the polypeptide further comprises lysine at position 28. E42. The polypeptide of E36 or E37, wherein the polypeptide further comprises aspartic acid at position 28. E43. The polypeptide of E1 or E39, wherein the polypeptide further comprises d-serine at position 2, 2aminoisobutyric acid at position 16, leucine at position 27, and lysine or aspartic acid at position 28. E44. The polypeptide of E1 or E39, wherein the polypeptide further comprises d-serine at position 2, 2aminoisobutyric acid at position 16, aspartic acid at position 24, leucine at position 27, and lysine at position 28. E45. The polypeptide of E1 or E39, wherein the polypeptide further comprises d-serine at position 2, 2aminoisobutyric acid at position 16, leucine at position 27, and lysine at position 28. E46. The polypeptide of E1 or E39, wherein the polypeptide further comprises d-serine at position 2, 2aminoisobutyric acid at position 16, lysine at position 24, leucine at position 27, and aspartic acid at position 28. E47. The polypeptide of E1 or E39, wherein the polypeptide further comprises d-serine at position 2, 2aminoisobutyric acid at position 16, aspartic acid at position 24, leucine at position 27, and lysine at position 28. E48. The polypeptide of E1 or E39, wherein the polypeptide further comprises d-serine at position 2, 2aminoisobutyric acid at position 16, lysine at position 17, alanine at position 24, leucine at position 27, and lysine at position 28. E49. The polypeptide of E1 or E39, wherein the polypeptide further comprises d-serine at position 2, 2aminoisobutyric acid at position 16, alanine at position 24, and lysine at position 28. E50. The polypeptide of E1 or E39, wherein the polypeptide further comprises d-serine at position 2, 2aminoisobutyric acid at position 16, lysine at position 17, glutamic acid at position 24, leucine at position 27, and lysine at position 28. E51. The polypeptide of E1 or E39, wherein the polypeptide further comprises d-serine at position 2, 2aminoisobutyric acid at position 16, β-(2-naphthyl)-L-alanine at position 18, lysine at position 24, leucine at position 27, and aspartic acid at position 28. E52. The polypeptide of E1 or E39, wherein the polypeptide further comprises d-serine at position 2, 2aminoisobutyric acid at position 16, β-(2-naphthyl)-L-alanine at position 18, alanine at position 24, leucine at position 27, and lysine at position 28. E53. A polypeptide that agonizes a glucagon receptor (“GCGR”), wherein: the polypeptide comprises at least 28 amino acids, wherein the polypeptide comprises 2aminoisobutyric acid at position 16 and lysine, serine, or aspartic acid at position 28; andthe polypeptide has at least 89% sequence identity to the amino acid sequence of SEQ ID NO: 1596. E54. The polypeptide of E53, wherein the polypeptide has at least 93% sequence identity to the amino acid sequence of SEQ ID NO: 1596. E55. The polypeptide of E53, wherein the polypeptide has at least 96% sequence identity to the amino acid sequence of SEQ ID NO: 1596. E56. The polypeptide of any one of E53-E56, wherein the polypeptide comprises lysine at position 28. E57. The polypeptide of any one of E53E56, wherein the polypeptide comprises serine at position 28. E58. The polypeptide of any one of E53E56, wherein the polypeptide comprises aspartic acid at position 28. E59. The polypeptide of any one of E53-E58, wherein the polypeptide further comprises one or more of:tyrosine at position 1;dserine, d-threonine, or 2-aminoisobutyric acid at position 2;histidine at position 7;lysine, citrulline, or glutamine at position 17;β-(2-naphthyl)-L-alanine or β-(4,4'-biphenyl)alanine at position 18;lysine, alanine, asparagine, glutamic acid, glycine, aspartic acid, histidine, threonine, or 2aminoisobutyric acid at position 24;tyrosine, 5-bromo-tryptophan, or 2-bromo-5-hydroxytryptophan at position 25; andleucine, glutamic acid, or αaminoadipic acid at position 27. E60. The polypeptide of E59, wherein the polypeptide further comprises dserine, dthreonine, or 2aminoisobutyric acid at position 2. E61. The polypeptide of E59 or E60, wherein the polypeptide further comprises d-serine at position 2. E62. The polypeptide of any one of E59E61, wherein the polypeptide further comprises leucine, glutamic acid, or αaminoadipic acid at position 27. E63. The polypeptide of any one of E59E62, wherein the polypeptide further comprises leucine at position 27. E64. The polypeptide of any one of E53E55, wherein the polypeptide comprises d-serine at position 2, 2aminoisobutyric acid at position 16, leucine at position 27, and lysine at position 28. E65. The polypeptide of any one of E53E64, wherein the polypeptide further comprises lysine, citrulline, or glutamine at position 17. E66. The polypeptide of E65, wherein the polypeptide further comprises lysine at position 17. E67. The polypeptide of any one of E53E55, wherein the polypeptide comprises d-serine at position 2, 2aminoisobutyric acid at position 16, lysine at position 17, leucine at position 27, and lysine at position 28.  E68. The polypeptide of any one of E53E64, wherein the polypeptide further comprises β-(2-naphthyl)-L-alanine or β-(4,4'-biphenyl)alanine at position 18. E69. The polypeptide of any one of E53E64, wherein the polypeptide further comprises lysine, alanine, asparagine, glutamic acid, glycine, aspartic acid, histidine, threonine, or 2aminoisobutyric acid at position 24. E70. The polypeptide of E69, wherein the polypeptide further comprises lysine at position 24. E71. The polypeptide of any one of E53E55, wherein the polypeptide comprises d-serine at position 2, 2aminoisobutyric acid at position 16, lysine, alanine, asparagine, glutamic acid, glycine, aspartic acid, histidine, threonine, or 2aminoisobutyric acid at position 24, and lysine at position 28. E72. The polypeptide of any one of E53E55, wherein the polypeptide further comprises histidine at position 7. E73. The polypeptide of any one of E53E55, wherein the polypeptide further comprises tyrosine at position 1.  E74. The polypeptide of any one of E53E55, wherein the polypeptide further comprises tyrosine, 5-bromo-tryptophan, or 2-bromo-5-hydroxytryptophan at position 25.  E75. The polypeptide of any one of E53E55, wherein the polypeptide comprises d-serine at position 2, 2-aminoisobutyric acid at position 16, tyrosine, 5-bromo-tryptophan, or 2bromo-5-hydroxytryptophan at position 25, leucine at position 27, and lysine at position 28.  E76. The polypeptide of any one of E53E75, comprising at least 29 amino acids. E77. The polypeptide of E76, wherein the polypeptide further comprises alanine, aspartic acid, glutamic acid, or serine at position 29. E78. The polypeptide of E77, wherein the polypeptide comprises d-serine at position 2, 2aminoisobutyric acid at position 16, lysine at position 28, and alanine, aspartic acid, glutamic acid, or serine at position 29. E79. A polypeptide that agonizes a glucagon receptor (“GCGR”), wherein: the polypeptide comprises at least 28 amino acids, wherein the polypeptide comprises 2aminoisobutyric acid at position 16, leucine at position 27, and lysine at position 28; andthe polypeptide has at least 89% sequence identity to the amino acid sequence of SEQ ID NO: 1615. E80. The polypeptide of E79, wherein the polypeptide has at least 93% sequence identity to the amino acid sequence of SEQ ID NO: 1615. E81. The polypeptide of E79, wherein the polypeptide has at least 96% sequence identity to the amino acid sequence of SEQ ID NO: 1615. E82. The polypeptide of any one of E79E81, wherein the polypeptide further comprises d-serine at position 2. E83. The polypeptide of any one of E79E82, wherein the polypeptide further comprises aspartic acid or glutamic acid at position 24. E84. The polypeptide of any one of E79E83, wherein the polypeptide further comprises d-serine at position 2 and aspartic acid or glutamic acid at position 24. E85. The polypeptide of any one of E79E84, wherein the polypeptide further comprises d-serine at position 2 and aspartic acid at position 24. E86. The polypeptide of any one of E79E85, wherein the polypeptide further comprises lysine at position 17. E87. The polypeptide of any one of E79E86, wherein the polypeptide further comprises d-serine at position 2, lysine at position 17, and aspartic acid at position 24. E88. A polypeptide that agonizes a glucagon receptor (“GCGR”), wherein: the polypeptide comprises at least 28 amino acids, wherein the polypeptide comprises 2aminoisobutyric acid at position 16, aspartic acid at position 24, and lysine at position 28; andthe polypeptide has at least 89% sequence identity to the amino acid sequence of SEQ ID NO: 1626. E89. The polypeptide of E88, wherein the polypeptide has at least 93% sequence identity to the amino acid sequence of SEQ ID NO: 1626. E90. The polypeptide of E88, wherein the polypeptide has at least 96% sequence identity to the amino acid sequence of SEQ ID NO: 1626. E91. The polypeptide of any one of E88E90, wherein the polypeptide further comprises d-serine at position 2. E92. The polypeptide of any one of E88E91, wherein the polypeptide further comprises lysine at position 17. E93. The polypeptide of any one of E88E92, wherein the polypeptide further comprises leucine at position 27. E94. A polypeptide that agonizes a glucagon receptor (“GCGR”) comprising the amino acid sequence of any one of SEQ ID NOs: 15871627. E95. The polypeptide of E94, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1596. E96. The polypeptide of E94, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1597. E97. The polypeptide of E94, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1615. E98. The polypeptide of E94, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1626. E99. The polypeptide of E94, wherein the polypeptide consists of the amino acid sequence of any one of SEQ ID NOs: 15871627. E100. The polypeptide of E99, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 1596. E101. The polypeptide of E99, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 1597. E102. The polypeptide of E99, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 1615. E103. The polypeptide of E99, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 1626. E104. The polypeptide of any one of E1E103, wherein the polypeptide agonizes human GCGR (“hGCGR”). E105. The polypeptide of any one of E1E104, wherein the polypeptide has a hGCGR EC50 of less than or equal to 500 pM. E106. The polypeptide of any one of E1E105, wherein the polypeptide has a human glucagon-like peptide-1 receptor (“hGLP-1R”) EC50:hGCGR EC50 ratio of at least 40:1 (e.g., at least 50:1, at least 60:1, at least 70:1, at least 80:1, at least 90:1, at least 100:1, at least 250:1, at least 500:1, at least 1000:1). E107. The polypeptide of any one of E1E106, wherein the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 100:1. E108. The polypeptide of any one of E1E107, wherein the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 500:1. E109. A molecule comprising: a first polypeptide that agonizes a glucagon receptor (“GCGR”), wherein the first polypeptide is selected from the polypeptides of any one of E1108; and a second polypeptide comprising the amino acid sequence of any one of SEQ ID NOs: 16281683,wherein the C-terminus of the second polypeptide is covalently linked to an εamino group of a lysine residue of the first polypeptide (e.g., an ε-amino group of a lysine residue of the first polypeptide has been condensed with a carboxyl group of the C-terminus of the second polypeptide to form an amide bond between the first polypeptide and the second polypeptide). E110. The molecule of E109, wherein the C-terminus of the second polypeptide is covalently linked to the εamino group of a lysine at position 24 or position 28 of the first polypeptide (e.g., the ε-amino group of a lysine residue at position 24 or position 28 of the first polypeptide has been condensed with a carboxyl group of the C-terminus of the second polypeptide to form an amide bond between the first polypeptide and the second polypeptide). E111. The molecule of E109 or E110, wherein the C-terminus of the second polypeptide is covalently linked to the εamino group of a lysine at position 24 of the first polypeptide. E112. The molecule of E109 or E110, wherein the C-terminus of the second polypeptide is covalently linked to the εamino group of a lysine at position 28 of the first polypeptide. E113. The molecule of any one of E109E112, wherein the second polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 16281630. E114. The molecule of any one of E109E113, wherein the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1628. E115. The molecule of any one of E109E113, wherein the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1629. E116. The molecule of any one of E109E113, wherein the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1630. E117. The molecule of any one of E109E113, wherein the first polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 15871627. E118. The molecule of any one of E109E117, wherein the first polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 1587, 1592, 1596, 1615, or 1626.  E119. The molecule of any one of E109E118, wherein the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1587.  E120. The molecule of any one of E109E118, wherein the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1592.  E121. The molecule of any one of E109E118, wherein the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1596.  E122. The molecule of any one of E109E118, wherein the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1615.  E123. The molecule of any one of E109E118, wherein the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1626.  E124. A molecule comprising: a polypeptide that agonizes a glucagon receptor (“GCGR”), wherein the polypeptide is selected from the polypeptides of any one of E1E108; and a half-life extending domain (e.g., an Fc-containing polypeptide). E125. The molecule of E124, wherein: the half-life extending domain is an Fc-containing polypeptide;an εamino group of a lysine residue of the polypeptide is covalently linked to a Cterminus of a linker polypeptide; andan N-terminus of the linker polypeptide is conjugated to a cysteine residue of the Fccontaining polypeptide. E126. The molecule of E125, wherein the linker polypeptide is a linear polypeptide. E127. The molecule of E125 or E126, wherein the linker polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 16281683. E128. The molecule of any one of E125E127, wherein the linker polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 16281630. E129. The molecule of any one of E125E128, wherein the linker polypeptide comprises the amino acid sequence of SEQ ID NO: 1628. E130. The molecule of any one of E125E128, wherein the linker polypeptide comprises the amino acid sequence of SEQ ID NO: 1629. E131. The molecule of any one of E125E128, wherein the linker polypeptide comprises the amino acid sequence of SEQ ID NO: 1630. E132. The molecule of any one of E124E131, wherein the polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 15871627. E133. The molecule of any one of E124E132, wherein the polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 1588 or 15961611. E134. The molecule of any one of E124E132, wherein the polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 1587, 1592, 1596, 1615, or 1626.  E135. The molecule of any one of E124E132, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1587.  E136. The molecule of any one of E124E132, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1592.  E137. The molecule of any one of E124E132, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1596.  E138. The molecule of any one of E124E132, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1615.  E139. The molecule of any one of E124E132, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1626.  E140. The molecule of any one of E124E139, wherein the half-life extending domain is an antibody fragment. E141. The molecule of any one of E124E139, wherein the half-life extending domain is an antibody. E142. The molecule of E140, wherein the antibody is of the IgG1-, IgG2-, or IgG4- subclass. E143. The molecule of E140 or E141, wherein the antibody is of the IgG1- or IgG2- subclass. E144. The molecule of any one of E141E143, wherein the antibody specifically binds to 2,4dinitrophenol (“DNP”).  E145. The molecule of any one of E141E143, wherein the antibody specifically binds to a glucosedependent insulinotropic polypeptide receptor (“GIPR”). E146. The molecule of any one of E141E143, wherein the antibody specifically binds to human GIPR. E147. The molecule of E145 or E146, wherein the antibody inhibits binding of GIP to the extracellular portion of human GIPR. E148. The molecule of E147, wherein the antibody comprises a CDRL1, a CDRL2, a CDRL3, a CDRH1, a CDRH2, and a CDRH3, wherein the CDRL1, the CDRL2, the CDRL3, the CDRH1, the CDRH2, and the CDRH3 comprise the amino acid sequences of SEQ ID NO: 702, SEQ ID NO: 859, SEQ ID NO: 1016, SEQ ID NO: 1173, SEQ ID NO: 1330, and SEQ ID NO: 1487, respectively. E149. The molecule of E147 or E148, wherein the antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 74 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 231. E150. The molecule of any one of E145E149, wherein the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 388 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 1571. E151. A molecule comprising:a first polypeptide that agonizes a glucagon receptor (“GCGR”); andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”). E152. The molecule of E151, wherein: an εamino group of a lysine residue of the first polypeptide is covalently linked to a Cterminus of a first linker polypeptide; andan N-terminus of the first linker polypeptide is conjugated to a cysteine residue of the antibody. E153. The molecule of E151 or E152, wherein the first polypeptide is selected from the polypeptides of any one of E1108. E154. The molecule of any one of E151E153, wherein the first polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 15871627. E155. The molecule of any one of E151E154, wherein the first polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 1587, 1592, 1596, 1615, or 1626.  E156. The molecule of any one of E151E155, wherein the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1587.  E157. The molecule of any one of E151E155, wherein the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1592.  E158. The molecule of any one of E151E155, wherein the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1596.  E159. The molecule of any one of E151E155, wherein the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1615.  E160. The molecule of any one of E151E155, wherein the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1626.  E161. The molecule of any one of E152E160, wherein the first linker polypeptide is a linear polypeptide. E162. The molecule of any one of E152E161, wherein the first linker polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 16281683. E163. The molecule of any one of E152E162, wherein the first linker polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 16281630. E164. The molecule of any one of E152E163, wherein the first linker polypeptide comprises the amino acid sequence of SEQ ID NO: 1628. E165. The molecule of any one of E152E163, wherein the first linker polypeptide comprises the amino acid sequence of SEQ ID NO: 1629. E166. The molecule of any one of E152E163, wherein the first linker polypeptide comprises the amino acid sequence of SEQ ID NO: 1630. E167. The molecule of any one of E152E166, wherein the cysteine residue of the antibody that is conjugated to the N-terminus of the first linker polypeptide is at a position selected from the group consisting of 88 of a light chain, 384 of a heavy chain, and 487 of a heavy chain, according to AHo numbering. E168. The molecule of E167, wherein the cysteine residue of the antibody that is conjugated to the Nterminus of the first linker polypeptide is at position 384 of a heavy chain, according to AHo numbering. E169. The molecule of any one of E151E168, further comprising a second polypeptide that agonizes a GCGR. E170. The molecule of E169, wherein: an εamino group of a lysine residue of the second polypeptide is covalently linked to a Cterminus of a second linker polypeptide; andan N-terminus of the second linker polypeptide is conjugated to a cysteine residue of the antibody. E171. The molecule of E169 or E170, wherein the second polypeptide is selected from the polypeptides of any one of E1108. E172. The molecule of any one of E169E171, wherein the second polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 15871627. E173. The molecule of any one of E169E172, wherein the second polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 1587, 1592, 1596, 1615, or 1626.  E174. The molecule of any one of E169E173, wherein the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1587.  E175. The molecule of any one of E169E173, wherein the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1592.  E176. The molecule of any one of E169E173, wherein the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1596.  E177. The molecule of any one of E169E173, wherein the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1615.  E178. The molecule of any one of E169E173, wherein the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1626.  E179. The molecule of any one of E169E178, wherein the first polypeptide has the same amino acid sequence as the second polypeptide. E180. The molecule of any one of E170E179, wherein the second linker polypeptide is a linear polypeptide. E181. The molecule of any one of E170E180, wherein the second linker polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 16281683. E182. The molecule of any one of E170E181, wherein the second linker polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 16281630. E183. The molecule of any one of E170E182, wherein the second linker polypeptide comprises the amino acid sequence of SEQ ID NO: 1628. E184. The molecule of any one of E170E182, wherein the second linker polypeptide comprises the amino acid sequence of SEQ ID NO: 1629. E185. The molecule of any one of E170E182, wherein the second linker polypeptide comprises the amino acid sequence of SEQ ID NO: 1630. E186. The molecule of any one of E170E185, wherein the first linker polypeptide has the same amino acid sequence as the second linker polypeptide. E187. The molecule of any one of E170E186, wherein the cysteine residue of the antibody that is conjugated to the N-terminus of the second linker polypeptide is at a position selected from the group consisting of 88 of a light chain, 384 of a heavy chain, and 487 of a heavy chain, according to AHo numbering. E188. The molecule of E187, wherein the cysteine residue of the antibody that is conjugated to the Nterminus of the second linker polypeptide is at position 384 of a heavy chain, according to AHo numbering. E189. The molecule of any one of E170E187, wherein the cysteine residues of the antibody that are conjugated to the N-termini of the first linker polypeptide and the second linker polypeptide are at positions selected from the group consisting of 88 of both light chains, 384 of both heavy chains, and 487 of both heavy chains, according to AHo numbering. E190. The molecule of E189, wherein the cysteine residues of the antibody that are conjugated to the Ntermini of the first linker polypeptide and the second linker polypeptide are at positions 384 of both heavy chains, according to AHo numbering. E191. The molecule of any one of E151E190, wherein the antibody comprises a CDRL1, a CDRL2, a CDRL3, a CDRH1, a CDRH2, and a CDRH3, wherein the CDRL1, the CDRL2, the CDRL3, the CDRH1, the CDRH2, and the CDRH3 comprise amino acid sequences selected from:i. SEQ ID NO: 629, SEQ ID NO: 786, SEQ ID NO: 943, SEQ ID NO: 1100, SEQ ID NO: 1257, and SEQ ID NO: 1414, respectively; ii. SEQ ID NO: 630, SEQ ID NO: 787, SEQ ID NO: 944, SEQ ID NO: 1101, SEQ ID NO: 1258, and SEQ ID NO: 1415, respectively; iii. SEQ ID NO: 631, SEQ ID NO: 788, SEQ ID NO: 945, SEQ ID NO: 1102, SEQ ID NO: 1259, and SEQ ID NO: 1416, respectively; iv. SEQ ID NO: 632, SEQ ID NO: 789, SEQ ID NO: 946, SEQ ID NO: 1103, SEQ ID NO: 1260, and SEQ ID NO: 1417, respectively; v. SEQ ID NO: 633, SEQ ID NO: 790, SEQ ID NO: 947, SEQ ID NO: 1104, SEQ ID NO: 1261, and SEQ ID NO: 1418, respectively; vi. SEQ ID NO: 634, SEQ ID NO: 791, SEQ ID NO: 948, SEQ ID NO: 1105, SEQ ID NO: 1262, and SEQ ID NO: 1419, respectively; vii. SEQ ID NO: 635, SEQ ID NO: 792, SEQ ID NO: 949, SEQ ID NO: 1106, SEQ ID NO: 1263, and SEQ ID NO: 1420, respectively; viii. SEQ ID NO: 636, SEQ ID NO: 793, SEQ ID NO: 950, SEQ ID NO: 1107, SEQ ID NO: 1264, and SEQ ID NO: 1421, respectively; ix. SEQ ID NO: 637, SEQ ID NO: 794, SEQ ID NO: 951, SEQ ID NO: 1108, SEQ ID NO: 1265, and SEQ ID NO: 1422, respectively; x. SEQ ID NO: 638, SEQ ID NO: 795, SEQ ID NO: 952, SEQ ID NO: 1109, SEQ ID NO: 1266, and SEQ ID NO: 1423, respectively; xi. SEQ ID NO: 639, SEQ ID NO: 796, SEQ ID NO: 953, SEQ ID NO: 1110, SEQ ID NO: 1267, and SEQ ID NO: 1424, respectively; xii. SEQ ID NO: 640, SEQ ID NO: 797, SEQ ID NO: 954, SEQ ID NO: 1111, SEQ ID NO: 1268, and SEQ ID NO: 1425, respectively; xiii. SEQ ID NO: 641, SEQ ID NO: 798, SEQ ID NO: 955, SEQ ID NO: 1112, SEQ ID NO: 1269, and SEQ ID NO: 1426, respectively; xiv. SEQ ID NO: 642, SEQ ID NO: 799, SEQ ID NO: 956, SEQ ID NO: 1113, SEQ ID NO: 1270, and SEQ ID NO: 1427, respectively; xv. SEQ ID NO: 643, SEQ ID NO: 800, SEQ ID NO: 957, SEQ ID NO: 1114, SEQ ID NO: 1271, and SEQ ID NO: 1428, respectively; xvi. SEQ ID NO: 644, SEQ ID NO: 801, SEQ ID NO: 958, SEQ ID NO: 1115, SEQ ID NO: 1272, and SEQ ID NO: 1429, respectively; xvii. SEQ ID NO: 645, SEQ ID NO: 802, SEQ ID NO: 959, SEQ ID NO: 1116, SEQ ID NO: 1273, and SEQ ID NO: 1430, respectively; xviii. SEQ ID NO: 646, SEQ ID NO: 803, SEQ ID NO: 960, SEQ ID NO: 1117, SEQ ID NO: 1274, and SEQ ID NO: 1431, respectively; xix. SEQ ID NO: 647, SEQ ID NO: 804, SEQ ID NO: 961, SEQ ID NO: 1118, SEQ ID NO: 1275, and SEQ ID NO: 1432, respectively; xx. SEQ ID NO: 648, SEQ ID NO: 805, SEQ ID NO: 962, SEQ ID NO: 1119, SEQ ID NO: 1276, and SEQ ID NO: 1433, respectively; xxi. SEQ ID NO: 649, SEQ ID NO: 806, SEQ ID NO: 963, SEQ ID NO: 1120, SEQ ID NO: 1277, and SEQ ID NO: 1434, respectively; xxii. SEQ ID NO: 650, SEQ ID NO: 807, SEQ ID NO: 964, SEQ ID NO: 1121, SEQ ID NO: 1278, and SEQ ID NO: 1435, respectively; xxiii. SEQ ID NO: 651, SEQ ID NO: 808, SEQ ID NO: 965, SEQ ID NO: 1122, SEQ ID NO: 1279, and SEQ ID NO: 1436, respectively; xxiv. SEQ ID NO: 652, SEQ ID NO: 809, SEQ ID NO: 966, SEQ ID NO: 1123, SEQ ID NO: 1280, and SEQ ID NO: 1437, respectively; xxv. SEQ ID NO: 653, SEQ ID NO: 810, SEQ ID NO: 967, SEQ ID NO: 1124, SEQ ID NO: 1281, and SEQ ID NO: 1438, respectively; xxvi. SEQ ID NO: 654, SEQ ID NO: 811, SEQ ID NO: 968, SEQ ID NO: 1125, SEQ ID NO: 1282, and SEQ ID NO: 1439, respectively; xxvii. SEQ ID NO: 655, SEQ ID NO: 812, SEQ ID NO: 969, SEQ ID NO: 1126, SEQ ID NO: 1283, and SEQ ID NO: 1440, respectively; xxviii. SEQ ID NO: 656, SEQ ID NO: 813, SEQ ID NO: 970, SEQ ID NO: 1127, SEQ ID NO: 1284, and SEQ ID NO: 1441, respectively; xxix. SEQ ID NO: 657, SEQ ID NO: 814, SEQ ID NO: 971, SEQ ID NO: 1128, SEQ ID NO: 1285, and SEQ ID NO: 1442, respectively; xxx. SEQ ID NO: 658, SEQ ID NO: 815, SEQ ID NO: 972, SEQ ID NO: 1129, SEQ ID NO: 1286, and SEQ ID NO: 1443, respectively; xxxi. SEQ ID NO: 659, SEQ ID NO: 816, SEQ ID NO: 973, SEQ ID NO: 1130, SEQ ID NO: 1287, and SEQ ID NO: 1444, respectively; xxxii. SEQ ID NO: 660, SEQ ID NO: 817, SEQ ID NO: 974, SEQ ID NO: 1131, SEQ ID NO: 1288, and SEQ ID NO: 1445, respectively; xxxiii. SEQ ID NO: 661, SEQ ID NO: 818, SEQ ID NO: 975, SEQ ID NO: 1132, SEQ ID NO: 1289, and SEQ ID NO: 1446, respectively; xxxiv. SEQ ID NO: 662, SEQ ID NO: 819, SEQ ID NO: 976, SEQ ID NO: 1133, SEQ ID NO: 1290, and SEQ ID NO: 1447, respectively; xxxv. SEQ ID NO: 663, SEQ ID NO: 820, SEQ ID NO: 977, SEQ ID NO: 1134, SEQ ID NO: 1291, and SEQ ID NO: 1448, respectively; xxxvi. SEQ ID NO: 664, SEQ ID NO: 821, SEQ ID NO: 978, SEQ ID NO: 1135, SEQ ID NO: 1292, and SEQ ID NO: 1449, respectively; xxxvii. SEQ ID NO: 665, SEQ ID NO: 822, SEQ ID NO: 979, SEQ ID NO: 1136, SEQ ID NO: 1293, and SEQ ID NO: 1450, respectively; xxxviii. SEQ ID NO: 666, SEQ ID NO: 823, SEQ ID NO: 980, SEQ ID NO: 1137, SEQ ID NO: 1294, and SEQ ID NO: 1451, respectively; xxxix. SEQ ID NO: 667, SEQ ID NO: 824, SEQ ID NO: 981, SEQ ID NO: 1138, SEQ ID NO: 1295, and SEQ ID NO: 1452, respectively; xl. SEQ ID NO: 668, SEQ ID NO: 825, SEQ ID NO: 982, SEQ ID NO: 1139, SEQ ID NO: 1296, and SEQ ID NO: 1453, respectively; xli. SEQ ID NO: 669, SEQ ID NO: 826, SEQ ID NO: 983, SEQ ID NO: 1140, SEQ ID NO: 1297, and SEQ ID NO: 1454, respectively; xlii. SEQ ID NO: 670, SEQ ID NO: 827, SEQ ID NO: 984, SEQ ID NO: 1141, SEQ ID NO: 1298, and SEQ ID NO: 1455, respectively; xliii. SEQ ID NO: 671, SEQ ID NO: 828, SEQ ID NO: 985, SEQ ID NO: 1142, SEQ ID NO: 1299, and SEQ ID NO: 1456, respectively; xliv. SEQ ID NO: 672, SEQ ID NO: 829, SEQ ID NO: 986, SEQ ID NO: 1143, SEQ ID NO: 1300, and SEQ ID NO: 1457, respectively; xlv. SEQ ID NO: 673, SEQ ID NO: 830, SEQ ID NO: 987, SEQ ID NO: 1144, SEQ ID NO: 1301, and SEQ ID NO: 1458, respectively; xlvi. SEQ ID NO: 674, SEQ ID NO: 831, SEQ ID NO: 988, SEQ ID NO: 1145, SEQ ID NO: 1302, and SEQ ID NO: 1459, respectively; xlvii. SEQ ID NO: 675, SEQ ID NO: 832, SEQ ID NO: 989, SEQ ID NO: 1146, SEQ ID NO: 1303, and SEQ ID NO: 1460, respectively; xlviii. SEQ ID NO: 676, SEQ ID NO: 833, SEQ ID NO: 990, SEQ ID NO: 1147, SEQ ID NO: 1304, and SEQ ID NO: 1461, respectively; xlix. SEQ ID NO: 677, SEQ ID NO: 834, SEQ ID NO: 991, SEQ ID NO: 1148, SEQ ID NO: 1305, and SEQ ID NO: 1462, respectively; l. SEQ ID NO: 678, SEQ ID NO: 835, SEQ ID NO: 992, SEQ ID NO: 1149, SEQ ID NO: 1306, and SEQ ID NO: 1463, respectively; li. SEQ ID NO: 679, SEQ ID NO: 836, SEQ ID NO: 993, SEQ ID NO: 1150, SEQ ID NO: 1307, and SEQ ID NO: 1464, respectively; lii. SEQ ID NO: 680, SEQ ID NO: 837, SEQ ID NO: 994, SEQ ID NO: 1151, SEQ ID NO: 1308, and SEQ ID NO: 1465, respectively; liii. SEQ ID NO: 681, SEQ ID NO: 838, SEQ ID NO: 995, SEQ ID NO: 1152, SEQ ID NO: 1309, and SEQ ID NO: 1466, respectively; liv. SEQ ID NO: 682, SEQ ID NO: 839, SEQ ID NO: 996, SEQ ID NO: 1153, SEQ ID NO: 1310, and SEQ ID NO: 1467, respectively; lv. SEQ ID NO: 683, SEQ ID NO: 840, SEQ ID NO: 997, SEQ ID NO: 1154, SEQ ID NO: 1311, and SEQ ID NO: 1468, respectively; lvi. SEQ ID NO: 684, SEQ ID NO: 841, SEQ ID NO: 998, SEQ ID NO: 1155, SEQ ID NO: 1312, and SEQ ID NO: 1469, respectively; lvii. SEQ ID NO: 685, SEQ ID NO: 842, SEQ ID NO: 999, SEQ ID NO: 1156, SEQ ID NO: 1313, and SEQ ID NO: 1470, respectively; lviii. SEQ ID NO: 686, SEQ ID NO: 843, SEQ ID NO: 1000, SEQ ID NO: 1157, SEQ ID NO: 1314, and SEQ ID NO: 1471, respectively; lix. SEQ ID NO: 687, SEQ ID NO: 844, SEQ ID NO: 1001, SEQ ID NO: 1158, SEQ ID NO: 1315, and SEQ ID NO: 1472, respectively; lx. SEQ ID NO: 688, SEQ ID NO: 845, SEQ ID NO: 1002, SEQ ID NO: 1159, SEQ ID NO: 1316, and SEQ ID NO: 1473, respectively; lxi. SEQ ID NO: 689, SEQ ID NO: 846, SEQ ID NO: 1003, SEQ ID NO: 1160, SEQ ID NO: 1317, and SEQ ID NO: 1474, respectively; lxii. SEQ ID NO: 690, SEQ ID NO: 847, SEQ ID NO: 1004, SEQ ID NO: 1161, SEQ ID NO: 1318, and SEQ ID NO: 1475, respectively; lxiii. SEQ ID NO: 691, SEQ ID NO: 848, SEQ ID NO: 1005, SEQ ID NO: 1162, SEQ ID NO: 1319, and SEQ ID NO: 1476, respectively; lxiv. SEQ ID NO: 692, SEQ ID NO: 849, SEQ ID NO: 1006, SEQ ID NO: 1163, SEQ ID NO: 1320, and SEQ ID NO: 1477, respectively; lxv. SEQ ID NO: 693, SEQ ID NO: 850, SEQ ID NO: 1007, SEQ ID NO: 1164, SEQ ID NO: 1321, and SEQ ID NO: 1478, respectively; lxvi. SEQ ID NO: 694, SEQ ID NO: 851, SEQ ID NO: 1008, SEQ ID NO: 1165, SEQ ID NO: 1322, and SEQ ID NO: 1479, respectively; lxvii. SEQ ID NO: 695, SEQ ID NO: 852, SEQ ID NO: 1009, SEQ ID NO: 1166, SEQ ID NO: 1323, and SEQ ID NO: 1480, respectively; lxviii. SEQ ID NO: 696, SEQ ID NO: 853, SEQ ID NO: 1010, SEQ ID NO: 1167, SEQ ID NO: 1324, and SEQ ID NO: 1481, respectively; lxix. SEQ ID NO: 697, SEQ ID NO: 854, SEQ ID NO: 1011, SEQ ID NO: 1168, SEQ ID NO: 1325, and SEQ ID NO: 1482, respectively; lxx. SEQ ID NO: 698, SEQ ID NO: 855, SEQ ID NO: 1012, SEQ ID NO: 1169, SEQ ID NO: 1326, and SEQ ID NO: 1483, respectively; lxxi. SEQ ID NO: 699, SEQ ID NO: 856, SEQ ID NO: 1013, SEQ ID NO: 1170, SEQ ID NO: 1327, and SEQ ID NO: 1484, respectively; lxxii. SEQ ID NO: 700, SEQ ID NO: 857, SEQ ID NO: 1014, SEQ ID NO: 1171, SEQ ID NO: 1328, and SEQ ID NO: 1485, respectively; lxxiii. SEQ ID NO: 701, SEQ ID NO: 858, SEQ ID NO: 1015, SEQ ID NO: 1172, SEQ ID NO: 1329, and SEQ ID NO: 1486, respectively; lxxiv. SEQ ID NO: 702, SEQ ID NO: 859, SEQ ID NO: 1016, SEQ ID NO: 1173, SEQ ID NO: 1330, and SEQ ID NO: 1487, respectively; lxxv. SEQ ID NO: 703, SEQ ID NO: 860, SEQ ID NO: 1017, SEQ ID NO: 1174, SEQ ID NO: 1331, and SEQ ID NO: 1488, respectively; lxxvi. SEQ ID NO: 704, SEQ ID NO: 861, SEQ ID NO: 1018, SEQ ID NO: 1175, SEQ ID NO: 1332, and SEQ ID NO: 1489, respectively; lxxvii. SEQ ID NO: 705, SEQ ID NO: 862, SEQ ID NO: 1019, SEQ ID NO: 1176, SEQ ID NO: 1333, and SEQ ID NO: 1490, respectively; lxxviii. SEQ ID NO: 706, SEQ ID NO: 863, SEQ ID NO: 1020, SEQ ID NO: 1177, SEQ ID NO: 1334, and SEQ ID NO: 1491, respectively; lxxix. SEQ ID NO: 707, SEQ ID NO: 864, SEQ ID NO: 1021, SEQ ID NO: 1178, SEQ ID NO: 1335, and SEQ ID NO: 1492, respectively; lxxx. SEQ ID NO: 708, SEQ ID NO: 865, SEQ ID NO: 1022, SEQ ID NO: 1179, SEQ ID NO: 1336, and SEQ ID NO: 1493, respectively; lxxxi. SEQ ID NO: 709, SEQ ID NO: 866, SEQ ID NO: 1023, SEQ ID NO: 1180, SEQ ID NO: 1337, and SEQ ID NO: 1494, respectively; lxxxii. SEQ ID NO: 710, SEQ ID NO: 867, SEQ ID NO: 1024, SEQ ID NO: 1181, SEQ ID NO: 1338, and SEQ ID NO: 1495, respectively; lxxxiii. SEQ ID NO: 711, SEQ ID NO: 868, SEQ ID NO: 1025, SEQ ID NO: 1182, SEQ ID NO: 1339, and SEQ ID NO: 1496, respectively; lxxxiv. SEQ ID NO: 712, SEQ ID NO: 869, SEQ ID NO: 1026, SEQ ID NO: 1183, SEQ ID NO: 1340, and SEQ ID NO: 1497, respectively; lxxxv. SEQ ID NO: 713, SEQ ID NO: 870, SEQ ID NO: 1027, SEQ ID NO: 1184, SEQ ID NO: 1341, and SEQ ID NO: 1498, respectively; lxxxvi. SEQ ID NO: 714, SEQ ID NO: 871, SEQ ID NO: 1028, SEQ ID NO: 1185, SEQ ID NO: 1342, and SEQ ID NO: 1499, respectively; lxxxvii. SEQ ID NO: 715, SEQ ID NO: 872, SEQ ID NO: 1029, SEQ ID NO: 1186, SEQ ID NO: 1343, and SEQ ID NO: 1500, respectively; lxxxviii. SEQ ID NO: 716, SEQ ID NO: 873, SEQ ID NO: 1030, SEQ ID NO: 1187, SEQ ID NO: 1344, and SEQ ID NO: 1501, respectively; lxxxix. SEQ ID NO: 717, SEQ ID NO: 874, SEQ ID NO: 1031, SEQ ID NO: 1188, SEQ ID NO: 1345, and SEQ ID NO: 1502, respectively; xc. SEQ ID NO: 718, SEQ ID NO: 875, SEQ ID NO: 1032, SEQ ID NO: 1189, SEQ ID NO: 1346, and SEQ ID NO: 1503, respectively; xci. SEQ ID NO: 719, SEQ ID NO: 876, SEQ ID NO: 1033, SEQ ID NO: 1190, SEQ ID NO: 1347, and SEQ ID NO: 1504, respectively; xcii. SEQ ID NO: 720, SEQ ID NO: 877, SEQ ID NO: 1034, SEQ ID NO: 1191, SEQ ID NO: 1348, and SEQ ID NO: 1505, respectively; xciii. SEQ ID NO: 721, SEQ ID NO: 878, SEQ ID NO: 1035, SEQ ID NO: 1192, SEQ ID NO: 1349, and SEQ ID NO: 1506, respectively; xciv. SEQ ID NO: 722, SEQ ID NO: 879, SEQ ID NO: 1036, SEQ ID NO: 1193, SEQ ID NO: 1350, and SEQ ID NO: 1507, respectively; xcv. SEQ ID NO: 723, SEQ ID NO: 880, SEQ ID NO: 1037, SEQ ID NO: 1194, SEQ ID NO: 1351, and SEQ ID NO: 1508, respectively; xcvi. SEQ ID NO: 724, SEQ ID NO: 881, SEQ ID NO: 1038, SEQ ID NO: 1195, SEQ ID NO: 1352, and SEQ ID NO: 1509, respectively; xcvii. SEQ ID NO: 725, SEQ ID NO: 882, SEQ ID NO: 1039, SEQ ID NO: 1196, SEQ ID NO: 1353, and SEQ ID NO: 1510, respectively; xcviii. SEQ ID NO: 726, SEQ ID NO: 883, SEQ ID NO: 1040, SEQ ID NO: 1197, SEQ ID NO: 1354, and SEQ ID NO: 1511, respectively; xcix. SEQ ID NO: 727, SEQ ID NO: 884, SEQ ID NO: 1041, SEQ ID NO: 1198, SEQ ID NO: 1355, and SEQ ID NO: 1512, respectively; c. SEQ ID NO: 728, SEQ ID NO: 885, SEQ ID NO: 1042, SEQ ID NO: 1199, SEQ ID NO: 1356, and SEQ ID NO: 1513, respectively; ci. SEQ ID NO: 729, SEQ ID NO: 886, SEQ ID NO: 1043, SEQ ID NO: 1200, SEQ ID NO: 1357, and SEQ ID NO: 1514, respectively; cii. SEQ ID NO: 730, SEQ ID NO: 887, SEQ ID NO: 1044, SEQ ID NO: 1201, SEQ ID NO: 1358, and SEQ ID NO: 1515, respectively; ciii. SEQ ID NO: 731, SEQ ID NO: 888, SEQ ID NO: 1045, SEQ ID NO: 1202, SEQ ID NO: 1359, and SEQ ID NO: 1516, respectively; civ. SEQ ID NO: 732, SEQ ID NO: 889, SEQ ID NO: 1046, SEQ ID NO: 1203, SEQ ID NO: 1360, and SEQ ID NO: 1517, respectively; cv. SEQ ID NO: 733, SEQ ID NO: 890, SEQ ID NO: 1047, SEQ ID NO: 1204, SEQ ID NO: 1361, and SEQ ID NO: 1518, respectively; cvi. SEQ ID NO: 734, SEQ ID NO: 891, SEQ ID NO: 1048, SEQ ID NO: 1205, SEQ ID NO: 1362, and SEQ ID NO: 1519, respectively; cvii. SEQ ID NO: 735, SEQ ID NO: 892, SEQ ID NO: 1049, SEQ ID NO: 1206, SEQ ID NO: 1363, and SEQ ID NO: 1520, respectively; cviii. SEQ ID NO: 736, SEQ ID NO: 893, SEQ ID NO: 1050, SEQ ID NO: 1207, SEQ ID NO: 1364, and SEQ ID NO: 1521, respectively; cix. SEQ ID NO: 737, SEQ ID NO: 894, SEQ ID NO: 1051, SEQ ID NO: 1208, SEQ ID NO: 1365, and SEQ ID NO: 1522, respectively; cx. SEQ ID NO: 738, SEQ ID NO: 895, SEQ ID NO: 1052, SEQ ID NO: 1209, SEQ ID NO: 1366, and SEQ ID NO: 1523, respectively; cxi. SEQ ID NO: 739, SEQ ID NO: 896, SEQ ID NO: 1053, SEQ ID NO: 1210, SEQ ID NO: 1367, and SEQ ID NO: 1524, respectively; cxii. SEQ ID NO: 740, SEQ ID NO: 897, SEQ ID NO: 1054, SEQ ID NO: 1211, SEQ ID NO: 1368, and SEQ ID NO: 1525, respectively; cxiii. SEQ ID NO: 741, SEQ ID NO: 898, SEQ ID NO: 1055, SEQ ID NO: 1212, SEQ ID NO: 1369, and SEQ ID NO: 1526, respectively; cxiv. SEQ ID NO: 742, SEQ ID NO: 899, SEQ ID NO: 1056, SEQ ID NO: 1213, SEQ ID NO: 1370, and SEQ ID NO: 1527, respectively; cxv. SEQ ID NO: 743, SEQ ID NO: 900, SEQ ID NO: 1057, SEQ ID NO: 1214, SEQ ID NO: 1371, and SEQ ID NO: 1528, respectively; cxvi. SEQ ID NO: 744, SEQ ID NO: 901, SEQ ID NO: 1058, SEQ ID NO: 1215, SEQ ID NO: 1372, and SEQ ID NO: 1529, respectively; cxvii. SEQ ID NO: 745, SEQ ID NO: 902, SEQ ID NO: 1059, SEQ ID NO: 1216, SEQ ID NO: 1373, and SEQ ID NO: 1530, respectively; cxviii. SEQ ID NO: 746, SEQ ID NO: 903, SEQ ID NO: 1060, SEQ ID NO: 1217, SEQ ID NO: 1374, and SEQ ID NO: 1531, respectively; cxix. SEQ ID NO: 747, SEQ ID NO: 904, SEQ ID NO: 1061, SEQ ID NO: 1218, SEQ ID NO: 1375, and SEQ ID NO: 1532, respectively; cxx. SEQ ID NO: 748, SEQ ID NO: 905, SEQ ID NO: 1062, SEQ ID NO: 1219, SEQ ID NO: 1376, and SEQ ID NO: 1533, respectively; cxxi. SEQ ID NO: 749, SEQ ID NO: 906, SEQ ID NO: 1063, SEQ ID NO: 1220, SEQ ID NO: 1377, and SEQ ID NO: 1534, respectively; cxxii. SEQ ID NO: 750, SEQ ID NO: 907, SEQ ID NO: 1064, SEQ ID NO: 1221, SEQ ID NO: 1378, and SEQ ID NO: 1535, respectively; cxxiii. SEQ ID NO: 751, SEQ ID NO: 908, SEQ ID NO: 1065, SEQ ID NO: 1222, SEQ ID NO: 1379, and SEQ ID NO: 1536, respectively; cxxiv. SEQ ID NO: 752, SEQ ID NO: 909, SEQ ID NO: 1066, SEQ ID NO: 1223, SEQ ID NO: 1380, and SEQ ID NO: 1537, respectively; cxxv. SEQ ID NO: 753, SEQ ID NO: 910, SEQ ID NO: 1067, SEQ ID NO: 1224, SEQ ID NO: 1381, and SEQ ID NO: 1538, respectively; cxxvi. SEQ ID NO: 754, SEQ ID NO: 911, SEQ ID NO: 1068, SEQ ID NO: 1225, SEQ ID NO: 1382, and SEQ ID NO: 1539, respectively; cxxvii. SEQ ID NO: 755, SEQ ID NO: 912, SEQ ID NO: 1069, SEQ ID NO: 1226, SEQ ID NO: 1383, and SEQ ID NO: 1540, respectively; cxxviii. SEQ ID NO: 756, SEQ ID NO: 913, SEQ ID NO: 1070, SEQ ID NO: 1227, SEQ ID NO: 1384, and SEQ ID NO: 1541, respectively; cxxix. SEQ ID NO: 757, SEQ ID NO: 914, SEQ ID NO: 1071, SEQ ID NO: 1228, SEQ ID NO: 1385, and SEQ ID NO: 1542, respectively; cxxx. SEQ ID NO: 758, SEQ ID NO: 915, SEQ ID NO: 1072, SEQ ID NO: 1229, SEQ ID NO: 1386, and SEQ ID NO: 1543, respectively; cxxxi. SEQ ID NO: 759, SEQ ID NO: 916, SEQ ID NO: 1073, SEQ ID NO: 1230, SEQ ID NO: 1387, and SEQ ID NO: 1544, respectively; cxxxii. SEQ ID NO: 760, SEQ ID NO: 917, SEQ ID NO: 1074, SEQ ID NO: 1231, SEQ ID NO: 1388, and SEQ ID NO: 1545, respectively; cxxxiii. SEQ ID NO: 761, SEQ ID NO: 918, SEQ ID NO: 1075, SEQ ID NO: 1232, SEQ ID NO: 1389, and SEQ ID NO: 1546, respectively; cxxxiv. SEQ ID NO: 762, SEQ ID NO: 919, SEQ ID NO: 1076, SEQ ID NO: 1233, SEQ ID NO: 1390, and SEQ ID NO: 1547, respectively; cxxxv. SEQ ID NO: 763, SEQ ID NO: 920, SEQ ID NO: 1077, SEQ ID NO: 1234, SEQ ID NO: 1391, and SEQ ID NO: 1548, respectively; cxxxvi. SEQ ID NO: 764, SEQ ID NO: 921, SEQ ID NO: 1078, SEQ ID NO: 1235, SEQ ID NO: 1392, and SEQ ID NO: 1549, respectively; cxxxvii. SEQ ID NO: 765, SEQ ID NO: 922, SEQ ID NO: 1079, SEQ ID NO: 1236, SEQ ID NO: 1393, and SEQ ID NO: 1550, respectively; cxxxviii. SEQ ID NO: 766, SEQ ID NO: 923, SEQ ID NO: 1080, SEQ ID NO: 1237, SEQ ID NO: 1394, and SEQ ID NO: 1551, respectively; cxxxix. SEQ ID NO: 767, SEQ ID NO: 924, SEQ ID NO: 1081, SEQ ID NO: 1238, SEQ ID NO: 1395, and SEQ ID NO: 1552, respectively; cxl. SEQ ID NO: 768, SEQ ID NO: 925, SEQ ID NO: 1082, SEQ ID NO: 1239, SEQ ID NO: 1396, and SEQ ID NO: 1553, respectively; cxli. SEQ ID NO: 769, SEQ ID NO: 926, SEQ ID NO: 1083, SEQ ID NO: 1240, SEQ ID NO: 1397, and SEQ ID NO: 1554, respectively; cxlii. SEQ ID NO: 770, SEQ ID NO: 927, SEQ ID NO: 1084, SEQ ID NO: 1241, SEQ ID NO: 1398, and SEQ ID NO: 1555, respectively; cxliii. SEQ ID NO: 771, SEQ ID NO: 928, SEQ ID NO: 1085, SEQ ID NO: 1242, SEQ ID NO: 1399, and SEQ ID NO: 1556, respectively; cxliv. SEQ ID NO: 772, SEQ ID NO: 929, SEQ ID NO: 1086, SEQ ID NO: 1243, SEQ ID NO: 1400, and SEQ ID NO: 1557, respectively; cxlv. SEQ ID NO: 773, SEQ ID NO: 930, SEQ ID NO: 1087, SEQ ID NO: 1244, SEQ ID NO: 1401, and SEQ ID NO: 1558, respectively; cxlvi. SEQ ID NO: 774, SEQ ID NO: 931, SEQ ID NO: 1088, SEQ ID NO: 1245, SEQ ID NO: 1402, and SEQ ID NO: 1559, respectively; cxlvii. SEQ ID NO: 775, SEQ ID NO: 932, SEQ ID NO: 1089, SEQ ID NO: 1246, SEQ ID NO: 1403, and SEQ ID NO: 1560, respectively; cxlviii. SEQ ID NO: 776, SEQ ID NO: 933, SEQ ID NO: 1090, SEQ ID NO: 1247, SEQ ID NO: 1404, and SEQ ID NO: 1561, respectively; cxlix. SEQ ID NO: 777, SEQ ID NO: 934, SEQ ID NO: 1091, SEQ ID NO: 1248, SEQ ID NO: 1405, and SEQ ID NO: 1562, respectively; cl. SEQ ID NO: 778, SEQ ID NO: 935, SEQ ID NO: 1092, SEQ ID NO: 1249, SEQ ID NO: 1406, and SEQ ID NO: 1563, respectively; cli. SEQ ID NO: 779, SEQ ID NO: 936, SEQ ID NO: 1093, SEQ ID NO: 1250, SEQ ID NO: 1407, and SEQ ID NO: 1564, respectively; clii. SEQ ID NO: 780, SEQ ID NO: 937, SEQ ID NO: 1094, SEQ ID NO: 1251, SEQ ID NO: 1408, and SEQ ID NO: 1565, respectively; cliii. SEQ ID NO: 781, SEQ ID NO: 938, SEQ ID NO: 1095, SEQ ID NO: 1252, SEQ ID NO: 1409, and SEQ ID NO: 1566, respectively; cliv. SEQ ID NO: 782, SEQ ID NO: 939, SEQ ID NO: 1096, SEQ ID NO: 1253, SEQ ID NO: 1410, and SEQ ID NO: 1567, respectively; clv. SEQ ID NO: 783, SEQ ID NO: 940, SEQ ID NO: 1097, SEQ ID NO: 1254, SEQ ID NO: 1411, and SEQ ID NO: 1568, respectively; clvi. SEQ ID NO: 784, SEQ ID NO: 941, SEQ ID NO: 1098, SEQ ID NO: 1255, SEQ ID NO: 1412, and SEQ ID NO: 1569, respectively; and clvii. SEQ ID NO: 785, SEQ ID NO: 942, SEQ ID NO: 1099, SEQ ID NO: 1256, SEQ ID NO: 1413, and SEQ ID NO: 1570, respectively,preferably wherein the CDRL1, the CDRL2, the CDRL3, the CDRH1, the CDRH2, and the CDRH3 comprise the amino acid sequences of SEQ ID NO: 702, SEQ ID NO: 859, SEQ ID NO: 1016, SEQ ID NO: 1173, SEQ ID NO: 1330, and SEQ ID NO: 1487, respectively. E192. The molecule of any one of E151E191, wherein the antibody comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region and the heavy chain variable region comprise amino acid sequences selected from:i. SEQ ID NO: 1 and SEQ ID NO: 158, respectively; ii. SEQ ID NO: 2 and SEQ ID NO: 159, respectively; iii. SEQ ID NO: 3 and SEQ ID NO: 160, respectively; iv. SEQ ID NO: 4 and SEQ ID NO: 161, respectively; v. SEQ ID NO: 5 and SEQ ID NO: 162, respectively; vi. SEQ ID NO: 6 and SEQ ID NO: 163, respectively; vii. SEQ ID NO: 7 and SEQ ID NO: 164, respectively; viii. SEQ ID NO: 8 and SEQ ID NO: 165, respectively; ix. SEQ ID NO: 9 and SEQ ID NO: 166, respectively; x. SEQ ID NO: 10 and SEQ ID NO: 167, respectively; xi. SEQ ID NO: 11 and SEQ ID NO: 168, respectively; xii. SEQ ID NO: 12 and SEQ ID NO: 169, respectively; xiii. SEQ ID NO: 13 and SEQ ID NO: 170, respectively; xiv. SEQ ID NO: 14 and SEQ ID NO: 171, respectively; xv. SEQ ID NO: 15 and SEQ ID NO: 172, respectively; xvi. SEQ ID NO: 16 and SEQ ID NO: 173, respectively; xvii. SEQ ID NO: 17 and SEQ ID NO: 174, respectively; xviii. SEQ ID NO: 18 and SEQ ID NO: 175, respectively; xix. SEQ ID NO: 19 and SEQ ID NO: 176, respectively; xx. SEQ ID NO: 20 and SEQ ID NO: 177, respectively; xxi. SEQ ID NO: 21 and SEQ ID NO: 178, respectively; xxii. SEQ ID NO: 22 and SEQ ID NO: 179, respectively; xxiii. SEQ ID NO: 23 and SEQ ID NO: 180, respectively; xxiv. SEQ ID NO: 24 and SEQ ID NO: 181, respectively; xxv. SEQ ID NO: 25 and SEQ ID NO: 182, respectively; xxvi. SEQ ID NO: 26 and SEQ ID NO: 183, respectively; xxvii. SEQ ID NO: 27 and SEQ ID NO: 184, respectively; xxviii. SEQ ID NO: 28 and SEQ ID NO: 185, respectively; xxix. SEQ ID NO: 29 and SEQ ID NO: 186, respectively; xxx. SEQ ID NO: 30 and SEQ ID NO: 187, respectively; xxxi. SEQ ID NO: 31 and SEQ ID NO: 188, respectively; xxxii. SEQ ID NO: 32 and SEQ ID NO: 189, respectively; xxxiii. SEQ ID NO: 33 and SEQ ID NO: 190, respectively; xxxiv. SEQ ID NO: 34 and SEQ ID NO: 191, respectively; xxxv. SEQ ID NO: 35 and SEQ ID NO: 192, respectively; xxxvi. SEQ ID NO: 36 and SEQ ID NO: 193, respectively; xxxvii. SEQ ID NO: 37 and SEQ ID NO: 194, respectively; xxxviii. SEQ ID NO: 38 and SEQ ID NO: 195, respectively; xxxix. SEQ ID NO: 39 and SEQ ID NO: 196, respectively; xl. SEQ ID NO: 40 and SEQ ID NO: 197, respectively; xli. SEQ ID NO: 41 and SEQ ID NO: 198, respectively; xlii. SEQ ID NO: 42 and SEQ ID NO: 199, respectively; xliii. SEQ ID NO: 43 and SEQ ID NO: 200, respectively; xliv. SEQ ID NO: 44 and SEQ ID NO: 201, respectively; xlv. SEQ ID NO: 45 and SEQ ID NO: 202, respectively; xlvi. SEQ ID NO: 46 and SEQ ID NO: 203, respectively; xlvii. SEQ ID NO: 47 and SEQ ID NO: 204, respectively; xlviii. SEQ ID NO: 48 and SEQ ID NO: 205, respectively; xlix. SEQ ID NO: 49 and SEQ ID NO: 206, respectively; l. SEQ ID NO: 50 and SEQ ID NO: 207, respectively; li. SEQ ID NO: 51 and SEQ ID NO: 208, respectively; lii. SEQ ID NO: 52 and SEQ ID NO: 209, respectively; liii. SEQ ID NO: 53 and SEQ ID NO: 210, respectively; liv. SEQ ID NO: 54 and SEQ ID NO: 211, respectively; lv. SEQ ID NO: 55 and SEQ ID NO: 212, respectively; lvi. SEQ ID NO: 56 and SEQ ID NO: 213, respectively; lvii. SEQ ID NO: 57 and SEQ ID NO: 214, respectively; lviii. SEQ ID NO: 58 and SEQ ID NO: 215, respectively; lix. SEQ ID NO: 59 and SEQ ID NO: 216, respectively; lx. SEQ ID NO: 60 and SEQ ID NO: 217, respectively; lxi. SEQ ID NO: 61 and SEQ ID NO: 218, respectively; lxii. SEQ ID NO: 62 and SEQ ID NO: 219, respectively; lxiii. SEQ ID NO: 63 and SEQ ID NO: 220, respectively; lxiv. SEQ ID NO: 64 and SEQ ID NO: 221, respectively; lxv. SEQ ID NO: 65 and SEQ ID NO: 222, respectively; lxvi. SEQ ID NO: 66 and SEQ ID NO: 223, respectively; lxvii. SEQ ID NO: 67 and SEQ ID NO: 224, respectively; lxviii. SEQ ID NO: 68 and SEQ ID NO: 225, respectively; lxix. SEQ ID NO: 69 and SEQ ID NO: 226, respectively; lxx. SEQ ID NO: 70 and SEQ ID NO: 227, respectively; lxxi. SEQ ID NO: 71 and SEQ ID NO: 228, respectively; lxxii. SEQ ID NO: 72 and SEQ ID NO: 229, respectively; lxxiii. SEQ ID NO: 73 and SEQ ID NO: 230, respectively; lxxiv. SEQ ID NO: 74 and SEQ ID NO: 231, respectively; lxxv. SEQ ID NO: 75 and SEQ ID NO: 232, respectively; lxxvi. SEQ ID NO: 76 and SEQ ID NO: 233, respectively; lxxvii. SEQ ID NO: 77 and SEQ ID NO: 234, respectively; lxxviii. SEQ ID NO: 78 and SEQ ID NO: 235, respectively; lxxix. SEQ ID NO: 79 and SEQ ID NO: 236, respectively; lxxx. SEQ ID NO: 80 and SEQ ID NO: 237, respectively; lxxxi. SEQ ID NO: 81 and SEQ ID NO: 238, respectively; lxxxii. SEQ ID NO: 82 and SEQ ID NO: 239, respectively; lxxxiii. SEQ ID NO: 83 and SEQ ID NO: 240, respectively; lxxxiv. SEQ ID NO: 84 and SEQ ID NO: 241, respectively; lxxxv. SEQ ID NO: 85 and SEQ ID NO: 242, respectively; lxxxvi. SEQ ID NO: 86 and SEQ ID NO: 243, respectively; lxxxvii. SEQ ID NO: 87 and SEQ ID NO: 244, respectively; lxxxviii. SEQ ID NO: 88 and SEQ ID NO: 245, respectively; lxxxix. SEQ ID NO: 89 and SEQ ID NO: 246, respectively; xc. SEQ ID NO: 90 and SEQ ID NO: 247, respectively; xci. SEQ ID NO: 91 and SEQ ID NO: 248, respectively; xcii. SEQ ID NO: 92 and SEQ ID NO: 249, respectively; xciii. SEQ ID NO: 93 and SEQ ID NO: 250, respectively; xciv. SEQ ID NO: 94 and SEQ ID NO: 251, respectively; xcv. SEQ ID NO: 95 and SEQ ID NO: 252, respectively; xcvi. SEQ ID NO: 96 and SEQ ID NO: 253, respectively; xcvii. SEQ ID NO: 97 and SEQ ID NO: 254, respectively; xcviii. SEQ ID NO: 98 and SEQ ID NO: 255, respectively; xcix. SEQ ID NO: 99 and SEQ ID NO: 256, respectively; c. SEQ ID NO: 100 and SEQ ID NO: 257, respectively; ci. SEQ ID NO: 101 and SEQ ID NO: 258, respectively; cii. SEQ ID NO: 102 and SEQ ID NO: 259, respectively; ciii. SEQ ID NO: 103 and SEQ ID NO: 260, respectively; civ. SEQ ID NO: 104 and SEQ ID NO: 261, respectively; cv. SEQ ID NO: 105 and SEQ ID NO: 262, respectively; cvi. SEQ ID NO: 106 and SEQ ID NO: 263, respectively; cvii. SEQ ID NO: 107 and SEQ ID NO: 264, respectively; cviii. SEQ ID NO: 108 and SEQ ID NO: 265, respectively; cix. SEQ ID NO: 109 and SEQ ID NO: 266, respectively; cx. SEQ ID NO: 110 and SEQ ID NO: 267, respectively; cxi. SEQ ID NO: 111 and SEQ ID NO: 268, respectively; cxii. SEQ ID NO: 112 and SEQ ID NO: 269, respectively; cxiii. SEQ ID NO: 113 and SEQ ID NO: 270, respectively; cxiv. SEQ ID NO: 114 and SEQ ID NO: 271, respectively; cxv. SEQ ID NO: 115 and SEQ ID NO: 272, respectively; cxvi. SEQ ID NO: 116 and SEQ ID NO: 273, respectively; cxvii. SEQ ID NO: 117 and SEQ ID NO: 274, respectively; cxviii. SEQ ID NO: 118 and SEQ ID NO: 275, respectively; cxix. SEQ ID NO: 119 and SEQ ID NO: 276, respectively; cxx. SEQ ID NO: 120 and SEQ ID NO: 277, respectively; cxxi. SEQ ID NO: 121 and SEQ ID NO: 278, respectively; cxxii. SEQ ID NO: 122 and SEQ ID NO: 279, respectively; cxxiii. SEQ ID NO: 123 and SEQ ID NO: 280, respectively; cxxiv. SEQ ID NO: 124 and SEQ ID NO: 281, respectively; cxxv. SEQ ID NO: 125 and SEQ ID NO: 282, respectively; cxxvi. SEQ ID NO: 126 and SEQ ID NO: 283, respectively; cxxvii. SEQ ID NO: 127 and SEQ ID NO: 284, respectively; cxxviii. SEQ ID NO: 128 and SEQ ID NO: 285, respectively; cxxix. SEQ ID NO: 129 and SEQ ID NO: 286, respectively; cxxx. SEQ ID NO: 130 and SEQ ID NO: 287, respectively; cxxxi. SEQ ID NO: 131 and SEQ ID NO: 288, respectively; cxxxii. SEQ ID NO: 132 and SEQ ID NO: 289, respectively; cxxxiii. SEQ ID NO: 133 and SEQ ID NO: 290, respectively; cxxxiv. SEQ ID NO: 134 and SEQ ID NO: 291, respectively; cxxxv. SEQ ID NO: 135 and SEQ ID NO: 292, respectively; cxxxvi. SEQ ID NO: 136 and SEQ ID NO: 293, respectively; cxxxvii. SEQ ID NO: 137 and SEQ ID NO: 294, respectively; cxxxviii. SEQ ID NO: 138 and SEQ ID NO: 295, respectively; cxxxix. SEQ ID NO: 139 and SEQ ID NO: 296, respectively; cxl. SEQ ID NO: 140 and SEQ ID NO: 297, respectively; cxli. SEQ ID NO: 141 and SEQ ID NO: 298, respectively; cxlii. SEQ ID NO: 142 and SEQ ID NO: 299, respectively; cxliii. SEQ ID NO: 143 and SEQ ID NO: 300, respectively; cxliv. SEQ ID NO: 144 and SEQ ID NO: 301, respectively; cxlv. SEQ ID NO: 145 and SEQ ID NO: 302, respectively; cxlvi. SEQ ID NO: 146 and SEQ ID NO: 303, respectively; cxlvii. SEQ ID NO: 147 and SEQ ID NO: 304, respectively; cxlviii. SEQ ID NO: 148 and SEQ ID NO: 305, respectively; cxlix. SEQ ID NO: 149 and SEQ ID NO: 306, respectively; cl. SEQ ID NO: 150 and SEQ ID NO: 307, respectively; cli. SEQ ID NO: 151 and SEQ ID NO: 308, respectively; clii. SEQ ID NO: 152 and SEQ ID NO: 309, respectively; cliii. SEQ ID NO: 153 and SEQ ID NO: 310, respectively; cliv. SEQ ID NO: 154 and SEQ ID NO: 311, respectively; clv. SEQ ID NO: 155 and SEQ ID NO: 312, respectively; clvi. SEQ ID NO: 156 and SEQ ID NO: 313, respectively; and clvii. SEQ ID NO: 157 and SEQ ID NO: 314, respectively,preferably wherein the light chain variable region and the heavy chain variable region comprise the amino acid sequences of SEQ ID NO: 74 and SEQ ID NO: 231, respectively. E193. The molecule of any one of E151167, E169E187, E188, E189, E191, or E192, wherein the antibody comprises a light chain and a heavy chain, wherein the light chain and heavy chain comprise amino acid sequences selected from:i. SEQ ID NO: 315 and SEQ ID NO: 472, respectively; ii. SEQ ID NO: 316 and SEQ ID NO: 473, respectively; iii. SEQ ID NO: 317 and SEQ ID NO: 474, respectively; iv. SEQ ID NO: 318 and SEQ ID NO: 475, respectively; v. SEQ ID NO: 319 and SEQ ID NO: 476, respectively; vi. SEQ ID NO: 320 and SEQ ID NO: 477, respectively; vii. SEQ ID NO: 321 and SEQ ID NO: 478, respectively; viii. SEQ ID NO: 322 and SEQ ID NO: 479, respectively; ix. SEQ ID NO: 323 and SEQ ID NO: 480, respectively; x. SEQ ID NO: 324 and SEQ ID NO: 481, respectively; xi. SEQ ID NO: 325 and SEQ ID NO: 482, respectively; xii. SEQ ID NO: 326 and SEQ ID NO: 483, respectively; xiii. SEQ ID NO: 327 and SEQ ID NO: 484, respectively; xiv. SEQ ID NO: 328 and SEQ ID NO: 485, respectively; xv. SEQ ID NO: 329 and SEQ ID NO: 486, respectively; xvi. SEQ ID NO: 330 and SEQ ID NO: 487, respectively; xvii. SEQ ID NO: 331 and SEQ ID NO: 488, respectively; xviii. SEQ ID NO: 332 and SEQ ID NO: 489, respectively; xix. SEQ ID NO: 333 and SEQ ID NO: 490, respectively; xx. SEQ ID NO: 334 and SEQ ID NO: 491, respectively; xxi. SEQ ID NO: 335 and SEQ ID NO: 492, respectively; xxii. SEQ ID NO: 336 and SEQ ID NO: 493, respectively; xxiii. SEQ ID NO: 337 and SEQ ID NO: 494, respectively; xxiv. SEQ ID NO: 338 and SEQ ID NO: 495, respectively; xxv. SEQ ID NO: 339 and SEQ ID NO: 496, respectively; xxvi. SEQ ID NO: 340 and SEQ ID NO: 497, respectively; xxvii. SEQ ID NO: 341 and SEQ ID NO: 498, respectively; xxviii. SEQ ID NO: 342 and SEQ ID NO: 499, respectively; xxix. SEQ ID NO: 343 and SEQ ID NO: 500, respectively; xxx. SEQ ID NO: 344 and SEQ ID NO: 501, respectively; xxxi. SEQ ID NO: 345 and SEQ ID NO: 502, respectively; xxxii. SEQ ID NO: 346 and SEQ ID NO: 503, respectively; xxxiii. SEQ ID NO: 347 and SEQ ID NO: 504, respectively; xxxiv. SEQ ID NO: 348 and SEQ ID NO: 505, respectively; xxxv. SEQ ID NO: 349 and SEQ ID NO: 506, respectively; xxxvi. SEQ ID NO: 350 and SEQ ID NO: 507, respectively; xxxvii. SEQ ID NO: 351 and SEQ ID NO: 508, respectively; xxxviii. SEQ ID NO: 352 and SEQ ID NO: 509, respectively; xxxix. SEQ ID NO: 353 and SEQ ID NO: 510, respectively; xl. SEQ ID NO: 354 and SEQ ID NO: 511, respectively; xli. SEQ ID NO: 355 and SEQ ID NO: 512, respectively; xlii. SEQ ID NO: 356 and SEQ ID NO: 513, respectively; xliii. SEQ ID NO: 357 and SEQ ID NO: 514, respectively; xliv. SEQ ID NO: 358 and SEQ ID NO: 515, respectively; xlv. SEQ ID NO: 359 and SEQ ID NO: 516, respectively; xlvi. SEQ ID NO: 360 and SEQ ID NO: 517, respectively; xlvii. SEQ ID NO: 361 and SEQ ID NO: 518, respectively; xlviii. SEQ ID NO: 362 and SEQ ID NO: 519, respectively; xlix. SEQ ID NO: 363 and SEQ ID NO: 520, respectively; l. SEQ ID NO: 364 and SEQ ID NO: 521, respectively; li. SEQ ID NO: 365 and SEQ ID NO: 522, respectively; lii. SEQ ID NO: 366 and SEQ ID NO: 523, respectively; liii. SEQ ID NO: 367 and SEQ ID NO: 524, respectively; liv. SEQ ID NO: 368 and SEQ ID NO: 525, respectively; lv. SEQ ID NO: 369 and SEQ ID NO: 526, respectively; lvi. SEQ ID NO: 370 and SEQ ID NO: 527, respectively; lvii. SEQ ID NO: 371 and SEQ ID NO: 528, respectively; lviii. SEQ ID NO: 372 and SEQ ID NO: 529, respectively;lix. SEQ ID NO: 373 and SEQ ID NO: 530, respectively; lx. SEQ ID NO: 374 and SEQ ID NO: 531, respectively; lxi. SEQ ID NO: 375 and SEQ ID NO: 532, respectively; lxii. SEQ ID NO: 376 and SEQ ID NO: 533, respectively; lxiii. SEQ ID NO: 377 and SEQ ID NO: 534, respectively; lxiv. SEQ ID NO: 378 and SEQ ID NO: 535, respectively; lxv. SEQ ID NO: 379 and SEQ ID NO: 536, respectively; lxvi. SEQ ID NO: 380 and SEQ ID NO: 537, respectively; lxvii. SEQ ID NO: 381 and SEQ ID NO: 538, respectively; lxviii. SEQ ID NO: 382 and SEQ ID NO: 539, respectively; lxix. SEQ ID NO: 383 and SEQ ID NO: 540, respectively; lxx. SEQ ID NO: 384 and SEQ ID NO: 541, respectively; lxxi. SEQ ID NO: 385 and SEQ ID NO: 542, respectively; lxxii. SEQ ID NO: 386 and SEQ ID NO: 543, respectively; lxxiii. SEQ ID NO: 387 and SEQ ID NO: 544, respectively; lxxiv. SEQ ID NO: 388 and SEQ ID NO: 545, respectively; lxxv. SEQ ID NO: 389 and SEQ ID NO: 546, respectively; lxxvi. SEQ ID NO: 390 and SEQ ID NO: 547, respectively; lxxvii. SEQ ID NO: 391 and SEQ ID NO: 548, respectively; lxxviii. SEQ ID NO: 392 and SEQ ID NO: 549, respectively; lxxix. SEQ ID NO: 393 and SEQ ID NO: 550, respectively; lxxx. SEQ ID NO: 394 and SEQ ID NO: 551, respectively; lxxxi. SEQ ID NO: 395 and SEQ ID NO: 552, respectively; lxxxii. SEQ ID NO: 396 and SEQ ID NO: 553, respectively; lxxxiii. SEQ ID NO: 397 and SEQ ID NO: 554, respectively; lxxxiv. SEQ ID NO: 398 and SEQ ID NO: 555, respectively; lxxxv. SEQ ID NO: 399 and SEQ ID NO: 556, respectively; lxxxvi. SEQ ID NO: 400 and SEQ ID NO: 557, respectively; lxxxvii. SEQ ID NO: 401 and SEQ ID NO: 558, respectively; lxxxviii. SEQ ID NO: 402 and SEQ ID NO: 559, respectively; lxxxix. SEQ ID NO: 403 and SEQ ID NO: 560, respectively; xc. SEQ ID NO: 404 and SEQ ID NO: 561, respectively; xci. SEQ ID NO: 405 and SEQ ID NO: 562, respectively; xcii. SEQ ID NO: 406 and SEQ ID NO: 563, respectively; xciii. SEQ ID NO: 407 and SEQ ID NO: 564, respectively; xciv. SEQ ID NO: 408 and SEQ ID NO: 565, respectively; xcv. SEQ ID NO: 409 and SEQ ID NO: 566, respectively; xcvi. SEQ ID NO: 410 and SEQ ID NO: 567, respectively; xcvii. SEQ ID NO: 411 and SEQ ID NO: 568, respectively; xcviii. SEQ ID NO: 412 and SEQ ID NO: 569, respectively; xcix. SEQ ID NO: 413 and SEQ ID NO: 570, respectively; c. SEQ ID NO: 414 and SEQ ID NO: 571, respectively; ci. SEQ ID NO: 415 and SEQ ID NO: 572, respectively; cii. SEQ ID NO: 416 and SEQ ID NO: 573, respectively; ciii. SEQ ID NO: 417 and SEQ ID NO: 574, respectively; civ. SEQ ID NO: 418 and SEQ ID NO: 575, respectively; cv. SEQ ID NO: 419 and SEQ ID NO: 576, respectively; cvi. SEQ ID NO: 420 and SEQ ID NO: 577, respectively; cvii. SEQ ID NO: 421 and SEQ ID NO: 578, respectively; cviii. SEQ ID NO: 422 and SEQ ID NO: 579, respectively; cix. SEQ ID NO: 423 and SEQ ID NO: 580, respectively; cx. SEQ ID NO: 424 and SEQ ID NO: 581, respectively; cxi. SEQ ID NO: 425 and SEQ ID NO: 582, respectively; cxii. SEQ ID NO: 426 and SEQ ID NO: 583, respectively; cxiii. SEQ ID NO: 427 and SEQ ID NO: 584, respectively; cxiv. SEQ ID NO: 428 and SEQ ID NO: 585, respectively; cxv. SEQ ID NO: 429 and SEQ ID NO: 586, respectively; cxvi. SEQ ID NO: 430 and SEQ ID NO: 587, respectively; cxvii. SEQ ID NO: 431 and SEQ ID NO: 588, respectively; cxviii. SEQ ID NO: 432 and SEQ ID NO: 589, respectively; cxix. SEQ ID NO: 433 and SEQ ID NO: 590, respectively; cxx. SEQ ID NO: 434 and SEQ ID NO: 591, respectively; cxxi. SEQ ID NO: 435 and SEQ ID NO: 592, respectively; cxxii. SEQ ID NO: 436 and SEQ ID NO: 593, respectively; cxxiii. SEQ ID NO: 437 and SEQ ID NO: 594, respectively; cxxiv. SEQ ID NO: 438 and SEQ ID NO: 595, respectively; cxxv. SEQ ID NO: 439 and SEQ ID NO: 596, respectively; cxxvi. SEQ ID NO: 440 and SEQ ID NO: 597, respectively; cxxvii. SEQ ID NO: 441 and SEQ ID NO: 598, respectively; cxxviii. SEQ ID NO: 442 and SEQ ID NO: 599, respectively; cxxix. SEQ ID NO: 443 and SEQ ID NO: 600, respectively; cxxx. SEQ ID NO: 444 and SEQ ID NO: 601, respectively; cxxxi. SEQ ID NO: 445 and SEQ ID NO: 602, respectively; cxxxii. SEQ ID NO: 446 and SEQ ID NO: 603, respectively; cxxxiii. SEQ ID NO: 447 and SEQ ID NO: 604, respectively; cxxxiv. SEQ ID NO: 448 and SEQ ID NO: 605, respectively; cxxxv. SEQ ID NO: 449 and SEQ ID NO: 606, respectively; cxxxvi. SEQ ID NO: 450 and SEQ ID NO: 607, respectively; cxxxvii. SEQ ID NO: 451 and SEQ ID NO: 608, respectively;cxxxviii. SEQ ID NO: 452 and SEQ ID NO: 609, respectively; cxxxix. SEQ ID NO: 453 and SEQ ID NO: 610, respectively; cxl. SEQ ID NO: 454 and SEQ ID NO: 611, respectively; cxli. SEQ ID NO: 455 and SEQ ID NO: 612, respectively; cxlii. SEQ ID NO: 456 and SEQ ID NO: 613, respectively; cxliii. SEQ ID NO: 457 and SEQ ID NO: 614, respectively; cxliv. SEQ ID NO: 458 and SEQ ID NO: 615, respectively; cxlv. SEQ ID NO: 459 and SEQ ID NO: 616, respectively; cxlvi. SEQ ID NO: 460 and SEQ ID NO: 617, respectively; cxlvii. SEQ ID NO: 461 and SEQ ID NO: 618, respectively; cxlviii. SEQ ID NO: 462 and SEQ ID NO: 619, respectively; cxlix. SEQ ID NO: 463 and SEQ ID NO: 620, respectively; cl. SEQ ID NO: 464 and SEQ ID NO: 621, respectively; cli. SEQ ID NO: 465 and SEQ ID NO: 622, respectively; clii. SEQ ID NO: 466 and SEQ ID NO: 623, respectively; cliii. SEQ ID NO: 467 and SEQ ID NO: 624, respectively; cliv. SEQ ID NO: 468 and SEQ ID NO: 625, respectively; clv. SEQ ID NO: 469 and SEQ ID NO: 626, respectively; clvi. SEQ ID NO: 470 and SEQ ID NO: 627, respectively; and clvii. SEQ ID NO: 471 and SEQ ID NO: 628, respectively,wherein the antibody comprises one or more cysteine amino acid substitution(s) at one or more position(s) selected from 88 of the light chain, 384 of the heavy chain, or 487 of the heavy chain, according to AHo numbering. E194. The molecule of E193, wherein: the light chain comprises the amino acid sequence of SEQ ID NO: 388 and the heavy chain comprises the amino acid sequence of SEQ ID NO: 1571; orthe light chain comprises the amino acid sequence of SEQ ID NO: 455 and the heavy chain comprises the amino acid sequence of SEQ ID NO: 1572; orthe light chain comprises the amino acid sequence of SEQ ID NO: 389 and the heavy chain comprises the amino acid sequence of SEQ ID NO: 1573; orthe light chain comprises the amino acid sequence of SEQ ID NO: 455 and the heavy chain comprises the amino acid sequence of SEQ ID NO: 1574; orthe light chain comprises the amino acid sequence of SEQ ID NO: 1575 and the heavy chain comprises the amino acid sequence of SEQ ID NO: 612, preferably wherein the light chain comprises the amino acid sequence of SEQ ID NO: 388 and the heavy chain comprises the amino acid sequence of SEQ ID NO: 1571. E195. A molecule comprising:a first polypeptide that agonizes a glucagon receptor (“GCGR”);a first linker polypeptide;an antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”);a second linker polypeptide; anda second polypeptide that agonizes a GCGR, wherein:an εamino group of a lysine residue of the first polypeptide is covalently linked to a Cterminus of the first linker polypeptide; an N-terminus of the first linker polypeptide is conjugated to a cysteine residue of the antibody;an εamino group of a lysine residue of the second polypeptide is covalently linked to a Cterminus of the second linker polypeptide; andan N-terminus of the second linker polypeptide is conjugated to a cysteine residue of the antibody. E196. The molecule of E195, wherein the first linker polypeptide and the second linker polypeptide independently comprise amino acid sequences selected from SEQ ID NOs: 16281683, preferably SEQ ID NOs: 16281630, preferably SEQ ID NO: 1630. E197. The molecule of E195 or E196, wherein the first polypeptide and the second polypeptide independently comprise amino acid sequences selected from SEQ ID NOs: 1587, 1592, 1596, 1615, and 1626. E198. The molecule of any one of E195E197, wherein the first polypeptide has the same amino acid sequence as the second polypeptide. E199. The molecule of any one of E195E198, wherein the first linker polypeptide has the same amino acid sequence as the second linker polypeptide. E200. The molecule of any one of E195E199, wherein: the first polypeptide has the same amino acid sequence as the second polypeptide; andthe first linker polypeptide has the same amino acid sequence as the second linker polypeptide. E201. The molecule of any one of E195E200, wherein the lysine residue of the first polypeptide comprising the εamino group that is covalently linked to the Cterminus of the first linker polypeptide is at position 24 or position 28. E202. The molecule of any one of E195E201, wherein the lysine residue of the second polypeptide comprising the εamino group that is covalently linked to the Cterminus of the second linker polypeptide is at position 24 or position 28. E203. The molecule of any one of E195E202, wherein: the lysine residue of the first polypeptide comprising the εamino group that is covalently linked to the Cterminus of the first linker polypeptide is at position 28; andthe lysine residue of the second polypeptide comprising the εamino group that is covalently linked to the Cterminus of the second linker polypeptide is at position 28. E204. The molecule of any one of E195E203, wherein the cysteine residues of the antibody that are conjugated to the N-termini of the first linker polypeptide and the second linker polypeptide are at positions selected from the group consisting of 88 of both light chains, 384 of both heavy chains, and 487 of both heavy chains, according to AHo numbering. E205. The molecule of E204, wherein the cysteine residues of the antibody that are conjugated to the Ntermini of the first linker polypeptide and the second linker polypeptide are at positions 384 of both heavy chains, according to AHo numbering. E206. The molecule of any one of E195E205, wherein:the lysine residue of the first polypeptide comprising the εamino group that is covalently linked to the Cterminus of the first linker polypeptide is at position 28; the lysine residue of the second polypeptide comprising the εamino group that is covalently linked to the Cterminus of the second linker polypeptide is at position 28; andthe cysteine residues of the antibody that are conjugated to the Ntermini of the first linker polypeptide and the second linker polypeptide are at positions 384 of both heavy chains, according to AHo numbering. E207. The molecule of any one of E195E206, wherein the antibody comprises a CDRL1, a CDRL2, a CDRL3, a CDRH1, a CDRH2, and a CDRH3, wherein the CDRL1, the CDRL2, the CDRL3, the CDRH1, the CDRH2, and the CDRH3 comprise the amino acid sequences of SEQ ID NO: 702, SEQ ID NO: 859, SEQ ID NO: 1016, SEQ ID NO: 1173, SEQ ID NO: 1330, and SEQ ID NO: 1487, respectively. E208. The molecule of any one of E195E207, wherein the antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 74 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 231. E209. The molecule of any one of E195E208, wherein the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 388 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 1571. E210. A molecule comprising:a polypeptide that agonizes a glucagon receptor (“GCGR”) comprising the amino acid sequence of SEQ ID NO: 1615;a linker polypeptide comprising the amino acid sequence of SEQ ID NO: 1629; andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a light chain and a heavy chain, wherein the light chain comprises the amino acid sequence of SEQ ID NO: 388 and the heavy chain comprises the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 28 of the polypeptide is covalently linked to a Cterminus of the linker polypeptide; andan N-terminus of the linker polypeptide is conjugated to a cysteine residue at position 275 of the heavy chain of the antibody. E211. A molecule comprising:a polypeptide that agonizes a glucagon receptor (“GCGR”) comprising the amino acid sequence of SEQ ID NO: 1626;a linker polypeptide comprising the amino acid sequence of SEQ ID NO: 1628; andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a light chain and a heavy chain, wherein the light chain comprises the amino acid sequence of SEQ ID NO: 388 and the heavy chain comprises the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 28 of the polypeptide is covalently linked to a Cterminus of the linker polypeptide; andan N-terminus of the linker polypeptide is conjugated to a cysteine residue at position 275 of the heavy chain of the antibody. E212. A molecule comprising:a polypeptide that agonizes a glucagon receptor (“GCGR”) comprising the amino acid sequence of SEQ ID NO: 1592;a linker polypeptide comprising the amino acid sequence of SEQ ID NO: 1628; andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a light chain and a heavy chain, wherein the light chain comprises the amino acid sequence of SEQ ID NO: 388 and the heavy chain comprises the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 24 of the polypeptide is covalently linked to a Cterminus of the linker polypeptide; andan N-terminus of the linker polypeptide is conjugated to a cysteine residue at position 275 of the heavy chain of the antibody. E213. A molecule comprising:a polypeptide that agonizes a glucagon receptor (“GCGR”) comprising the amino acid sequence of SEQ ID NO: 1626;a linker polypeptide comprising the amino acid sequence of SEQ ID NO: 1629; andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a light chain and a heavy chain, wherein the light chain comprises the amino acid sequence of SEQ ID NO: 388 and the heavy chain comprises the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 28 of the polypeptide is covalently linked to a Cterminus of the linker polypeptide; andan N-terminus of the linker polypeptide is conjugated to a cysteine residue at position 275 of the heavy chain of the antibody. E214. A molecule comprising:a polypeptide that agonizes a glucagon receptor (“GCGR”) comprising the amino acid sequence of SEQ ID NO: 1587;a linker polypeptide comprising the amino acid sequence of SEQ ID NO: 1628; andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a light chain and a heavy chain, wherein the light chain comprises the amino acid sequence of SEQ ID NO: 388 and the heavy chain comprises the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 28 of the polypeptide is covalently linked to a Cterminus of the linker polypeptide; andan N-terminus of the linker polypeptide is conjugated to a cysteine residue at position 275 of the heavy chain of the antibody. E215. A molecule comprising:a polypeptide that agonizes a glucagon receptor (“GCGR”) comprising the amino acid sequence of SEQ ID NO: 1587;a linker polypeptide comprising the amino acid sequence of SEQ ID NO: 1630; andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a light chain and a heavy chain, wherein the light chain comprises the amino acid sequence of SEQ ID NO: 388 and the heavy chain comprises the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 28 of the polypeptide is covalently linked to a Cterminus of the linker polypeptide; andan N-terminus of the linker polypeptide is conjugated to a cysteine residue at position 275 of the heavy chain of the antibody. E216. A molecule comprising:a first polypeptide and a second polypeptide that agonize a glucagon receptor (“GCGR”), wherein the first polypeptide and the second polypeptide each comprise the amino acid sequence of SEQ ID NO: 1615;a first linker polypeptide and a second linker polypeptide, wherein the first linker polypeptide and the second linker polypeptide each comprise the amino acid sequence of SEQ ID NO: 1629; andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a first light chain and a second light chain, wherein the first light chain and the second light chain each comprise the amino acid sequence of SEQ ID NO: 388, and a first heavy chain and a second heavy chain, wherein the first heavy chain and the second heavy chain each comprise the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 28 of the first polypeptide is covalently linked to a Cterminus of the first linker polypeptide; an N-terminus of the first linker polypeptide is conjugated to a cysteine residue at position 275 of the first heavy chain of the antibody;an εamino group of a lysine residue at position 28 of the second polypeptide is covalently linked to a Cterminus of the second linker polypeptide; andan N-terminus of the second linker polypeptide is conjugated to a cysteine residue at position 275 of the second heavy chain of the antibody. E217. A molecule comprising:a first polypeptide and a second polypeptide that agonize a glucagon receptor (“GCGR”), wherein the first polypeptide and the second polypeptide each comprise the amino acid sequence of SEQ ID NO: 1626;a first linker polypeptide and a second linker polypeptide, wherein the first linker polypeptide and the second linker polypeptide each comprise the amino acid sequence of SEQ ID NO: 1628; andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a first light chain and a second light chain, wherein the first light chain and the second light chain each comprise the amino acid sequence of SEQ ID NO: 388, and a first heavy chain and a second heavy chain, wherein the first heavy chain and the second heavy chain each comprise the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 28 of the first polypeptide is covalently linked to a Cterminus of the first linker polypeptide; an N-terminus of the first linker polypeptide is conjugated to a cysteine residue at position 275 of the first heavy chain of the antibody;an εamino group of a lysine residue at position 28 of the second polypeptide is covalently linked to a Cterminus of the second linker polypeptide; andan N-terminus of the second linker polypeptide is conjugated to a cysteine residue at position 275 of the second heavy chain of the antibody. E218. A molecule comprising:a first polypeptide and a second polypeptide that agonize a glucagon receptor (“GCGR”), wherein the first polypeptide and the second polypeptide each comprise the amino acid sequence of SEQ ID NO: 1592;a first linker polypeptide and a second linker polypeptide, wherein the first linker polypeptide and the second linker polypeptide each comprise the amino acid sequence of SEQ ID NO: 1628; andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a first light chain and a second light chain, wherein the first light chain and the second light chain each comprise the amino acid sequence of SEQ ID NO: 388, and a first heavy chain and a second heavy chain, wherein the first heavy chain and the second heavy chain each comprise the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 24 of the first polypeptide is covalently linked to a Cterminus of the first linker polypeptide; an N-terminus of the first linker polypeptide is conjugated to a cysteine residue at position 275 of the first heavy chain of the antibody;an εamino group of a lysine residue at position 24 of the second polypeptide is covalently linked to a Cterminus of the second linker polypeptide; andan N-terminus of the second linker polypeptide is conjugated to a cysteine residue at position 275 of the second heavy chain of the antibody. E219. A molecule comprising:a first polypeptide and a second polypeptide that agonize a glucagon receptor (“GCGR”), wherein the first polypeptide and the second polypeptide each comprise the amino acid sequence of SEQ ID NO: 1626;a first linker polypeptide and a second linker polypeptide, wherein the first linker polypeptide and the second linker polypeptide each comprise the amino acid sequence of SEQ ID NO: 1629; andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a first light chain and a second light chain, wherein the first light chain and the second light chain each comprise the amino acid sequence of SEQ ID NO: 388, and a first heavy chain and a second heavy chain, wherein the first heavy chain and the second heavy chain each comprise the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 28 of the first polypeptide is covalently linked to a Cterminus of the first linker polypeptide; an N-terminus of the first linker polypeptide is conjugated to a cysteine residue at position 275 of the first heavy chain of the antibody;an εamino group of a lysine residue at position 28 of the second polypeptide is covalently linked to a Cterminus of the second linker polypeptide; andan N-terminus of the second linker polypeptide is conjugated to a cysteine residue at position 275 of the second heavy chain of the antibody. E220. A molecule comprising:a first polypeptide and a second polypeptide that agonize a glucagon receptor (“GCGR”), wherein the first polypeptide and the second polypeptide each comprise the amino acid sequence of SEQ ID NO: 1587;a first linker polypeptide and a second linker polypeptide, wherein the first linker polypeptide and the second linker polypeptide each comprise the amino acid sequence of SEQ ID NO: 1628; andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a first light chain and a second light chain, wherein the first light chain and the second light chain each comprise the amino acid sequence of SEQ ID NO: 388, and a first heavy chain and a second heavy chain, wherein the first heavy chain and the second heavy chain each comprise the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 28 of the first polypeptide is covalently linked to a Cterminus of the first linker polypeptide; an N-terminus of the first linker polypeptide is conjugated to a cysteine residue at position 275 of the first heavy chain of the antibody;an εamino group of a lysine residue at position 28 of the second polypeptide is covalently linked to a Cterminus of the second linker polypeptide; andan N-terminus of the second linker polypeptide is conjugated to a cysteine residue at position 275 of the second heavy chain of the antibody. E221. A molecule comprising:a first polypeptide and a second polypeptide that agonize a glucagon receptor (“GCGR”), wherein the first polypeptide and the second polypeptide each comprise the amino acid sequence of SEQ ID NO: 1587;a first linker polypeptide and a second linker polypeptide, wherein the first linker polypeptide and the second linker polypeptide each comprise the amino acid sequence of SEQ ID NO: 1630; andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a first light chain and a second light chain, wherein the first light chain and the second light chain each comprise the amino acid sequence of SEQ ID NO: 388, and a first heavy chain and a second heavy chain, wherein the first heavy chain and the second heavy chain each comprise the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 28 of the first polypeptide is covalently linked to a Cterminus of the first linker polypeptide; an N-terminus of the first linker polypeptide is conjugated to a cysteine residue at position 275 of the first heavy chain of the antibody;an εamino group of a lysine residue at position 28 of the second polypeptide is covalently linked to a Cterminus of the second linker polypeptide; andan N-terminus of the second linker polypeptide is conjugated to a cysteine residue at position 275 of the second heavy chain of the antibody. E222. A pharmaceutical composition comprising: a polypeptide of any one of E1E108 or a molecule of any one of E109E221; and a pharmaceutically acceptable excipient. E223. A method of treating obesity in a subject in need thereof, the method comprising administering a polypeptide of any one of E1E108, a molecule of any one of E109E221, or a pharmaceutical composition of E222 to the subject. E224. A polypeptide of any one of E1E108, a molecule of any one of E109E221, or a pharmaceutical composition of E222 for use in treating obesity. E225. Use of a polypeptide of any one of E1E108 or a molecule of any one of E109E221 in the manufacture of a medicament for treating obesity. E226. The method of E223, the polypeptide, molecule or pharmaceutical composition for use of E224, and the use of E225, wherein treating obesity comprises lowering blood glucose, insulin, triglyceride, or cholesterol levels; reducing body weight; and / or improving glucose tolerance, energy expenditure, or insulin sensitivity. E227. A method of reducing body weight and / or food intake in a subject in need thereof, the method comprising administering a polypeptide of any one of E1E108, a molecule of any one of E109E221, or a pharmaceutical composition of E222 to the subject. E228. A polypeptide of any one of E1E108, a molecule of any one of E109E221, or a pharmaceutical composition of E222 for use in reducing body weight and / or food intake in a subject in need thereof. E229. Use of a polypeptide of any one of E1E108 or a molecule of any one of E109E221 in the manufacture of a medicament for reducing body weight and / or food intake in a subject in need thereof. E230. The method of E227, the polypeptide, molecule or pharmaceutical composition for use of E228, and the use of E229, wherein the subject is overweight or obese. E231. A method of treating obesity in a subject in need thereof, the method comprising administering a polypeptide of any one of E1E108, a molecule of any one of E109E221, or a pharmaceutical composition of E222 to the subject in combination with a GLP1 agonist. E232. A polypeptide of any one of E1E108, a molecule of any one of E109E221, or a pharmaceutical composition of E222 for use in a method of treating obesity in a subject in need thereof, wherein the method comprises administering the polypeptide, molecule, or pharmaceutical composition to the subject in combination with a GLP-1 agonist. E233. The method of E231 or the polypeptide, molecule or pharmaceutical composition for use of E232, wherein treating obesity comprises lowering blood glucose, insulin, triglyceride, or cholesterol levels; reducing body weight; and / or improving glucose tolerance, energy expenditure, or insulin sensitivity. E234. The method of E231 or the polypeptide, molecule or pharmaceutical composition for use of E232, wherein, prior to the administering, the subject experienced a weightloss plateau. E235. The method of E231 or the polypeptide, molecule or pharmaceutical composition for use of E232, wherein the GLP1 agonist is semaglutide. E236. A method of reducing body weight and / or food intake in a subject in need thereof, the method comprising administering a polypeptide of any one of E1E108, a molecule of any one of E109E221, or a pharmaceutical composition of E222 to the subject in combination with a GLP1 agonist. E237. A polypeptide of any one of E1E108, a molecule of any one of E109E221, or a pharmaceutical composition of E222 for use in a method of reducing body weight and / or food intake in a subject in need thereof, wherein the method comprises administering the polypeptide, molecule, or pharmaceutical composition to the subject in combination with a GLP-1 agonist. E238. The method of E236 or the polypeptide, molecule, or pharmaceutical composition for use of E237, wherein the subject is overweight or obese. E239. The method of E236 or the polypeptide, molecule, or pharmaceutical composition for use of E237, wherein the GLP1 agonist is semaglutide. E240. The method of E236 or the polypeptide, molecule, or pharmaceutical composition for use of E237, wherein the subject is overweight or obese and the GLP1 agonist is semaglutide. E241. The method of any one of E236 or E238E240 or the polypeptide, molecule, or pharmaceutical composition for use of any one of E237E240, wherein the GLP1 agonist and the polypeptide, molecule, or pharmaceutical composition for use are administered in consecutive, non-overlapping dosing intervals, wherein the GLP-1 agonist is administered prior to the polypeptide, molecule, or pharmaceutical composition. E242. The method of any one of E236 or E238E240 or the polypeptide, molecule, or pharmaceutical composition for use of any one of E237E240, wherein the GLP1 agonist and the polypeptide, molecule, or pharmaceutical composition for use are administered concurrently. E243. The method or the polypeptide, molecule, or pharmaceutical composition for use of E242, wherein at least one dose of the GLP1 agonist is administered prior to a first administration of the polypeptide, molecule, or pharmaceutical composition.  BRIEF DESCRIPTION OF THE DRAWINGS

[50] FIG. 1A depicts cAMP levels expressed as a fluorescence ratio of 665 / 620 nm in CHOK1 cells stably expressing human GCGR following exposure to six example GIPRxGCG conjugates and a positive control.

[51] FIG. 1B depicts cAMP levels expressed as a fluorescence ratio of 665 / 620 nm in primary human hepatocytes expressing human GCGR following exposure to an example GIPRxGCG conjugate and a positive control.

[52] FIG. 1C depicts cAMP levels expressed as a fluorescence ratio of 665 / 620 nm in primary mouse hepatocytes expressing mouse GCGR following exposure to an example GIPRxGCG conjugate and a positive control.

[53] FIG. 2 shows cAMP levels expressed as a fluorescence ratio of 665 / 620 nm in CHOK1 cells stably expressing human GLP-1R following exposure to six example GIPRxGCG conjugates and a positive control.

[54] FIG. 3A provides cAMP levels expressed as a fluorescence ratio of 665 / 620 nm in HEK 293T cells stably expressing human GIPR following exposure to six example GIPRxGCG conjugates and a positive control.

[55] FIG. 3B provides cAMP levels expressed as a fluorescence ratio of 665 / 620 nm in CHO AM1D cells expressing mouse GIPR following exposure to an example GIPRxGCG conjugate and a positive control.

[56] FIGs. 4A-4D depict changes in body weight from baseline for mice with diet-induced obesity treated with either vehicle, a long-lasting GCG agonist (DNPxGCG conjugate), or a GIPRxGCG conjugate.

[57] FIG. 5A shows changes in body weight from baseline for mice with diet-induced obesity treated with either vehicle, a long-lasting GCG agonist (DNPxGCG conjugate), or a GIPRxGCG conjugate.

[58] FIGs. 5B and 5C show blood glucose levels 3 hours (FIG. 5B) or 24 and 72 hours (FIG. 5C), respectively, post-injection of vehicle, a long-lasting GCG agonist (DNPxGCG conjugate), or a GIPRxGCG conjugate in diet-induced obese mice.

[59] FIG. 6A depicts changes in body weight from baseline for mice with diet-induced obesity treated with vehicle or one of six example GIPRxGCG conjugates.

[60] FIG. 6B shows liver triglycerides in milligrams of triacylglycerol (TGA) per gram of liver tissue on day 14 of a study in which mice with diet-induced obesity were treated with vehicle or one of six example GIPRxGCG conjugates.

[61] FIGs. 6C6E provide liver tissue (FIG. 6C), inguinal white adipose tissue (FIG. 6D), and epididymal white adipose tissue (FIG. 6E) weights on day 14 of a study in which mice with dietinduced obesity were treated with vehicle or one of six example GIPRxGCG conjugates.

[62] FIGs. 6F6J depict plasma glucose (FIG. 6F), plasma insulin (FIG. 6G), plasma cholesterol (FIG. 6H), plasma low-density lipoprotein (LDL)-cholesterol (C) (FIG. 6I), and plasma triglyceride (FIG. 6J) levels on day 14 of a study in which mice with dietinduced obesity were treated with vehicle or one of six example GIPRxGCG conjugates.

[63] FIGs. 7A and 7B show blood glucose levels over 90 minutes (FIG. 7A) and glucose area under the curve (AUC) (FIG. 7B) observed during a oral glucose tolerance test (OGTT) in diet-induced obese (DIO) mice pre-treated with vehicle or one of five example GIPRxGCG conjugates.

[64] FIGs. 7C and 7D show plasma insulin levels over 90 minutes (FIG. 7C) and insulin area under the curve (AUC) (FIG. 7D) observed during OGTT in DIO mice pre-treated with vehicle or one of five example GIPRxGCG conjugates.

[65] FIG. 8A depicts changes in body weight from baseline for DIO mice treated with vehicle, the GLP-1 agonist semaglutide, semaglutide followed by a GIPRxGCG conjugate, or semaglutide plus a GIPRxGCG conjugate over a 28-day study period.

[66] FIG. 8B depicts daily food intake for DIO mice treated with vehicle, the GLP-1 agonist semaglutide, semaglutide followed by a GIPRxGCG conjugate, or semaglutide plus a GIPRxGCG conjugate over a 28-day study period.

[67] FIGs. 8C8G provide inguinal white adipose tissue (FIG. 8C), epididymal white adipose tissue (FIG. 8D), liver tissue (FIG. 8E), kidney tissue (paired) (FIG. 8F), and brain tissue (FIG. 8G) weights on day 28 of a study in which mice with dietinduced obesity were treated with vehicle, semaglutide, semaglutide followed by a GIPRxGCG conjugate, or semaglutide plus a GIPRxGCG conjugate.

[68] FIGs. 8H-8M show plasma triglyceride (FIG. 8H), plasma cholesterol (FIG. 8I), plasma highdensity lipoprotein (HDL)-cholesterol (C) (FIG. 8J), plasma LDL-C (FIG. 8K), plasma glucose (FIG. 8L), and plasma insulin levels (FIG. 8M) on day 28 of a study in which mice with dietinduced obesity were treated with vehicle, semaglutide, semaglutide followed by a GIPRxGCG conjugate, or semaglutide plus a GIPRxGCG conjugate.

[69] FIG. 9 depicts the structure of a molecule provided herein. The molecule comprises a polypeptide agonist of GCGR (SEQ ID NO: 1587) covalently linked via an amide bond formed between an εamino group of a lysine residue at position 28 and the C-terminus of a polypeptide linker (SEQ ID NO: 1628), wherein the N-terminus of the polypeptide linker has been bromoacetylated to permit further conjugation to an anti-GIPR antibody via a bromoacetyl-thiol reaction with a thiol group of a cysteine residue. For example, in GIPRxGCG conjugate 51671, two molecules with the structure depicted in FIG. 9 are covalently linked to an anti-GIPR antibody comprising two heavy chains, each comprising the amino acid sequence of SEQ ID NO: 1571, and two light chains, each comprising the amino acid sequence of SEQ ID NO: 388, wherein each molecule of FIG. 9 is covalently linked to the anti-GIPR antibody via a thiolbromoacetyl reaction between the bromoacetylated N-terminus and a thiol group of a cysteine residue at position 275 of each heavy chain, which results in the formation of a thioether linkage that comprises a sulfur atom of the cysteine residue (one molecule per heavy chain).

[70] FIG. 10 depicts the partial structure of a molecule provided herein. The squiggly line represents a connection point between the partial structure and a sulfur atom of a cysteine residue of an anti-GIPR antibody described herein.DETAILED DESCRIPTION

[71] Disclosed herein are polypeptides having activity as agonists of a glucagon receptor, molecules comprising such polypeptides, pharmaceutical compositions comprising the polypeptides and molecules, and uses and methods in weight management and treating disorders, including obesity, with the polypeptides, molecules, and pharmaceutical compositions described herein. DEFINITIONS:

[72] The following definitions are provided to assist in understanding the scope of this disclosure. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which this disclosure belongs.

[73] As used herein, the terms “a” and “an” mean “one or more” unless specifically indicated otherwise. Additionally, “one or more” and “at least one” are used interchangeably herein. Furthermore, unless otherwise required by context, singular terms shall include pluralities, and plural terms shall include the singular.[1] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Unless otherwise required by context, numeric ranges are inclusive of the numbers defining the range (i.e., the endpoints). Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.[2] Other than in the Examples, or where otherwise indicated, all numbers expressing quantities (e.g., of ingredients or reaction conditions) used herein should be understood as modified in all instances by the term “about.” As used herein, “about,” when used in connection with a measurable numerical variable, refers to the indicated value of the variable and to all values of the variable that are within the experimental error of the indicated value (e.g., within the 95% confidence interval for the mean) or ± 10% of the indicated value, whichever is greater.

[74] Generally, nomenclatures used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics, and protein and nucleic acid chemistry and hybridization described herein are those wellknown and commonly used in the art. For example, the methods and techniques of the present application (e.g., recombinant polypeptide and nucleic acid methods) are generally performed according to conventional methods wellknown in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2001), Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates (1992), and Harlow and Lane Antibodies: A Laboratory Manual Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1990), which are incorporated herein by reference. Illustratively, protein purification methods that can be employed to isolate a polypeptide, as well as associated materials and reagents, are known in the art, and additional purification methods that may be useful for isolating a polypeptide can be found in references such as Bootcov MR, 1997, Proc. Natl. Acad. Sci. USA 94:11514-9, Fairlie WD, 2000, Gene 254: 67-76. Enzymatic reactions and purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art or as described herein. The terminology used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well-known and commonly used in the art. Illustratively, standard techniques can be used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients. It should be understood that the subject matter of this disclosure is not limited to the particular methodology, protocols, and reagents, etc., described herein and as such may vary.

[75] The term “naturally occurring,” as used herein in connection with biological materials such as polypeptides, nucleic acids, host cells, and the like, refers to materials which are found in nature.

[76] As used herein, a “recombinant protein” is a protein made using recombinant techniques, i.e., through the expression of a recombinant nucleic acid, as described herein. Methods and techniques for the production of recombinant proteins are wellknown in the art.

[77] As used herein, the terms “amino acid” and “residue” are used interchangeably and, when used in the context of a polypeptide, refer to both naturally occurring and synthetic amino acids, as well as amino acid analogs, amino acid mimetics, and non-naturally occurring amino acids that are chemically similar to the naturally occurring amino acids.

[78] As used herein, a “naturally occurring amino acid” is an amino acid that is encoded by the genetic code, as well as those amino acids that are encoded by the genetic code that are modified after synthesis, such as, e.g., hydroxyproline, γ-carboxyglutamate, and Ophosphoserine. An amino acid analog is a compound that has the same basic chemical structure as a naturally occurring amino acid, i.e., an α carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, or methionine methyl sulfonium. Such analogs can have modified R groups (e.g., norleucine) or modified peptide backbones, but will retain the same basic chemical structure as a naturally occurring amino acid.

[79] Naturally occurring residues can be divided into classes based on common side chain properties:1) hydrophobic: norleucine, Met, Ala, Val, Leu, Ile;2) neutral hydrophilic: Cys, Ser, Thr;3) acidic: Asp, Glu;4) basic: Asn, Gln, His, Lys, Arg;5) residues that influence chain orientation: Gly, Pro; and6) aromatic: Trp, Tyr, Phe.

[80] Additional groups of amino acids can also be formulated using the principles described in, e.g., Creighton (1984) PROTEINS: STRUCTURE AND MOLECULAR PROPERTIES (2d Ed. 1993), W.H. Freeman and Company. In some instances, it can be useful to further characterize substitutions based on two or more of such features (e.g., substitution with a “small polar” residue, such as a Thr residue, can represent a highly conservative substitution in an appropriate context).

[81] As used herein, a “conservative amino acid substitution” can involve a substitution of a native amino acid residue (i.e., a residue found in a given position of a reference polypeptide sequence) with a nonnative residue (i.e., a residue that is not found in a given position of the reference sequence) such that there is little or no effect on the polarity or charge of the amino acid residue at that position. Conservative amino acid substitutions also encompass non-naturally occurring amino acid residues that are typically incorporated by chemical peptide synthesis rather than by synthesis in biological systems. These include peptidomimetics, and other reversed or inverted forms of amino acid moieties.

[82] Conservative substitutions can involve the exchange of a member of one of these classes for another member of the same class. Non-conservative substitutions can involve the exchange of a member of one of these classes for a member from another class.

[83] Synthetic, rare, or modified amino acid residues having known similar physiochemical properties to those of an above-described grouping can be used as a “conservative” substitute for a particular amino acid residue in a sequence. For example, a D-Arg residue may serve as a substitute for a typical L-Arg residue. It also can be the case that a particular substitution can be described in terms of two or more of the above described classes (e.g., a substitution with a small and hydrophobic residue means substituting one amino acid with a residue(s) that is found in both of the above-described classes or other synthetic, rare, or modified residues that are known in the art to have similar physiochemical properties to such residues meeting both definitions).

[84] Conservative substitutions can be determined by considering the hydropathic index of amino acids. The hydropathic profile of a protein is calculated by assigning each amino acid a numerical value (“hydropathy index”) and then repetitively averaging these values along the peptide chain. Each amino acid has been assigned a hydropathic index on the basis of its hydrophobicity and charge characteristics, e.g.: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine / cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).

[85] The importance of the hydropathic profile in conferring interactive biological function on a protein is understood in the art (see, e.g., Kyte et al., 1982, J. Mol. Biol. 157:105-131). It is known that certain amino acids may be substituted for other amino acids having a similar hydropathic index or score and still retain a similar biological activity. In making changes based upon the hydropathic index, in certain embodiments, the substitution of amino acids whose hydropathic indices are within ±2 is included. In some embodiments, those which are within ±1 are included, and in some embodiments, those within ±0.5 are included.

[86] It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity, particularly where the biologically functional protein or peptide thereby created is intended for use in immunological embodiments. In some embodiments, the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with its immunogenicity and antigen-binding or immunogenicity, that is, with a biological property of the protein.

[87] The following hydrophilicity values have been assigned to these amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0±1); glutamate (+3.0±1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5±1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5) and tryptophan (-3.4). In making changes based upon similar hydrophilicity values, in certain embodiments, the substitution of amino acids whose hydrophilicity values are within ±2 is included, in other embodiments, those which are within ±1 are included, and in still other embodiments, those within ±0.5 are included. In some instances, one may also identify epitopes from primary amino acid sequences on the basis of hydrophilicity. These regions are also referred to as “epitopic core regions.”

[88] Non-limiting examples of conservative amino acid substitutions are set forth in Table 1.Table 1. Non-Limiting Example Conservative Amino Acid SubstitutionsOriginalExample SubstitutionsSpecific Example SubstitutionsAla (A)Val, Leu, IleValArg (R)Lys, Gln, AsnLysAsn (N)Gln, His, Asp, Lys, ArgGlnAsp (D)Glu, AsnGluCys (C)Ser, AlaSerGln (Q)Asn, GluAsnGlu (E)Asp, GlnAspGly (G)AlaAlaHis (H)Asn, Gln, Lys, ArgArgIle (I)Leu, Val, Met, Ala, PheLeuLeu (L)Norleucine, Ile, Val, Met, AlaIleLys (K)Arg, Gln, AsnArgMet (M)Leu, Phe, IleLeuPhe (F)Leu, Val, Ile, Ala, TyrTyrPro (P)AlaAlaSer (S)ThrThrThr (T)SerSerTrp (W)Tyr, PheTyrTyr (Y)Trp, Phe, Thr, SerPheVal (V)Ile, Leu, Met, Phe, AlaLeu 

[89] As used herein, an “amino acid mimetic” is a chemical compound that has a structure that is different from the general chemical structure of an amino acid but that functions in a manner similar to a naturally occurring amino acid. Examples include, but are not limited to, a methacryloyl or acryloyl derivative of an amide, β-, γ-, δ-imino acids (such as, e.g., piperidine4carboxylic acid), and the like.

[90] As used herein, a “non-naturally occurring amino acid” is a compound that has the same basic chemical structure as a naturally occurring amino acid but is not incorporated into a growing polypeptide chain by the translation complex. “Non-naturally occurring amino acid” also refers to, but is not limited to, amino acids that occur by modification (e.g., posttranslational modification(s)) of a naturally encoded amino acid (including but not limited to, the 20 common amino acids) but are not themselves naturally incorporated into a growing polypeptide chain by the translation complex. A non-limiting list of examples of non-naturally occurring amino acids that can be inserted into a polypeptide sequence or substituted for a wildtype residue in a polypeptide sequence include β-amino acids, homoamino acids, cyclic amino acids, and amino acids with derivatized side chains. Examples include (in the L-form or D-form; abbreviated as in parentheses) but are not limited to: citrulline (Cit), homocitrulline (hCit), Nα-methylcitrulline (NMeCit), Nαmethylhomocitrulline (Nα-MeHoCit), ornithine (Orn), Nα-Methylornithine (Nα-MeOrn or NMeOrn), sarcosine (Sar), homolysine (hLys or hK), homoarginine (hArg or hR), homoglutamine (hQ), Nαmethylarginine (NMeR), Nα-methylleucine (Nα-MeL or NMeL), N-methylhomolysine (NMeHoK), Nα-methylglutamine (NMeQ), norleucine (Nle), norvaline (Nva), 1,2,3,4-tetrahydroisoquinoline (Tic), Octahydroindole-2-carboxylic acid (Oic), 3-(1-naphthyl)alanine (1-Nal), 3-(2-naphthyl)alanine (2Nal), 1,2,3,4-tetrahydroisoquinoline (Tic), 2-indanylglycine (IgI), para-iodophenylalanine (pIPhe), para-aminophenylalanine (4AmP or 4-Amino-Phe), 4-guanidino phenylalanine (Guf), glycyllysine (abbreviated “K(Nε-glycyl)” or “K(glycyl)” or “K(gly)”), nitrophenylalanine (nitrophe), aminophenylalanine (aminophe or Amino-Phe), benzylphenylalanine (benzylphe), γcarboxyglutamic acid (γ-carboxyglu), hydroxyproline (hydroxypro), p-carboxyl-phenylalanine (Cpa), α-aminoadipic acid (Aad), Nα-methyl valine (NMeVal), N-α-methyl leucine (NMeLeu), Nαmethylnorleucine (NMeNle), cyclopentylglycine (Cpg), cyclohexylglycine (Chg), acetylarginine (acetylarg), α, β-diaminopropionoic acid (Dpr), α, γ-diaminobutyric acid (Dab), diaminopropionic acid (Dap), cyclohexylalanine (Cha), 4-methyl-phenylalanine (MePhe), β, β-diphenyl-alanine (BiPhA), aminobutyric acid (Abu), 4-phenyl-phenylalanine (or biphenylalanine; 4Bip), α-amino-isobutyric acid (Aib), beta-alanine, beta-aminopropionic acid, piperidinic acid, aminocaprioic acid, aminoheptanoic acid, aminopimelic acid, desmosine, diaminopimelic acid, N-ethylglycine, Nethylaspargine, hydroxylysine, allo-hydroxylysine, isodesmosine, allo-isoleucine, Nmethylglycine, Nmethylisoleucine, N-methylvaline, 4-hydroxyproline (Hyp), γ-carboxyglutamate, ε-N,N,N-trimethyllysine, ε-N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3methylhistidine, 5-hydroxylysine, ω-methylarginine, 4-amino-O-phthalic acid (4APA), and other similar amino acids, and derivatized forms of any of those specifically listed.

[91] As used herein, the term “antigen” refers to a molecule or a portion of a molecule capable of being bound by a selective binding agent, such as an antigen binding protein (including, e.g., an antibody), and additionally capable of being used in an animal to produce antibodies capable of binding to that antigen. An antigen may possess one or more epitopes that are capable of interacting with different antigen binding proteins, e.g., antibodies.

[92] As used herein, an “antigenbinding region” refers to a protein, or a portion of a protein, that specifically binds a specified antigen. For example, that portion of an antigenbinding protein that contains the amino acid residues that interact with an antigen and confer on the antigenbinding protein its specificity and affinity for the antigen is referred to as “antigen binding region.” An antigenbinding region typically includes one or more “complementary binding regions” (“CDRs”) of an immunoglobulin, single-chain immunoglobulin, or camelid antibody. Certain antigen binding regions also include one or more “framework” regions. A “CDR” is an amino acid sequence that contributes to antigen binding specificity and affinity. “Framework” regions can aid in maintaining the proper conformation of the CDRs to promote binding between the antigenbinding region and an antigen.

[93] As used herein, the term “polypeptide” refers to a polymer of amino acid residues. Polypeptides comprising between two and fifty amino acids may also be referred to as “peptides” herein. “Polypeptide” further encompasses an amino acid polymer in which one or more amino acid residues is an analog or mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers. The term can also encompass an amino acid polymer that have been modified, e.g., by the addition of carbohydrate residues to form glycoproteins, or phosphorylated. Polypeptides can be produced by a naturally-occurring and non-recombinant cell, or polypeptides can be produced by a genetically-engineered or recombinant cell, and comprise molecules having the amino acid sequence of the native protein, or molecules having deletions from, additions to, and / or substitutions of one or more amino acids of the native sequence. The terms “polypeptide” and “protein” are used interchangeably herein.

[94] As used herein, the term “polypeptide fragment” refers to a polypeptide that has an amino-terminal deletion, a carboxyl-terminal deletion, and / or an internal deletion as compared with a reference polypeptide. Such fragments may also contain modified amino acids as compared with the reference polypeptide. In certain embodiments, fragments are five to 500 amino acids long. For example, fragments may be at least 5, 6, 8, 10, 14, 20, 50, 70, 100, 110, 150, 200, 250, 300, 350, 400, or 450 amino acids long.

[95] As used herein, a “variant” of a polypeptide (e.g., an antigenbinding protein such as an antibody) comprises an amino acid sequence wherein one or more amino acid residues are inserted into, deleted from and / or substituted into the amino acid sequence relative to a reference polypeptide sequence. Variants include fusion proteins.

[96] As used herein, a “derivative” of a polypeptide is a polypeptide (e.g., an antigen binding protein such as an antibody) that has been chemically modified in some manner distinct from insertion, deletion, or substitution variants, such as, e.g., via conjugation to another chemical moiety.

[97] As used herein, the terms “chemical derivative” or “chemically derivatized,” with respect to a polypeptide, refer to a polypeptide that comprises one or more residues that have been chemically derivatized by reaction of a functional side group. Such derivatized molecules include, for example, those molecules in which free amino groups have been derivatized to form amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl groups, chloroacetyl groups, or formyl groups. For example, free carboxyl groups can be derivatized to form salts, methyl and ethyl esters, or other types of esters or hydrazides. Additionally, free hydroxyl groups can be derivatized to form O-acyl or O-alkyl derivatives, and the imidazole nitrogen of histidine can be derivatized to form Nim-benzylhistidine.

[98] Non-limiting examples of derivatizations also include the following:

[99] Chemical modification of the amino terminal of the polypeptide: In some embodiments, the Nterminus can be acylated or modified to a substituted amine, or derivatized with another functional group, such as an aromatic moiety (e.g., an indole acid, benzyl (Bzl or Bn), dibenzyl (DiBzl or Bn2), or benzyloxycarbonyl (Cbz or Z)), N,N-dimethylglycine, or creatine). For example, in some embodiments, an acyl moiety, such as, but not limited to, a formyl, acetyl (Ac), propanoyl, butanyl, heptanyl, hexanoyl, octanoyl, or nonanoyl, can be covalently linked to the N-terminal end of the polypeptide. Other example Nterminal derivative groups include, but are not limited to, -NRR1 (other than -NH2), -NRC(O)R1, -NRC(O)OR1, -NRS(O)2R1, -NHC(O)NHR1, succinimide, or benzyloxycarbonyl-NH- (Cbz-NH-), wherein R and R1 are each independently hydrogen or C1-4 alkyl and wherein the phenyl ring may be substituted with 1 to 3 substituents independently selected from C1-4 alkyl, C1-4 alkoxy, chloro, and bromo.

[100] Bond substitutions: In some embodiments, one or more peptidyl [-C(O)NR-] linkages (bonds) between amino acid residues can be replaced by a non-peptidyl linkage. Example nonpeptidyl linkages include, but are not limited to, -CH2-carbamate [-CH2-OC(O)NR-], phosphonate, -CH2-sulfonamide [CH2-S(O)2NR-], urea [-NHC(O)NH-], -CH2-secondary amine, and alkylated peptide [C(O)NR6-, wherein R6 is C1-4 alkyl].

[101] Derivatization of one or more individual amino acid residues: In some embodiments, lysinyl residues and amino terminal residues can be reacted with succinic or other carboxylic acid anhydrides, which reverse the charge of the lysinyl residues. Other suitable reagents for derivatizing alpha-amino-containing residues include, but are not limited to, imidoesters such as methyl picolinimidate; pyridoxal phosphate; pyridoxal; chloroborohydride; trinitrobenzenesulfonic acid; O-methylisourea; 2,4 pentanedione; and transaminase-catalyzed reaction with glyoxylate.

[102] In some embodiments, arginyl residues can be modified by reaction with any one or more of several conventional reagents, including phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione, and ninhydrin. Derivatization of arginyl residues requires that the reaction be performed in alkaline conditions because of the high pKa of the guanidine functional group. Furthermore, these reagents can react with the groups of lysine as well as the arginine epsilonamino group.

[103] Specific modification of tyrosyl residues has been studied extensively, with particular interest in introducing spectral labels into tyrosyl residues by reaction with aromatic diazonium compounds or tetranitromethane. Most commonly, N-acetylimidizole and tetranitromethane are used to form O-acetyl tyrosyl species and 3-nitro derivatives, respectively.

[104] In some embodiments, carboxyl sidechain groups (aspartyl or glutamyl) can be selectively modified by reaction with carbodiimides (R'-N=C=N-R') such as 1-cyclohexyl-3-(2-morpholinyl-(4-ethyl) carbodiimide or 1-ethyl-3-(4-azonia-4,4-dimethylpentyl) carbodiimide. Furthermore, in some embodiment, aspartyl and glutamyl residues can be converted to asparaginyl and glutaminyl residues by reaction with ammonium ions.

[105] In some embodiments, glutaminyl and asparaginyl residues can be deamidated to the corresponding glutamyl and aspartyl residues. In alternative embodiments, these residues are deamidated under mildly acidic conditions.

[106] In some embodiments, cysteinyl residues can be replaced by amino acid residues or other moieties either to eliminate disulfide bonding or, conversely, to stabilize cross-linking. (See, e.g., Bhatnagar et al., J. Med. Chem., 39:3814-3819 (1996)).

[107] Other possible modifications include, but are not limited to, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, oxidation of the sulfur atom in Cys, methylation of the alpha-amino groups of lysine, arginine, and histidine side chains. Creighton, Proteins: Structure and Molecule Properties (W. H. Freeman & Co., San Francisco), 79-86 (1983).

[108] As used herein, the term “alkyl” refers to a saturated straight chain hydrocarbon or saturated branched chain hydrocarbon containing the indicated number of carbon atoms. For example, C3alkyl means an alkyl group that has 3 carbon atoms (e.g., n-propyl or isopropyl). For example, a C1-6alkyl refers to an alkyl group having 1 to 6 carbon atoms. Where a range is indicated, all members of that range and all subgroups within that range are envisioned. For example, a C1-6alkyl includes alkyl groups having 1, 2, 3, 4, 5, or 6 carbon atoms (or any combination of the foregoing), as well as all subgroups in the indicated range (e.g., 1-2, 1-3, 1-4, 1-5, 1-6, 2-3, 2-4, 2-5, 2-6, 3-4, 3-5, 3-6, 4-5, 4-6, or 5-6 carbon atoms, or any combination of the foregoing ranges)). A “C1-4 alkyl” includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or t-butyl. Nonlimiting examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, and n-hexyl.

[109] A molecule of the present disclosure that includes a polypeptide which is covalently linked, attached, or bound, either directly or indirectly through a linker moiety (e.g., a linker polypeptide), to another polypeptide, such as, e.g., an anti-GIPR antibody of the present disclosure, may be described herein as a “conjugate.”

[110] As used herein, the term “thiol” refers to a —SH group.

[111] As used herein, the terms “alkoxy” and “alkoxyl” are interchangeable and refer to an —O-alkyl group, where the alkyl group is as defined elsewhere herein. For example, a C3alkoxy group means the alkoxy group has 3 carbon atoms (e.g., OCH2CH2CH3). Where a range is indicated, all members of that range and all subgroups within that range are envisioned. For example, a C1-6alkoxy includes alkoxy groups having 2, 3, 4, 5, or 6 carbon atoms, or any combination of the foregoing, as well as all subgroups in the indicated range (e.g., 2-3, 2-4, 2-5, 2-6, 3-4, 3-5, 3-6, 4-5, 4-6, and 5-6 carbon atoms, or any combination of the foregoing). Nonlimiting examples of alkoxy groups include methoxy, ethoxy, n-propoxy, 1-methylethyloxy (iso-propoxy), n-butoxy, isobutoxy, sec-butoxy, and tert-butoxy.

[112] As used herein, the term “linker moiety” refers to a biologically acceptable peptidyl or nonpeptidyl organic group that is covalently bound to a first molecule (e.g., a first polypeptide) and covalently joins or conjugates the molecule to a second molecule (e.g., a second polypeptide). Where the linker moiety consists of a polypeptide or a polypeptide derivative (e.g., a polypeptide that has been chemically modified at one or both of the N-terminus and C-terminus to incorporate a functional group that permits conjugation to the first or second molecule), it may be referred to as a “linker polypeptide” herein. For example, in some embodiments, a linker polypeptide may comprise an acetylated N-terminus (e.g., when a thiol-bromoacetyl reaction was used to conjugate the derivatized N-terminus of the linker polypeptide to a cysteine residue of a polypeptide by forming a thioether linkage that comprises a sulfur atom of the cysteine residue).

[113] As used herein, the term “isolated polypeptide” refers to a polypeptide that has been separated from at least about 50 percent of polypeptides, lipids, carbohydrates, polynucleotides, or other materials with which the polypeptide is naturally found when isolated from a source cell. In some embodiments, the isolated polypeptide is substantially free from any other contaminating polypeptides or other contaminants that are found in its natural environment that would interfere with its therapeutic, diagnostic, prophylactic, or research use.

[114] As used herein, the term “antigenbinding protein” refers to any protein that specifically binds a specified target antigen, such as a GIPR polypeptide (e.g., a human GIPR polypeptide such as those provided in SEQ ID NOs: 1577, 1578, or 1579). The term encompasses intact antibodies that comprise at least two full-length heavy chains and two full-length light chains, as well as derivatives, variants, fragments, and mutations thereof. An antigenbinding protein also includes domain antibodies such as nanobodies and scFvs as described further below.

[115] An antigenbinding protein, such as, e.g., an anti-GIPR polypeptide, is said to “specifically bind” its target antigen when the antigen binding protein exhibits essentially background binding to non-target antigen molecules. An antigen binding protein that specifically binds a target antigen may, however, cross-react with target antigens from different species. Typically, an antigen binding protein specifically binds its target antigen when the dissociation constant (KD) is ≤10-7 M as measured via a surface plasma resonance technique (e.g., BIACore, GE-Healthcare Uppsala, Sweden) or Kinetic Exclusion Assay (KinExA, Sapidyne, Boise, Idaho). An antigenbinding protein specifically binds its target antigen with “high affinity” when the KD is ≤5x 10-9 M, and with “very high affinity” when the KD is ≤5x 10-10 M, as measured using methods described.

[116] As used herein, the term “epitope” is the portion of a molecule that is bound by an antigenbinding protein (e.g., an antibody). The term includes any determinant capable of specifically binding to an antigenbinding protein, such as an antibody. An epitope can be contiguous or non-contiguous (discontinuous) (e.g., amino acid residues that are not contiguous to one another in an amino acid sequence but that within in context of the molecule are bound by the antigenbinding protein). A conformational epitope is an epitope that exists within the conformation of an active protein but is not present in a denatured protein. In some embodiments, epitopes may be mimetic in that they comprise a three dimensional structure that is similar to an epitope used to generate the antigenbinding protein, yet comprise none or only some of the amino acid residues found in that epitope used to generate the antigen binding protein. More often, epitopes reside on proteins, but in some instances may reside on other kinds of molecules, such as nucleic acids. Epitope determinants may include chemically active surface groupings of molecules such as amino acids, sugar side chains, phosphoryl or sulfonyl groups, and may have specific three dimensional structural characteristics, and / or specific charge characteristics. Generally, antigenbinding proteins specific for a particular target antigen will preferentially recognize an epitope on the target antigen in a complex mixture of proteins and / or macromolecules.

[117] As used herein, a “bivalent antigenbinding protein” (e.g., a bivalent antibody) comprises two antigen binding regions. In some instances, the two binding regions have the same antigen specificities. Bivalent antigen binding proteins and bivalent antibodies may be bispecific.

[118] As used herein, a “multispecific antigenbinding protein” (e.g., a multispecific antibody) is an antigen-binding protein that targets more than one antigen or epitope.

[119] As used herein, a “bispecific,” “dual-specific” or “bifunctional” antigen-binding protein (e.g., antibody) is a hybrid antigenbinding protein having two different antigen binding sites. Bispecific antigenbinding proteins are a subclass of multispecific antigenbinding proteins and may be produced by a variety of methods including, but not limited to, fusion of hybridomas or linking of Fab' fragments. See, e.g., Songsivilai and Lachmann, 1990, Clin. Exp. Immunol. 79:315-321; Kostelny et al., 1992, J. Immunol. 148:1547-1553. The two binding sites of a bispecific antigen binding protein will bind to two different epitopes, which may reside on the same or different protein targets.

[120] As used herein, the term “antibody” refers to an intact immunoglobulin of any isotype, and includes, for instance, chimeric, humanized, fully human, and bispecific antibodies. An “antibody” as such is a species of an antigenbinding protein. An antibody generally comprises two full-length heavy chains and two full-length light chains. Antibodies may be derived solely from a single source, or may be “chimeric,” that is, different portions of the antibody may be derived from two different antibodies as described further below.

[121] As used herein, the term “light chain” or “immunoglobulin light chain” refers to a polypeptide comprising, from amino terminus (N-terminus) to carboxyl terminus (Cterminus), a single immunoglobulin light chain variable region (VL) and a single immunoglobulin light chain constant domain (CL). The immunoglobulin light chain constant domain (CL) can be a human kappa (κ) or human lambda (λ) constant domain.

[122] As used herein, the term “heavy chain” or “immunoglobulin heavy chain” refers to a polypeptide comprising, from amino terminus (N-terminus) to carboxyl terminus (Cterminus), a single immunoglobulin heavy chain variable region (VH), an immunoglobulin heavy chain constant domain 1 (CH1), an immunoglobulin hinge region, an immunoglobulin heavy chain constant domain 2 (CH2), an immunoglobulin heavy chain constant domain 3 (CH3), and optionally an immunoglobulin heavy chain constant domain 4 (CH4). Heavy chains are classified as mu (μ), delta (Δ), gamma (γ), alpha (α), and epsilon (ε), and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively. The IgG-class and IgA-class antibodies are further divided into subclasses, namely, IgG1, IgG2, IgG3, and IgG4, and IgA1 and IgA2, respectively. The heavy chains in IgG, IgA, and IgD antibodies have three constant domains (CH1, CH2, and CH3), whereas the heavy chains in IgM and IgE antibodies have four constant domains (CH1, CH2, CH3, and CH4). The immunoglobulin heavy chain constant domains can be from any immunoglobulin isotype, including subtypes. The antibody chains are linked together via inter-polypeptide disulfide bonds between the CL domain and the CH1 domain (i.e. between the light and heavy chain) and between the hinge regions of the two antibody heavy chains.

[123] Variable regions of immunoglobulin chains generally exhibit the same overall structure, comprising relatively conserved framework regions (FR) joined by three hypervariable regions, more often called “complementarity determining regions” or CDRs. The CDRs from the two chains of each heavy chain and light chain pair typically are aligned by the framework regions to form a structure that binds specifically to a specific epitope on the target protein. From N-terminus to C-terminus, naturally-occurring light and heavy chain variable regions both typically conform with the following order of these elements: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. A numbering system has been devised for assigning numbers to amino acids that occupy positions in each of these domains. This numbering system is defined in Kabat Sequences of Proteins of Immunological Interest (1987 and 1991, NIH, Bethesda, MD), or Chothia & Lesk, 1987, J. Mol. Biol. 196:901-917; Chothia et al., 1989, Nature 342:878-883. The CDRs and FRs of a given antibody may be identified using this system. Other numbering systems for the amino acids in immunoglobulin chains include IMGT® (the international ImMunoGeneTics information system; Lefranc et al., Dev. Comp. Immunol. 29:185-203; 2005) and AHo (Honegger and Pluckthun, J. Mol. Biol. 309(3):657-670; 2001).

[124] As used herein, the term “immunologically functional fragment” (or simply “fragment” or “functional fragment”) of an antibody is an antigenbinding protein comprising a portion (regardless of how that portion is obtained or synthesized) of an antibody that lacks at least some of the amino acids present in a full-length chain but which is capable of specifically binding to the same antigen at the same epitope as the antibody. Such fragments are biologically active in that they bind specifically to the target antigen and can compete with other antigen binding proteins, including intact antibodies, for specific binding to a given epitope. These biologically active fragments may be produced by recombinant DNA techniques, or may be produced by enzymatic or chemical cleavage of antigen binding proteins, including intact antibodies. Immunologically functional immunoglobulin fragments include, but are not limited to, Fab, Fab', and F(ab')2 fragments.

[125] Papain digestion of antibodies produces two identical antigen-binding proteins, called “Fab” fragments, each with a single antigen-binding site, and a residual “Fc” fragment which contains all but the first domain of the immunoglobulin heavy chain constant region. The Fab fragment contains the variable domains from the light and heavy chains, as well as the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Thus, a “Fab fragment” is comprised of one immunoglobulin light chain (light chain variable region (VL) and constant region (CL)) and the CH1 domain and variable region (VH) of one immunoglobulin heavy chain. The heavy chain of a Fab molecule cannot form a disulfide bond with another heavy chain molecule. The “Fd fragment” comprises the VH and CH1 domains from an immunoglobulin heavy chain. The Fd fragment represents the heavy chain component of the Fab fragment.

[126] As used herein, a “Fc fragment” or “Fc region” of an immunoglobulin generally comprises two constant domains, a CH2 domain and a CH3 domain, and optionally comprises a CH4 domain. The Fc region may be an Fc region from an IgG1, IgG2, IgG3, or IgG4 immunoglobulin. In some embodiments, the Fc region comprises CH2 and CH3 domains from a human IgG1 or human IgG2 immunoglobulin. The Fc region may retain effector function, such as C1q binding, complement dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), and phagocytosis. In other embodiments, the Fc region may be modified to reduce or eliminate effector function.

[127] As used herein, a “Fab' fragment” contains one light chain and a portion of one heavy chain that contains the VH domain and the CH1 domain and also the region between the CH1 and CH2 domains, such that an interchain disulfide bond can be formed between the two heavy chains of two Fab' fragments to form an F(ab')2 molecule.

[128] As used herein, a “F(ab')2 fragment” contains two light chains and two heavy chains containing a portion of the constant region between the CH1 and CH2 domains, such that an interchain disulfide bond is formed between the two heavy chains. A F(ab')2 fragment thus is composed of two Fab' fragments that are held together by a disulfide bond between the two heavy chains.

[129] As used herein, a “Fv region” comprises the variable regions from both the heavy and light chains, but lacks the constant regions. The “Fv” fragment is the minimum fragment that contains a complete antigen recognition and binding site from an antibody. This fragment consists of a dimer of one immunoglobulin heavy chain variable region (VH) and one immunoglobulin light chain variable region (VL) in tight, non-covalent association. It is in this configuration that the three CDRs of each variable region interact to define an antigen binding site on the surface of the VH-VL dimer. A single light chain or heavy chain variable region (or half of an Fv fragment comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site comprising both VH and VL.

[130] As used herein, a “single-chain variable fragment” or “scFv fragment” comprises the VH and VL regions of an antibody, wherein these regions are present in a single polypeptide chain, and optionally comprising a peptide linker between the VH and VL regions that enables the Fv to form the desired structure for antigen binding (see e.g., Bird et al., Science, Vol. 242:423-426, 1988; and Huston et al., Proc. Natl. Acad. Sci. USA, Vol. 85:5879-5883, 1988).

[131] As used herein, a “nanobody” is the heavy chain variable region of a heavy-chain antibody. Such variable domains are the smallest fully functional antigen-binding fragment of such heavy-chain antibodies with a molecular mass of only 15 kDa. See Cortez-Retamozo et al., Cancer Research 64:2853-57, 2004. Functional heavy-chain antibodies devoid of light chains are naturally occurring in certain species of animals, such as nurse sharks, wobbegong sharks, and Camelidae, such as camels, dromedaries, alpacas and llamas. The antigen-binding site is reduced to a single domain, the VHH domain, in these animals. These antibodies form antigen-binding regions using only heavy chain variable region, i.e., these functional antibodies are homodimers of heavy chains only having the structure H2L2 (referred to as “heavy-chain antibodies” or “HCAbs”). Camelized VHH reportedly recombines with IgG2 and IgG3 constant regions that contain hinge, CH2, and CH3 domains and lack a CH1 domain. Camelized VHH domains have been found to bind to antigen with high affinity (Desmyter et al., J. Biol. Chem., Vol. 276:26285-90, 2001) and possess high stability in solution (Ewert et al., Biochemistry, Vol. 41:3628-36, 2002). Methods for generating antibodies having camelized heavy chains are described in, for example, U.S. Patent Publication Nos. 2005 / 0136049 and 2005 / 0037421. Alternative scaffolds can be made from human variable-like domains that more closely match the shark V-NAR scaffold and may provide a framework for a long penetrating loop structure.

[132] As used herein, the term “heavy chain-only antibody” refers to an immunoglobulin protein consisting of two heavy chain polypeptides (such as, e.g., heavy chain polypeptides that are about 50-70 kDa each). A “heavy chain-only antibody” lacks the two light chain polypeptides found in a conventional antibody. Heavy-chain antibodies constitute about onefourth of the IgG antibodies produced by the camelids, e.g., camels and llamas (HamersCasterman C., et al. Nature. 363, 446-448 (1993)). These molecules are formed by two heavy chains but are devoid of light chains. As a consequence, the variable antigen binding part is referred to as the VHH domain, and it represents the smallest naturally occurring, intact, antigen-binding site, being only around 120 amino acids in length (Desmyter, A., et al. J. Biol. Chem. 276, 26285-26290 (2001)). Heavy chain antibodies with a high specificity and affinity can be generated against a variety of antigens through immunization (van der Linden, R. H., et al. Biochim. Biophys. Acta. 1431, 3746 (1999)), and the VHH portion can be readily cloned and expressed in yeast (Frenken, L. G. J., et al. J. Biotechnol. 78, 11-21 (2000)). Their levels of expression, solubility and stability are significantly higher than those of classical F(ab) or Fv fragments (Ghahroudi, M. A. et al. FEBS Lett. 414, 521-526 (1997)). Sharks have also been shown to have a single VH-like domain in their antibodies, termed VNAR. (Nuttall et al. Eur. J. Biochem. 270, 3543-3554 (2003); Nuttall et al. Function and Bioinformatics 55, 187-197 (2004); Dooley et al., Molecular Immunology 40, 25-33 (2003).)

[133] In some embodiments, a “heavy chain-only antibody” is a dimeric antibody comprising a VH antigenbinding domain and the CH2 and CH3 constant domains, in the absence of the CH1 domain. In some embodiments, a heavy chainonly antibody is composed of a variable region antigenbinding domain composed of framework 1, CDR1, framework 2, CDR2, framework 3, CDR3, and framework 4. In some embodiments, a heavy chain-only antibody is composed of an antigen-binding domain, at least part of a hinge region, and CH2 and CH3 domains. In some embodiments, a heavy chain-only antibody is composed of an antigen-binding domain, at least part of a hinge region, and a CH2 domain. In some embodiments, a heavy chain-only antibody is composed of an antigen-binding domain, at least part of a hinge region, and a CH3 domain.

[134] Heavy chain-only antibodies in which the CH2 and / or CH3 domain is truncated are also included herein. The heavy chainonly antibodies described herein may belong to the IgG subclass, but heavy chain-only antibodies belonging to other subclasses, such as IgM, IgA, IgD and IgE subclass, are also included herein. In some embodiments, a heavy chain-only antibody may belong to the IgG1, IgG2, IgG3, or IgG4 subtype, e.g., the IgG1 or IgG4 subtype. In some embodiments, a heavy chain antibodyonly is of the IgG1 or IgG4 subtype, wherein one or more of the CH domains is modified to alter an effector function of the antibody. In some embodiments, a heavy chain-only antibody is of the IgG4 subtype, wherein one or more of the CH domains is modified to alter an effector function of the antibody. In some embodiments, a heavy chain-only antibody is of the IgG1 subtype, wherein one or more of the CH domains is modified to alter an effector function of the antibody. Modifications of CH domains that alter effector function are further described herein. Non-limiting examples of heavy-chain-only antibodies are described, for example, in WO2018 / 039180, the disclosure of which is incorporated herein by reference herein in its entirety.

[135] As used herein, the term “three-chain antibody like molecule” or “TCA” refers to an antibody-like molecule comprising, consisting essentially of, or consisting of three polypeptide subunits, two of which comprise, consist essentially of, or consist of one heavy and one light chain of an antibody, or antigen-binding fragments of such antibody chains, comprising an antigen-binding region and at least one CH domain. This heavy chain / light chain pair has binding specificity for a first antigen. The third polypeptide subunit comprises, consists essentially of, or consists of a heavy-chain only antibody comprising an Fc portion comprising CH2 and / or CH3 and / or CH4 domains, in the absence of a CH1 domain, and one or more antigen binding domains (such as, e.g., two antigen binding domains) that binds an epitope of a second antigen or a different epitope of the first antigen, where such binding domain is derived from or has sequence identity with the variable region of an antibody heavy or light chain. Parts of such variable region may be encoded by VH and / or VL gene segments, D and JH gene segments, or JL gene segments. The variable region may be encoded by rearranged VHDJH, VLDJH, VHJL, or VLJL gene segments.

[136] As used herein, the term “identical,” in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same.

[137] As used herein, “percent identity” means the percent of identical residues between the amino acids or nucleotides in compared molecules and is calculated based on the size of the smallest of the molecules being compared. For these calculations, gaps in alignments (if any) can be addressed by a particular mathematical model or computer program (i.e., an “algorithm”). Methods that can be used to calculate the identity of the aligned nucleic acids or polypeptides include those described in Computational Molecular Biology, (Lesk, A. M., ed.), (1988) New York: Oxford University Press; Biocomputing Informatics and Genome Projects, (Smith, D. W., ed.), 1993, New York: Academic Press; Computer Analysis of Sequence Data, Part I, (Griffin, A. M., and Griffin, H. G., eds.), 1994, New Jersey: Humana Press; von Heinje, G., (1987) Sequence Analysis in Molecular Biology, New York: Academic Press; Sequence Analysis Primer, (Gribskov, M. and Devereux, J., eds.), 1991, New York: M. Stockton Press; and Carillo et al., (1988) SIAM J. Applied Math. 48:1073.

[138] In calculating percent identity, the sequences being compared are aligned in a way that gives the largest match between the sequences. The computer program used to determine percent identity is the GCG program package, which includes GAP (Devereux et al., (1984) Nucl. Acid Res. 12:387; Genetics Computer Group, University of Wisconsin, Madison, WI). The computer algorithm GAP is used to align the two polypeptides or polynucleotides for which the percent sequence identity is to be determined. The sequences are aligned for optimal matching of their respective amino acid or nucleotide (the “matched span”, as determined by the algorithm). A gap opening penalty (which is calculated as 3x the average diagonal, wherein the “average diagonal” is the average of the diagonal of the comparison matrix being used; the “diagonal” is the score or number assigned to each perfect amino acid match by the particular comparison matrix) and a gap extension penalty (which is usually 1 / 10 times the gap opening penalty), as well as a comparison matrix such as PAM 250 or BLOSUM 62 are used in conjunction with the algorithm. In some embodiments, a standard comparison matrix (see, Dayhoff et al., (1978) Atlas of Protein Sequence and Structure 5:345-352 for the PAM 250 comparison matrix; Henikoff et al., (1992) Proc. Natl. Acad. Sci. U.S.A. 89:10915-10919 for the BLOSUM 62 comparison matrix) is also used by the algorithm.

[139] Recommended parameters for determining percent identity for polypeptides or nucleotide sequences using the GAP program are the following: Algorithm: Needleman et al., 1970, J. Mol. Biol. 48:443-453; Comparison matrix: BLOSUM 62 from Henikoff et al., 1992, supra; Gap Penalty: 12 (but with no penalty for end gaps) Gap Length Penalty: 4 Threshold of Similarity: 0

[140] Certain alignment schemes for aligning two amino acid sequences can result in matching of only a short region of the two sequences, and this small, aligned region can have very high sequence identity even though there is no significant relationship between the two full-length sequences. Accordingly, the selected alignment method (e.g., the GAP program) can be adjusted if so desired to result in an alignment that spans at least 50 contiguous amino acids of the target polypeptide.

[141] As used herein, the terms “GIP,” “gastric inhibitory polypeptide,” “glucose-dependent insulinotropic polypeptide,” and “GIP ligand” are used interchangeably and refer to a naturallyoccurring wild-type polypeptide expressed in a mammal, such as a human or a mouse, and include naturally occurring alleles (e.g., naturally occurring allelic forms of human GIP protein). For the purposes of this disclosure, the term “GIP” can be used interchangeably to refer to any mature GIP polypeptide.

[142] The 42 amino acid sequence of mature human GIP is:YAEGTFISDY SIAMDKIHQQ DFVNWLLAQK GKKNDWKHNI TQ (SEQ ID NO: 1582).

[143] The 42 amino acid sequence of mature murine GIP is:YAEGTFISDY SIAMDKIRQQ DFVNWLLAQR GKKSDWKHNI TQ (SEQ ID NO: 1583).

[144] The 42 amino acid sequence of mature rat GIP is:YAEGTFISDY SIAMDKIRQQ DFVNWLLAQK GKKNDWKHNL TQ (SEQ ID NO: 1584).

[145] Additionally, as used herein, the terms “GIPR polypeptide” and “GIPR protein” are used interchangeably and refer to a naturally-occurring wild-type polypeptide expressed in a mammal, such as a human or a mouse, and include naturally occurring alleles (e.g., naturally occurring allelic forms of human GIPR protein). For the purposes of this disclosure, the term “GIPR polypeptide” can be used interchangeably to refer to any full-length GIPR polypeptide, e.g., SEQ ID NO: 1577, which consists of 466 amino acid residues, or SEQ ID NO: 1578, which consists of 430 amino acid residues, or SEQ ID NO: 1579, which consists of 493 amino acid resides, or SEQ ID NO: 1580, which consists of 460 amino acids residues, or SEQ ID NO: 1581, which consists of 230 amino acids residues.

[146] The 466 amino acid sequence of human GIPR is (Volz et al., FEBS Lett. 373:23-29 (1995); NCBI Reference Sequence: NP_0001555):MTTSPILQLL LRLSLCGLLL QRAETGSKGQ TAGELYQRWE RYRRECQETL AAAEPPSGLA CNGSFDMYVC WDYAAPNATA RASCPWYLPW HHHVAAGFVL RQCGSDGQWG LWRDHTQCEN PEKNEAFLDQ RLILERLQVM YTVGYSLSLA TLLLALLILS LFRRLHCTRN YIHINLFTSF MLRAAAILSR DRLLPRPGPY LGDQALALWN QALAACRTAQ IVTQYCVGAN YTWLLVEGVY LHSLLVLVGG SEEGHFRYYL LLGWGAPALF VIPWVIVRYL YENTQCWERN EVKAIWWIIR TPILMTILIN FLIFIRILGI LLSKLRTRQM RCRDYRLRLA RSTLTLVPLL GVHEVVFAPV TEEQARGALR FAKLGFEIFL SSFQGFLVSV LYCFINKEVQ SEIRRGWHHC RLRRSLGEEQ RQLPERAFRA LPSGSGPGEV PTSRGLSSGT LPGPGNEASR ELESYC (SEQ ID NO: 1577)

[147] A 430 amino acid isoform of human GIPR (isoform X1), predicted by automated computational analysis, has the sequence (NCBI Reference Sequence XP_005258790):MTTSPILQLL LRLSLCGLLL QRAETGSKGQ TAGELYQRWE RYRRECQETL AAAEPPSVAA GFVLRQCGSD GQWGLWRDHT QCENPEKNEA FLDQRLILER LQVMYTVGYS LSLATLLLAL LILSLFRRLH CTRNYIHINL FTSFMLRAAA ILSRDRLLPR PGPYLGDQAL ALWNQALAAC RTAQIVTQYC VGANYTWLLV EGVYLHSLLV LVGGSEEGHF RYYLLLGWGA PALFVIPWVI VRYLYENTQC WERNEVKAIW WIIRTPILMT ILINFLIFIR ILGILLSKLR TRQMRCRDYR LRLARSTLTL VPLLGVHEVV FAPVTEEQAR GALRFAKLGF EIFLSSFQGF LVSVLYCFIN KEVQSEIRRG WHHCRLRRSL GEEQRQLPER AFRALPSGSG PGEVPTSRGL SSGTLPGPGN EASRELESYC (SEQ ID NO: 1578)

[148] A 493 amino acid isoform of human GIPR, produced by alternative splicing, has the sequence (Gremlich et al., Diabetes 44:1202-8 (1995); UniProtKB Sequence Identifier: P48546-2):MTTSPILQLL LRLSLCGLLL QRAETGSKGQ TAGELYQRWE RYRRECQETL AAAEPPSGLA CNGSFDMYVC WDYAAPNATA RASCPWYLPW HHHVAAGFVL RQCGSDGQWG LWRDHTQCEN PEKNEAFLDQ RLILERLQVM YTVGYSLSLA TLLLALLILS LFRRLHCTRN YIHINLFTSF MLRAAAILSR DRLLPRPGPY LGDQALALWN QALAACRTAQ IVTQYCVGAN YTWLLVEGVY LHSLLVLVGG SEEGHFRYYL LLGWGAPALF VIPWVIVRYL YENTQCWERN EVKAIWWIIR TPILMTILIN FLIFIRILGI LLSKLRTRQM RCRDYRLRLA RSTLTLVPLL GVHEVVFAPV TEEQARGALR FAKLGFEIFL SSFQGFLVSV LYCFINKEVG RDPAAAPALW RRRGTAPPLS AIVSQVQSEI RRGWHHCRLR RSLGEEQRQL PERAFRALPS GSGPGEVPTS RGLSSGTLPG PGNEASRELE SYC (SEQ ID NO: 1579)

[149] The 460 amino acid sequence of murine GIPR is (NCBI Reference Sequence: NP_001074284; UniProtKB / Swiss-Prot Q0P543-1); see Vassilatis et al., PNAS USA 2003, 100:4903-4908.MPLRLLLLLL WLWGLQWAET DSEGQTTTGE LYQRWEHYGQ ECQKMLETTE PPSGLACNGS FDMYACWNYT AANTTARVSC PWYLPWFRQV SAGFVFRQCG SDGQWGSWRD HTQCENPEKN GAFQDQTLIL ERLQIMYTVG YSLSLTTLLL ALLILSLFRR LHCTRNYIHM NLFTSFMLRA AAILTRDQLL PPLGPYTGDQ APTPWNQALA ACRTAQIMTQ YCVGANYTWL LVEGVYLHHL LVIVGRSEKG HFRCYLLLGW GAPALFVIPW VIVRYLRENT QCWERNEVKA IWWIIRTPIL ITILINFLIF IRILGILVSK LRTRQMRCPD YRLRLARSTL TLVPLLGVHE VVFAPVTEEQ VEGSLRFAKL AFEIFLSSFQ GFLVSVLYCFINKEVQSEIRQ GWRHRRLRLS LQEQRPRPHQ ELAPRAVPLS SACREAAVGN ALPSGMLHVP GDEVLESYC (SEQ ID NO: 1580)

[150] A 230 amino acid isoform of murine GIPR, produced by alternative splicing, has the sequence (Gerhard et al., Genome Res, 14:2121-2127 (2004); NCBI Reference Sequence: AAI20674):MPLRLLLLLL WLWGLQWAET DSEGQTTTGE LYQRWEHYGQ ECQKMLETTE PPSGLACNGS FDMYACWNYT AANTTARVSC PWYLPWFRQV SAGFVFRQCG SDGQWGSWRD HTQCENPEKN GAFQDQTLIL ERLQIMYTVG YSLSLTTLLL ALLILSLFRR LHCTRNYIHM NLFTSFMLRA AAILTRDQLL PPLGPYTGDQ APTPWNQVLH RLLPGGTKTF PIYFRTFPHH (SEQ ID NO: 1581)

[151] As stated herein, the term “GIPR polypeptide” encompasses naturally occurring GIPR polypeptide sequences, e.g., human amino acid sequences SEQ ID NOs: 1577, 1578, or 1579. The term “GIPR polypeptide,” however, also encompasses polypeptides comprising an amino acid sequence that has been modified relative to the amino acid sequence of a naturally occurring GIPR polypeptide sequence, e.g., SEQ ID NOs: 1577, 1578, or 1579, by one or more amino acids, such that the sequence is at least 90% identical to SEQ ID NOs: 1577, 1578, or 1579. Such modifications include, but are not limited to, one or more amino acid substitutions, including substitutions with non-naturally occurring amino acids, non-naturally-occurring amino acid analogs, and amino acid mimetics. For example, GIPR polypeptides can be generated by introducing one or more amino acid substitutions, either conservative or non-conservative and using naturally or non-naturally occurring amino acids, at particular positions of the GIPR polypeptide.

[152] In some embodiments, a GIPR polypeptide comprises an amino acid sequence that is at least 90 percent identical to a naturally-occurring GIPR polypeptide (e.g., SEQ ID NOs: 1577, 1578, or 1579). In some embodiments, a GIPR polypeptide comprises an amino acid sequence that is at least 95, at least 96, at least 97, at least 98, or at least 99 percent identical to a naturallyoccurring GIPR polypeptide amino acid sequence (e.g., SEQ ID NOs: 1577, 1578, or 1579). Such GIPR polypeptides preferably, but need not, possess at least one activity of a wildtype GIPR polypeptide, such as the ability to bind GIP. The present disclosure also encompasses nucleic acid molecules encoding such GIPR polypeptide sequences.

[153] As used herein, the term “GIPR activity assay” (also referred to as a “GIPR functional assay”) means an assay that can be used to measure GIP or a GIP binding protein activity in a cellular setting. In some embodiments, the “activity assay” or “functional assay” can be a cAMP assay in GIPRexpressing cells, in which GIP can induce cAMP signal, and the activity of a GIP / GIPR binding protein could be measured in the presence / absence of GIP ligand, in which IC50 / EC50 and degree of inhibition / activation can be obtained (Biochemical and Biophysical Research Communications (2002) 290:1420–1426). In other embodiments, the “activity assay” or “functional assay” can be an insulin secretion assay in pancreatic beta cells, in which GIP can induce glucose-dependent insulin secretion, and the activity of a GIP / GIPR binding protein could be measured in the presence / absence of GIP ligand, in which IC50 / EC50 and degree of inhibition / activation can be obtained (Biochemical and Biophysical Research Communications (2002) 290:1420–1426).

[154] As used herein, the term “GIPR binding assay” refers to an assay that can be used to measure binding of GIP to GIPR. In some embodiments, a “GIPR binding assay” can be an assay using Fluorometric Microvolume Assay Technology (“FMAT”) or Fluorescence-Activated Cell Sorting (“FACS”) that measures fluorescence-labeled GIP binding to GIPR expression cells, and GIP / GIPR binding protein’s activity can be measured for displacing fluorescence-labeled GIP binding to GIPR expression cells. In other embodiments, a “GIPR binding assay” can be an assay that measures radioactive-labeled GIP binding to GIPR expression cells, and GIP / GIPR binding protein’s activity can be measured for displacing radioactive labeled GIP binding to GIPR expression cells (Biochimica et Biophysica Acta (2001) 1547:143-155).

[155] As used herein, a “GIPR antagonist” refers to a molecule that reduces or inhibits GIP activation of GIPR. Such antagonists include chemically synthesized small molecules and antigen binding proteins. In some embodiments, a GIPR antagonist may reduce or inhibit GIP activation of GIPR by preventing binding of GIP to GIPR.

[156] As used herein, the term “compete,” when used in the context of antigenbinding proteins (e.g., antibodies), means competition between antigenbinding proteins is determined by an assay in which the tested antigenbinding protein (e.g., antibody or immunologically functional fragment thereof) prevents or inhibits specific binding of a reference antigenbinding protein to a common antigen (e.g., GIPR or a fragment thereof). Numerous types of competitive binding assays can be used, for example: solid phase direct or indirect radioimmunoassay (RIA); solid phase direct or indirect enzyme immunoassay (EIA); sandwich competition assay (see, e.g., Stahli et al., 1983, Methods in Enzymology 9:242-253); solid phase direct biotin-avidin EIA (see, e.g., Kirkland et al., 1986, J. Immunol. 137:3614-3619); solid phase direct labeled assay; solid phase direct labeled sandwich assay (see, e.g., Harlow and Lane, 1988, Antibodies, A Laboratory Manual, Cold Spring Harbor Press); solid phase direct label RIA using I-125 label (see, e.g., Morel et al., 1988, Molec. Immunol. 25:7-15); solid phase direct biotin-avidin EIA (see, e.g., Cheung, et al., 1990, Virology 176:546-552); and direct labeled RIA (Moldenhauer et al., 1990, Scand. J. Immunol. 32:77-82). Typically, such an assay involves the use of purified antigen bound to a solid surface or cells bearing either of these, an unlabeled test antigen binding protein, and a labeled reference antigen binding protein. Competitive inhibition is measured by determining the amount of label bound to the solid surface or cells in the presence of the test antigen binding protein. Usually, the test antigenbinding protein is present in excess. Commonly, when a competing antigen binding protein is present in excess, it will inhibit specific binding of a reference antigen binding protein to a common antigen by at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, or at least 75%. In some instances, binding is inhibited by at least 80%, at least 85%, at least 90%, at least 95%, or at least 97%.

[157] As used herein, the term “encoding” refers to a polynucleotide sequence encoding one or more amino acids. The term does not require a start or stop codon.

[158] As used herein, the term “polynucleotide” or “nucleic acid” includes both single-stranded and double-stranded nucleotide polymers. The nucleotides comprising the polynucleotide can be ribonucleotides or deoxyribonucleotides or a modified form of either type of nucleotide. The modifications include base modifications such as bromouridine and inosine derivatives, ribose modifications such as 2’,3’-dideoxyribose, and internucleotide linkage modifications such as phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phoshoraniladate, and phosphoroamidate.

[159] As used herein, the term “oligonucleotide” means a polynucleotide comprising 200 or fewer nucleotides. In some embodiments, oligonucleotides are 10 to 60 bases in length. In other embodiments, oligonucleotides are 12, 13, 14, 15, 16, 17, 18, 19, or 20 to 40 nucleotides in length. Oligonucleotides may be single stranded or double stranded, e.g., for use in the construction of a mutant gene. Oligonucleotides may be sense or antisense oligonucleotides. An oligonucleotide can include a label, including a radiolabel, a fluorescent label, a hapten or an antigenic label, for detection assays. Oligonucleotides may be used, for example, as PCR primers, cloning primers, or hybridization probes.

[160] Unless specified otherwise, the left-hand end of any single-stranded polynucleotide sequence discussed herein is the 5' end; the left-hand direction of double-stranded polynucleotide sequences is referred to as the 5' direction. The direction of 5' to 3' addition of nascent RNA transcripts is referred to as the transcription direction; sequence regions on the DNA strand having the same sequence as the RNA transcript that are 5' to the 5' end of the RNA transcript are referred to as “upstream sequences;” sequence regions on the DNA strand having the same sequence as the RNA transcript that are 3' to the 3' end of the RNA transcript are referred to as “downstream sequences.”

[161] As used herein, the term “control sequence” refers to a polynucleotide sequence that can affect the expression and processing of coding sequences to which it is ligated. The nature of such control sequences may depend upon the host organism. In some embodiments, control sequences for prokaryotes may include a promoter, a ribosomal binding site, and a transcription termination sequence. For example, control sequences for eukaryotes may include promoters comprising one or a plurality of recognition sites for transcription factors, transcription enhancer sequences, and transcription termination sequences. “Control sequences” can include leader sequences and / or fusion partner sequences.

[162] As used herein, the term “isolated nucleic acid molecule” refers to a single- or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5’ to the 3’ end, or an analog thereof, that has been separated from at least about 50 percent of polypeptides, peptides, lipids, carbohydrates, polynucleotides, or other materials with which the nucleic acid is naturally found when total nucleic acid is isolated from the source cells. In some embodiments, an isolated nucleic acid molecule is substantially free from any other contaminating nucleic acid molecules or other molecules that are found in the natural environment of the nucleic acid that would interfere with its use in polypeptide production or its therapeutic, diagnostic, prophylactic, or research use.

[163] Polypeptides described herein can be engineered and / or produced using standard molecular biology methodology. For example, a nucleic acid sequence encoding a GIPR, which can comprise all or a portion of SEQ ID NOs: 1577, 1578, or 1579, can be isolated and / or amplified from genomic DNA, or cDNA using appropriate oligonucleotide primers. Primers can be designed based on the nucleic and amino acid sequences provided herein according to standard (RT)-PCR amplification techniques. The amplified GIPR nucleic acid can then be cloned into a suitable vector and characterized by DNA sequence analysis.

[164] Oligonucleotides for use as probes in isolating or amplifying all or a portion of the amino acid sequences provided herein can be designed and generated using standard synthetic techniques, e.g., automated DNA synthesis apparatus, or can be isolated from a longer sequence of DNA.

[165] As used herein, the term “host cell” means a cell that has been transformed with a nucleic acid sequence and thereby expresses a gene of interest. The term includes the progeny of the parent cell, whether or not the progeny is identical in morphology or in genetic make-up to the original parent cell, so long as the gene of interest is present. In some embodiments, the host cell is a mammalian, non-human host cell. Representative host cells include, but are not limited to, those hosts typically used for cloning and expression, including Escherichia coli strains TOP10F′, TOP10, DH10B, DH5a, HB101, W3110, BL21(DE3) and BL21 (DE3)pLysS, BLUESCRIPT (Stratagene), mammalian cell lines CHO, CHO-K1, HEK293, 293-EBNA pIN vectors (Van Heeke & Schuster, J. Biol. Chem. 264: 5503-5509 (1989); pET vectors (Novagen, Madison Wis.).

[166] In some embodiments, host cells comprising vectors disclosed herein are provided. In some embodiments, a vector or nucleic acid is integrated into the host cell genome; in other embodiments, the vector is extra-chromosomal.

[167] As used herein, the term “vector” means any molecule or entity (e.g., nucleic acid, plasmid, bacteriophage, or virus) used to transfer protein coding information into a host cell. A “vector” refers to a delivery vehicle that (a) promotes the expression of a polypeptide-encoding nucleic acid sequence; (b) promotes the production of the polypeptide therefrom; (c) promotes the transfection / transformation of target cells therewith; (d) promotes the replication of the nucleic acid sequence; (e) promotes stability of the nucleic acid; (f) promotes detection of the nucleic acid and / or transformed / transfected cells; and / or (g) otherwise imparts advantageous biological and / or physiochemical function to the polypeptide-encoding nucleic acid. A vector can be any suitable molecule or entity, including chromosomal, non-chromosomal, and synthetic nucleic acid vectors (a nucleic acid sequence comprising a suitable set of expression control elements). Non-limiting examples of vectors include derivatives of SV40, bacterial plasmids, phage DNA, baculovirus, yeast plasmids, vectors derived from combinations of plasmids and phage DNA, and viral nucleic acid (RNA or DNA) vectors.

[168] As used herein, the term “expression vector” or “expression construct” refers to a vector that is suitable for transformation of a host cell and contains nucleic acid sequences that direct and / or control (in conjunction with the host cell) expression of one or more heterologous coding regions operatively linked thereto. An expression construct may include, but is not limited to, sequences that affect or control transcription, translation, and, if introns are present, affect RNA splicing of a coding region operably linked thereto.

[169] In order to express a polypeptide provided herein, the appropriate coding sequence(s) can be cloned into a suitable vector and after introduction in a suitable host, the sequence can be expressed to produce the encoded polypeptide according to standard cloning and expression techniques, which are known in the art (e.g., as described in Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989). In some embodiments, the present disclosure provides such vectors comprising a nucleic acid sequence encoding an amino acid sequence described herein.

[170] A recombinant expression vector can be designed for expression of a protein in prokaryotic (e.g., E. coli) or eukaryotic cells (e.g., insect cells, using baculovirus expression vectors, yeast cells, or mammalian cells). Alternatively, a recombinant expression vector can be transcribed and translated in vitro, for example, using T7 promoter regulatory sequences and T7 polymerase and an in vitro translation system. In some embodiments, the vector contains a promoter upstream of the cloning site containing the nucleic acid sequence encoding the polypeptide. Examples of promoters, which can be switched on and off, include, but are not limited to, the lac promoter, the T7 promoter, the trc promoter, the tac promoter, and the trp promoter.

[171] A vector can comprise or be associated with any suitable promoter, enhancer, and other expression-facilitating elements. Examples of such elements include strong expression promoters (e.g., a human CMV IE promoter / enhancer, an RSV promoter, SV40 promoter, SL3-3 promoter, MMTV promoter, or HIV LTR promoter, EF1alpha promoter, CAG promoter), effective poly (A) termination sequences, an origin of replication for plasmid product in E. coli, an antibiotic resistance gene as a selectable marker, and / or a convenient cloning site (e.g., a polylinker). Vectors also can comprise an inducible promoter as opposed to a constitutive promoter such as CMV IE. In some embodiments, a nucleic acid comprising an amino acid sequence described herein which is operably linked to a tissuespecific promoter which promotes expression of the sequence in a metabolically-relevant tissue, such as liver or pancreatic tissue, is provided.

[172] In some embodiments, a nucleic acid can be positioned in and / or delivered to a host cell or host animal via a viral vector. Any suitable viral vector can be used in this capacity. A viral vector can comprise any number of viral polynucleotides, alone or in combination with one or more viral proteins, which facilitate delivery, replication, and / or expression of the nucleic acid of the present disclosure in a desired host cell. The viral vector can be a polynucleotide comprising all or part of a viral genome, a viral protein / nucleic acid conjugate, a virus-like particle (VLP), or an intact virus particle comprising viral nucleic acids and a GIPR polypeptide-encoding nucleic acid. A viral particle viral vector can comprise a wild-type viral particle or a modified viral particle. The viral vector can be a vector which requires the presence of another vector or wild-type virus for replication and / or expression (e.g., a viral vector can be a helper-dependent virus), such as an adenoviral vector amplicon. Typically, such viral vectors consist of a wild-type viral particle, or a viral particle modified in its protein and / or nucleic acid content to increase transgene capacity or aid in transfection and / or expression of the nucleic acid (examples of such vectors include the herpes virus / AAV amplicons). Typically, a viral vector is similar to and / or derived from a virus that normally infects humans. Suitable viral vector particles in this respect, include, but are not limited to, adenoviral vector particles (including any virus of or derived from a virus of the adenoviridae), adeno-associated viral vector particles (AAV vector particles) or other parvoviruses and parvoviral vector particles, papillomaviral vector particles, flaviviral vectors, alphaviral vectors, herpes viral vectors, pox virus vectors, retroviral vectors, including lentiviral vectors.

[173] As used herein, “operably linked” means that the components to which the term is applied are in a relationship that allows them to carry out their inherent functions under suitable conditions. For example, a control sequence in a vector that is "operably linked" to a protein coding sequence is ligated thereto so that expression of the protein coding sequence is achieved under conditions compatible with the transcriptional activity of the control sequences.

[174] As used herein, the terms “glucagon agonist” and “glucagon receptor (GCGR) agonist” are used interchangeably and refer to a molecule that mimics a biological activity of a glucagon molecule with respect to a glucagon receptor.

[175] As used herein, the term “glucagon analog” refers to a molecule which elicits a biological activity similar to that of glucagon, when evaluated by art-known measures such as receptor binding assays or in vivo blood glucose assays as described, e.g., by Hargrove et al., Regulatory Peptides, 141:113-119 (2007), the disclosure of which is incorporated by reference herein. In some embodiments, the term “glucagon analog” refers to a peptide that has an amino acid sequence with 1, 2, 3, 4, 5, 6, 7 or 8 amino acid substitutions, insertions, deletions, or a combination of two or more of the preceding, when compared to the amino acid sequence of a glucagon. In some embodiments, the glucagon analog is glucagon-NH2. Glucagon analogs include the amidated forms, the acid form, the pharmaceutically acceptable salt form, and any other physiologically active form of the molecule. In some embodiments, a simple nomenclature is used to describe the glucagon receptor agonist, e.g., “glucagon (s2)” glucagon” or “glucagon S2s” designates an analog of glucagon wherein the naturally occurring L-serine at position 2 has been substituted with D-serine.

[176] As used herein, the terms “GLP1 agonist” and “GLP-1R agonist” are used interchangeably and refer to a molecule that mimics a biological activity of a GLP-1 molecule with respect to a GLP1R.

[177] As used herein, a “GIPR antagonist” refers to a molecule that partially or fully blocks, inhibits, or neutralizes a biological activity of a GIPR molecule.

[178] As used herein, the term “pharmaceutically acceptable” refers to a species or component that is generally safe, non-toxic, and neither biologically nor otherwise undesirable for use in a subject.

[179] As used herein, the term “pharmaceutically acceptable excipient” refers to a broad range of ingredients that may be combined with a polypeptide or molecule disclosed herein to prepare a pharmaceutically acceptable composition or formulation. Excipients include, for example, vehicles (e.g., solvents, dispersion media), coatings, isotonic and absorption delaying agents, diluents, colorants, glidants, disintegrants, flavoring agents, coatings, binders, sweeteners, lubricants, sorbents, and preservatives (e.g., antibacterial and antifungal agents).

[180] As used herein, “substantially pure” means that the described species is the predominant species present, that is, on a molar basis it is more abundant than any other individual species in the same mixture. In some embodiments, a substantially pure molecule is a composition wherein the object species comprises at least 50% (on a molar basis) of all macromolecular species present. In other embodiments, a substantially pure composition will comprise at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of all macromolecular species present in the composition. In other embodiments, the object species is purified to essential homogeneity wherein contaminating species cannot be detected in the composition by conventional detection methods and thus the composition consists of a single detectable macromolecular species.

[181] As used herein, the term “treating” refers to any indicia of success in the treatment or amelioration of an injury, pathology, or condition, including any objective or subjective parameter, such as, e.g., abatement, remission, diminishing of symptoms or making the injury, pathology, or condition more tolerable to the patient, slowing in the rate of degeneration or decline, making the final point of degeneration less debilitating, or improving a patient’s physical or mental well-being. The treatment or amelioration of symptoms can be based on objective or subjective parameters, including, e.g., the results of a physical examination, neuropsychiatric exam, or a psychiatric evaluation.

[182] As used herein, the term “therapeutically effective amount” refers to that amount of a polypeptide or molecule disclosed herein that elicits a desired biological or medical response in a cell, a tissue, a system, or a subject. The desired biological or medical response does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses. Thus, a therapeutically effective amount may be administered in one or more administrations.

[183] As used herein, the term “patient” or “subject” refers to humans and other mammals. The term “mammal” as used herein includes, for example, humans, non-human primates, cattle, sheep, goats, pigs, horses, cats, dog, rabbits, rodents (e.g., rats or mice), and monkeys. Human subjects include neonates, infants, juveniles, adults, and geriatric subjects. In some embodiments, the subject or patient is a human. In some embodiments, the subject or patient is an adult human. GLUCAGON RECEPTOR AGONISTS

[184] The present disclosure provides polypeptides that agonize a glucagon receptor (“GCGR”). Such polypeptides may be referred to as polypeptide agonists, glucagon receptor agonists, or GCGR agonists herein. The polypeptide agonists provided herein are glucagon analogs that mimic at least one biological activity of a glucagon molecule (SEQ ID NO: 1576) with respect to a glucagon receptor. Relative to native glucagon, such polypeptide agonists may possess one or more advantageous properties. For example, in some embodiments, a polypeptide agonist may exhibit improved stability relative to native glucagon.

[185] Non-limiting examples of polypeptide agonists of the present disclosure are presented in Table 2. Table 2. Examples of GCG Receptor Agonist SequencesDescriptionSequenceSEQ ID NO:[s2,Aib16,K17,D24,5-BrW25,L27,K28]-GCG-OHHsQGT FTSDY SKYLD [Aib]KRAQ DFVD[5-BrW] LLKT1587[s2,Aib16,5-BrW25,L27,K28]-GCG-OHHsQGT FTSDY SKYLD [Aib]RRAQ DFVQ[5-BrW] LLKT1588[s2,Aib16,K24,5-BrW25,L27,D28]-GCG-OHHsQGT FTSDY SKYLD [Aib]RRAQ DFVK[5-BrW] LLDT1589[s2,Aib16,K17,Ala24,5-BrW25,L27,K28]-GCG-OHHsQGT FTSDY SKYLD [Aib]KRAQ DFVA[5-BrW] LLKT1590[s2,Aib16,A24,5-BrW25,K28]-GCG-OHHsQGT FTSDY SKYLD [Aib]RRAQ DFVA[5-BrW] LLKT1591[s2,Aib16,K17,K24,5-BrW25,L27,D28]-GCG-OHHsQGT FTSDY SKYLD [Aib]KRAQ DFVK[5-BrW] LLDT1592[s2,Aib16,K17,E24,5-BrW25,L27,K28]-GCG-OHHsQGT FTSDY SKYLD [Aib]KRAQ DFVE[5-BrW] LLKT1593[s2,Aib16,2-Nal18,K24,5-BrW25,L27,D28]-GCG-OHHsQGT FTSDY SKYLD [Aib]R[2-Nal]AQ DFVK[5-BrW] LLDT1594[s2,Aib16,2-Nal18,Ala24,5-BrW25,L27,K28]-GCG-OHHsQGT FTSDY SKYLD [Aib]R[2-Nal]AQ DFVA[5-BrW] LLKT1595[s2,Aib16,L27,K28]-GCG-OHHsQGT FTSDY SKYLD [Aib]RRAQ DFVQW LLKT1596[s2,Aib16,K24,L27,D28]-GCG-OHHsQGT FTSDY SKYLD [Aib]RRAQ DFVKW LLDT1597[s2,Aib16,K24,E27,S28]-GCG-OHHsQGT FTSDY SKYLD [Aib]RRAQ DFVKW LEST1598[s2,Aib16,K17,L27,K28]-GCG-OHHsQGT FTSDY SKYLD [Aib]KRAQ DFVQW LLKT1599[Y1,s2,Aib16,L27,K28]-GCG-OHYsQGT FTSDY SKYLD [Aib]RRAQ DFVQW LLKT1600[Y1,Aib2,Aib16,L27,K28]-GCG-OHY[Aib]QGT FTSDY SKYLD [Aib]RRAQ DFVQW LLKT1601[t2,Aib16,L27,K28]-GCG-OHHtQGT FTSDY SKYLD [Aib]RRAQ DFVQW LLKT1602[s2,Aib16,A24,L27,K28]-GCG-OHHsQGT FTSDY SKYLD [Aib]RRAQ DFVAW LLKT1603[s2,Aib16,Aib24,L27,K28]-GCG-OHHsQGT FTSDY SKYLD [Aib]RRAQ DFV[Aib]W LLKT1604[s2,Aib16,Aib24,E27,K28]-GCG-OHHsQGT FTSDY SKYLD [Aib]RRAQ DFV[Aib]W LEKT1605[s2,Aib16,Y25,L27,K28]-GCG-OHHsQGT FTSDY SKYLD [Aib]RRAQ DFVQY LLKT1606[s2,Aib16,Bip18,L27,K28]-GCG-OHHsQGT FTSDY SKYLD [Aib]R[Bip]AQ DFVQW LLKT1607[s2,Aib16,2-NaI18,L27,K28]-GCG-OHHsQGT FTSDY SKYLD [Aib]R[2-Nal]AQ DFVQW LLKT1608[s2,Aib16,Cit17,L27,K28]-GCG-OHHsQGT FTSDY SKYLD [Aib][Cit]RAQ DFVQW LLKT1609[s2,Aib16,Aad27,K28]-GCG-OHHSQGT FTSDY SKYLD [Aib]RRAQ DFVQW L[Aad]KT1610[s2,Aib16,Q17,L27,K28]-GCG-OHHsQGT FTSDY SKYLD [Aib]QRAQ DFVQW LLKT1611[s2,H7,Aib16,L27,K28,E29]-GCG-OHHsQGT FHSDY SKYLD [Aib]RRAQ DFVQW LLKE1612[s2,Aib16,K24,L27,D28,S29]-GCG-OHHsQGT FTSDY SKYLD [Aib]RRAQ DFVKW LLDS1613[s2,Aib16,G24,L27,K28]-GCG-OHHSQGT FTSDY SKYLD [Aib]RRAQ DFVGW LLKT1614[s2,Aib16,D24,L27,K28]-GCG-OHHsQGT FTSDY SKYLD [Aib]RRAQ DFVDW LLKT1615[s2,Aib16,D24,L27,K28,E29]-GCG-OHHsQGT FTSDY SKYLD [Aib]RRAQ DFVDW LLKE1616[s2,Aib16,H24,L27,K28]-GCG-OHHsQGT FTSDY SKYLD [Aib]RRAQ DFVHW LLKT1617[s2,Aib16,K24,L27,K28]-GCG-OHHsQGT FTSDY SKYLD [Aib]RRAQ DFVKW LLKT1618[s2,Aib16,N24,L27,K28]-GCG-OHHsQGT FTSDY SKYLD [Aib]RRAQ DFVNW LLKT1619[s2,Aib16,T24,L27,K28]-GCG-OHHsQGT FTSDY SKYLD [Aib]RRAQ DFVTW LLKT1620[s2,Aib16,E24,L27,K28]-GCG-OHHsQGT FTSDY SKYLD [Aib]RRAQ DFVEW LLKT1621[s2,Aib16,L27,K28,D29]-GCG-OHHsQGT FTSDY SKYLD [Aib]RRAQ DFVQW LLKD1622[s2,Aib16,L27,K28,A29]-GCG-OHHsQGT FTSDY SKYLD [Aib]RRAQ DFVQW LLKA1623[s2,Aib16,BhTrp25,L27,K28]-GCG-OHHsQGT FTSDY SKYLD [Aib]RRAQ DFVQ[BhTrp] LLKT1624[s2,Aib16,K17,K24,L27,D28]-GCG-OHHSQGT FTSDY SKYLD [Aib]KRAQ DFVKW LLDT1625[s2,Aib16,K17,D24,L27,K28]-GCG-OHHsQGT FTSDY SKYLD [Aib]KRAQ DFVDW LLKT1626[s2,Aib16,K17,E24,L27,K28]-GCG-OHHsQGT FTSDY SKYLD [Aib]KRAQ DFVEW LLKT1627[s2,Aib16,q24,L27,K28]-GCG-OHHsQGT FTSDY SKYLD [Aib]RRAQ DFVqW LLKT1747 

[186] Provided herein is a polypeptide that agonizes a glucagon receptor (“GCGR”), wherein: the polypeptide comprises at least 25 amino acids, wherein the polypeptide comprises 5bromo-tryptophan at position 25; andthe polypeptide has at least 79% sequence identity to the amino acid sequence of SEQ ID NO: 1587.

[187] In some embodiments, the polypeptide is a linear polypeptide. In some embodiments, the polypeptide is a peptide. In some embodiments, the peptide is a linear peptide.

[188] In some embodiments, the polypeptide comprises at least 27 (e.g., at least 27, at least 28, at least 29; 27, 28, 29) amino acids. In some embodiments, the polypeptide comprises at least 28 amino acids. In some embodiments, the polypeptide comprises at least 29 amino acids.

[189] In some embodiments, the polypeptide comprises 29 amino acids.

[190] In some embodiments, the polypeptide has at least 82% sequence identity to the amino acid sequence of SEQ ID NO: 1587. In some embodiments, the polypeptide has at least 86% sequence identity to the amino acid sequence of SEQ ID NO: 1587. In some embodiments, the polypeptide has at least 89% sequence identity to the amino acid sequence of SEQ ID NO: 1587. In some embodiments, the polypeptide has at least 93% sequence identity to the amino acid sequence of SEQ ID NO: 1587. In some embodiments, the polypeptide has at least 96% sequence identity to the amino acid sequence of SEQ ID NO: 1587.

[191] In some embodiments, the polypeptide comprises an amino acid sequence having at most six (e.g., zero, one, two, three, four, five or six) amino acid modifications relative to SEQ ID NO: 1587. In some embodiments, the polypeptide comprises an amino acid sequence having at most five amino acid modifications relative to SEQ ID NO: 1587. In some embodiments, the polypeptide comprises an amino acid sequence having at most four amino acid modifications relative to SEQ ID NO: 1587. In some embodiments, the polypeptide comprises an amino acid sequence having at most three amino acid modifications relative to SEQ ID NO: 1587. In some embodiments, the polypeptide comprises an amino acid sequence having at most two amino acid modifications relative to SEQ ID NO: 1587. In some embodiments, the polypeptide comprises an amino acid sequence having at most one amino acid modification relative to SEQ ID NO: 1587.

[192] In some embodiments, each amino acid modification, if any, is an amino acid substitution. In some embodiments, each amino acid modification, if any, is a conservative amino acid substitution. In some embodiments, each amino acid modification, if any, is a conservative amino acid substitution listed in Table 1.

[193] In some embodiments, the at most one amino acid modification is an amino acid deletion. In some embodiments, the at most one amino acid modification is an amino acid addition.

[194] In some embodiments, the polypeptide comprises one or more (e.g., two or more, three or more, four or more, five or more; one, two, three, four, five, or six) of: d-serine at position 2; 2aminoisobutyric acid at position 16; lysine at position 17; β-(2-naphthyl)-L-alanine at position 18; aspartic acid, lysine, alanine, or glutamic acid at position 24; and leucine at position 27. In some embodiments, the polypeptide comprises d-serine at position 2. In some embodiments, the polypeptide comprises 2aminoisobutyric acid at position 16. In some embodiments, the polypeptide comprises lysine at position 17. In some embodiments, the polypeptide comprises β(2-naphthyl)-L-alanine at position 18. In some embodiments, the polypeptide comprises aspartic acid, lysine, alanine, or glutamic acid at position 24. In some embodiments, the polypeptide comprises aspartic acid at position 24. In some embodiments, the polypeptide comprises lysine at position 24. In some embodiments, the polypeptide comprises alanine at position 24. In some embodiments, the polypeptide comprises glutamic acid at position 24. In some embodiments, the polypeptide comprises leucine at position 27.

[195] In some embodiments, the polypeptide comprises lysine or aspartic acid at position 28. In some embodiments, the polypeptide comprises lysine at position 28. In some embodiments, the polypeptide comprises aspartic acid at position 28.

[196] In some embodiments, the polypeptide comprises d-serine at position 2 and 2aminoisobutyric acid at position 16. In some embodiments, the polypeptide comprises d-serine at position 2, 2aminoisobutyric acid at position 16, and leucine at position 27. In some embodiments, the polypeptide further comprises lysine or aspartic acid at position 28. In some embodiments, the polypeptide further comprises lysine at position 28. In some embodiments, the polypeptide comprises further aspartic acid at position 28.

[197] In some embodiments, the polypeptide comprises d-serine at position 2, 2aminoisobutyric acid at position 16, leucine at position 27, and lysine or aspartic acid at position 28. In some embodiments, the polypeptide comprises d-serine at position 2, 2aminoisobutyric acid at position 16, leucine at position 27, and lysine at position 28. In some embodiments, the polypeptide comprises d-serine at position 2, 2aminoisobutyric acid at position 16, leucine at position 27, and aspartic acid at position 28.

[198] In some embodiments, the polypeptide comprises d-serine at position 2, 2aminoisobutyric acid at position 16, leucine at position 27, and lysine at position 28. In some embodiments, the polypeptide comprises d-serine at position 2, 2aminoisobutyric acid at position 16, aspartic acid at position 24, leucine at position 27, and lysine at position 28.

[199] In some embodiments, the polypeptide comprises d-serine at position 2, 2aminoisobutyric acid at position 16, lysine at position 24, leucine at position 27, and aspartic acid at position 28.

[200] In some embodiments, the polypeptide comprises d-serine at position 2, 2aminoisobutyric acid at position 16, aspartic acid at position 24, leucine at position 27, and lysine at position 28.

[201] In some embodiments, the polypeptide comprises d-serine at position 2, 2aminoisobutyric acid at position 16, alanine at position 24, and lysine at position 28. In some embodiments, the polypeptide comprises d-serine at position 2, 2aminoisobutyric acid at position 16, lysine at position 17, alanine at position 24, leucine at position 27, and lysine at position 28. In some embodiments, the polypeptide comprises d-serine at position 2, 2aminoisobutyric acid at position 16, lysine at position 17, glutamic acid at position 24, leucine at position 27, and lysine at position 28.

[202] In some embodiments, the polypeptide comprises d-serine at position 2, 2aminoisobutyric acid at position 16, β-(2-naphthyl)-L-alanine at position 18, lysine or alanine at position 24, leucine at position 27, and lysine or aspartic acid at position 28. In some embodiments, the polypeptide comprises d-serine at position 2, 2aminoisobutyric acid at position 16, β-(2-naphthyl)-L-alanine at position 18, lysine at position 24, leucine at position 27, and aspartic acid at position 28. In some embodiments, the polypeptide comprises d-serine at position 2, 2aminoisobutyric acid at position 16, β-(2-naphthyl)-L-alanine at position 18, alanine at position 24, leucine at position 27, and lysine at position 28.

[203] In some embodiments, the polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 15871595. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1587. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1588. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1589. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1590. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1591. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1592. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1593. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1594. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1595.

[204] In some embodiments, the polypeptide consists of the amino acid sequence of any one of SEQ ID NOs: 15871595. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1587. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1588. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1589. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1590. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1591. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1592. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1593. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1594. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1595.

[205] In some embodiments, the polypeptide agonizes human GCGR (“hGCGR”). In some embodiments, the hGCGR comprises the amino acid sequence of SEQ ID NO: 1576.

[206] In some embodiments, the polypeptide has a hGCGR EC50 of less than or equal to 500 pM (e.g., less than or equal to 475 pM, less than or equal to 450 pM, less than or equal to 425 pM, less than or equal to 400 pM, less than or equal to 375 pM, less than or equal to 350 pM, less than or equal to 325 pM, less than or equal to 300 pM, less than or equal to 275 pM, less than or equal to 250 pM, less than or equal to 225 pM, less than or equal to 200 pM, less than or equal to 175 pM, less than or equal to 150 pM, less than or equal to 125 pM, less than or equal to 100 pM). In some embodiments, the hGCGR EC50 is measured in a functional assay described in “EXAMPLE 1: GCG Receptor Agonist Activity.”

[207] In some embodiments, the polypeptide has a hGCGR EC50 of 50 pM, 55 pM, 60 pM, 65 pM, 70 pM, 75 pM, 80 pM, 85 pM, 90 pM, 95 pM, 100 pM, 105 pM, 110 pM, 115 pM, 120 pM, 125 pM, 130 pM, 135 pM, 140 pM, 145 pM, 150 pM, 155 pM, 200 pM, 205 pM, 210 pM, 215 pM, 220 pM, 225 pM, 230 pM, 235 pM, 240 pM, 245 pM, 250 pM, 255 pM, 260 pM, 265 pM, 270 pM, 275 pM, 280 pM, 285 pM, 290 pM, 295 pM, 300 pM, 305 pM, 310 pM, 315 pM, 320 pM, 325 pM, 330 pM, 335 pM, 340 pM, 345 pM, 350 pM, 355 pM, 360 pM, 365 pM, 370 pM, 375 pM, 380 pM, 385 pM, 390 pM, 395 pM, 400 pM, 405 pM, 410 pM, 415 pM, 420 pM, 425 pM, 430 pM, 435 pM, 440 pM, 445 pM, 450 pM, 455 pM, 460 pM, 465 pM, 470 pM, 475 pM, 480 pM, 485 pM, 490 pM, 495 pM, or 500 pM. In some embodiments, the hGCGR EC50 is measured in a functional assay described in “EXAMPLE 1: GCG Receptor Agonist Activity.”

[208] In some embodiments, the polypeptide has a human glucagon-like peptide-1 receptor (“hGLP1R”) EC50:hGCGR EC50 ratio of at least 40:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 50:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 60:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 70:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 80:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 90:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 100:1.In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 150:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 200:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 250:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 300:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 350:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 400:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 450:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 500:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 550:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 650:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 700:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 750:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 800:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 850:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 900:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 950:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 1000:1. In some embodiments, the hGCGR EC50 is measured in a functional assay described in “EXAMPLE 1: GCG Receptor Agonist Activity” and the hGLP1R EC50 is measured in a functional assay described in “EXAMPLE 2: GLP1 Receptor Agonist Activity.”

[209] In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of 40:1, 45:1, 50:1, 55:1, 60:1, 65:1, 70:1, 75:1, 80:1, 85:1, 90:1, 95:1, 100:1, 125:1, 150:1, 175:1, 200:1, 225:1, 250:1, 275:1, 300:1, 325:1, 350:1, 375:1, 400:1, 425:1, 450:1, 475:1, 500:1, 525:1, 550:1, 575:1, 600:1, 625:1, 650:1, 675:1, 700:1, 725:1, 750:1, 775:1, 800:1, 825:1, 850:1, 875:1, 900:1, 925:1, 950:1, 975:1, or 1000:1. In some embodiments, the hGCGR EC50 is measured in a functional assay described in “EXAMPLE 1: GCG Receptor Agonist Activity” and the hGLP1R EC50 is measured in a functional assay described in “EXAMPLE 2: GLP1 Receptor Agonist Activity.”

[210] Provided herein is a polypeptide that agonizes a GCGR, wherein:the polypeptide comprises at least 28 amino acids, wherein the polypeptide comprises 2aminoisobutyric acid at position 16 and lysine, serine, or aspartic acid at position 28; andthe polypeptide has at least 89% sequence identity to the amino acid sequence of SEQ ID NO: 1596.

[211] In some embodiments, the polypeptide comprises lysine at position 28.

[212] In some embodiments, the polypeptide comprises serine at position 28.

[213] In some embodiments, the polypeptide comprises aspartic acid at position 28.

[214] In some embodiments, the polypeptide is a linear polypeptide. In some embodiments, the polypeptide is a peptide. In some embodiments, the peptide is a linear peptide.

[215] In some embodiments, the polypeptide comprises 29 amino acids.

[216] In some embodiments, the polypeptide has at least 93% sequence identity to the amino acid sequence of SEQ ID NO: 1596. In some embodiments, the polypeptide has at least 96% sequence identity to the amino acid sequence of SEQ ID NO: 1596.

[217] In some embodiments, the polypeptide comprises an amino acid sequence having at most three (e.g., zero, one, two, three) amino acid modifications relative to SEQ ID NO: 1596. In some embodiments, the polypeptide comprises an amino acid sequence having at most two amino acid modifications relative to SEQ ID NO: 1596. In some embodiments, the polypeptide comprises an amino acid sequence having at most one amino acid modification relative to SEQ ID NO: 1596.

[218] In some embodiments, each amino acid modification, if any, is an amino acid substitution. In some embodiments, each amino acid modification, if any, is a conservative amino acid substitution. In some embodiments, each amino acid modification, if any, is a conservative amino acid substitution listed in Table 1.

[219] In some embodiments, the at most one amino acid modification is an amino acid deletion. In some embodiments, the at most one amino acid modification is an amino acid addition.

[220] In some embodiments, the polypeptide comprises one or more (e.g., two or more, three of more, four or more, five or more; one, two, three, four, or five) of the following: tyrosine at position 1; dserine, d-threonine, or 2-aminoisobutyric acid at position 2; histidine at position 7; lysine, citrulline, or glutamine at position 17; β-(2-naphthyl)-L-alanine or β-(4,4'-biphenyl)alanine at position 18; lysine, alanine, asparagine, glutamic acid, glycine, aspartic acid, histidine, threonine, or 2aminoisobutyric acid at position 24; tyrosine, 5-bromo-tryptophan, or 2bromo-5-hydroxytryptophan at position 25; leucine, glutamic acid, or αaminoadipic acid at position 27; and alanine, aspartic acid, glutamic acid, or serine at position 29.

[221] In some embodiments, the polypeptide comprises tyrosine at position 1.

[222] In some embodiments, the polypeptide comprises dserine, d-threonine, or 2aminoisobutyric acid at position 2. In some embodiments, the polypeptide comprises dserine at position 2. In some embodiments, the polypeptide comprises d-threonine at position 2. In some embodiments, the polypeptide comprises 2aminoisobutyric acid at position 2.

[223] In some embodiments, the polypeptide comprises histidine at position 7.

[224] In some embodiments, the polypeptide comprises lysine, citrulline, or glutamine at position 17. In some embodiments, the polypeptide comprises lysine at position 17. In some embodiments, the polypeptide comprises citrulline at position 17. In some embodiments, the polypeptide comprises glutamine at position 17.

[225] In some embodiments, the polypeptide comprises β-(2-naphthyl)-L-alanine or β-(4,4'-biphenyl)alanine at position 18. In some embodiments, the polypeptide comprises β-(2-naphthyl)-L-alanine at position 18. In some embodiments, the polypeptide comprises β-(4,4'-biphenyl)alanine at position 18.

[226] In some embodiments, the polypeptide comprises lysine, alanine, asparagine, glutamic acid, glycine, aspartic acid, histidine, threonine, or 2aminoisobutyric acid at position 24. In some embodiments, the polypeptide comprises lysine at position 24. In some embodiments, the polypeptide comprises alanine at position 24. In some embodiments, the polypeptide comprises asparagine at position 24. In some embodiments, the polypeptide comprises glutamic acid at position 24. In some embodiments, the polypeptide comprises glycine at position 24. In some embodiments, the polypeptide comprises aspartic acid at position 24. In some embodiments, the polypeptide comprises histidine at position 24. In some embodiments, the polypeptide comprises threonine at position 24. In some embodiments, the polypeptide comprises 2aminoisobutyric acid at position 24.

[227] In some embodiments, the polypeptide comprises tyrosine, 5-bromo-tryptophan, or 2bromo-5-hydroxytryptophan at position 25. In some embodiments, the polypeptide comprises tyrosine at position 25. In some embodiments, the polypeptide comprises 5-bromo-tryptophan at position 25. In some embodiments, the polypeptide comprises 2bromo-5-hydroxytryptophan at position 25.

[228] In some embodiments, the polypeptide comprises leucine, glutamic acid, or αaminoadipic acid at position 27. In some embodiments, the polypeptide comprises leucine at position 27. In some embodiments, the polypeptide comprises glutamic acid at position 27. In some embodiments, the polypeptide comprises αaminoadipic acid at position 27.

[229] In some embodiments, the polypeptide comprises alanine, aspartic acid, glutamic acid, or serine at position 29. In some embodiments, the polypeptide comprises alanine at position 29. In some embodiments, the polypeptide comprises aspartic acid at position 29. In some embodiments, the polypeptide comprises glutamic acid at position 29. In some embodiments, the polypeptide comprises serine at position 29.

[230] In some embodiments, the polypeptide comprises d-serine at position 2, 2aminoisobutyric acid at position 16, leucine at position 27, and lysine at position 28.

[231] In some embodiments, the polypeptide comprises d-serine at position 2, 2aminoisobutyric acid at position 16, lysine at position 17, leucine at position 27, and lysine at position 28.

[232] In some embodiments, the polypeptide comprises d-serine at position 2, 2aminoisobutyric acid at position 16, lysine, alanine, asparagine, glutamic acid, glycine, aspartic acid, histidine, threonine, or 2aminoisobutyric acid at position 24, and lysine at position 28.

[233] In some embodiments, the polypeptide comprises d-serine at position 2, 2aminoisobutyric acid at position 16, tyrosine, 5-bromo-tryptophan, or 2bromo-5-hydroxytryptophan at position 25, leucine at position 27, and lysine at position 28.

[234] In some embodiments, the polypeptide comprises d-serine at position 2, 2aminoisobutyric acid at position 16, lysine at position 28, and alanine, aspartic acid, glutamic acid, or serine at position 29.

[235] In some embodiments, the polypeptide agonizes human GCGR (“hGCGR”). In some embodiments, the hGCGR comprises the amino acid sequence of SEQ ID NO: 1576.

[236] In some embodiments, the polypeptide has a hGCGR EC50 of less than or equal to 500 pM (e.g., less than or equal to 475 pM, less than or equal to 450 pM, less than or equal to 425 pM, less than or equal to 400 pM, less than or equal to 375 pM, less than or equal to 350 pM, less than or equal to 325 pM, less than or equal to 300 pM, less than or equal to 275 pM, less than or equal to 250 pM, less than or equal to 225 pM, less than or equal to 200 pM, less than or equal to 175 pM, less than or equal to 150 pM, less than or equal to 125 pM, less than or equal to 100 pM). In some embodiments, the hGCGR EC50 is measured in a functional assay described in “EXAMPLE 1: GCG Receptor Agonist Activity.”

[237] In some embodiments, the polypeptide has a hGCGR EC50 of 50 pM, 55 pM, 60 pM, 65 pM, 70 pM, 75 pM, 80 pM, 85 pM, 90 pM, 95 pM, 100 pM, 105 pM, 110 pM, 115 pM, 120 pM, 125 pM, 130 pM, 135 pM, 140 pM, 145 pM, 150 pM, 155 pM, 200 pM, 205 pM, 210 pM, 215 pM, 220 pM, 225 pM, 230 pM, 235 pM, 240 pM, 245 pM, 250 pM, 255 pM, 260 pM, 265 pM, 270 pM, 275 pM, 280 pM, 285 pM, 290 pM, 295 pM, 300 pM, 305 pM, 310 pM, 315 pM, 320 pM, 325 pM, 330 pM, 335 pM, 340 pM, 345 pM, 350 pM, 355 pM, 360 pM, 365 pM, 370 pM, 375 pM, 380 pM, 385 pM, 390 pM, 395 pM, 400 pM, 405 pM, 410 pM, 415 pM, 420 pM, 425 pM, 430 pM, 435 pM, 440 pM, 445 pM, 450 pM, 455 pM, 460 pM, 465 pM, 470 pM, 475 pM, 480 pM, 485 pM, 490 pM, 495 pM, or 500 pM. In some embodiments, the hGCGR EC50 is measured in a functional assay described in “EXAMPLE 1: GCG Receptor Agonist Activity.”

[238] In some embodiments, the polypeptide has a human glucagon-like peptide-1 receptor (“hGLP1R”) EC50:hGCGR EC50 ratio of at least 40:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 50:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 60:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 70:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 80:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 90:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 100:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 150:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 200:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 250:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 300:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 350:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 400:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 450:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 500:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 550:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 650:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 700:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 750:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 800:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 850:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 900:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 950:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 1000:1. In some embodiments, the hGCGR EC50 is measured in a functional assay described in “EXAMPLE 1: GCG Receptor Agonist Activity” and the hGLP1R EC50 is measured in a functional assay described in “EXAMPLE 2: GLP1 Receptor Agonist Activity.”

[239] In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of 40:1, 45:1, 50:1, 55:1, 60:1, 65:1, 70:1, 75:1, 80:1, 85:1, 90:1, 95:1, 100:1, 125:1, 150:1, 175:1, 200:1, 225:1, 250:1, 275:1, 300:1, 325:1, 350:1, 375:1, 400:1, 425:1, 450:1, 475:1, 500:1, 525:1, 550:1, 575:1, 600:1, 625:1, 650:1, 675:1, 700:1, 725:1, 750:1, 775:1, 800:1, 825:1, 850:1, 875:1, 900:1, 925:1, 950:1, 975:1, or 1000:1. In some embodiments, the hGCGR EC50 is measured in a functional assay described in “EXAMPLE 1: GCG Receptor Agonist Activity” and the hGLP1R EC50 is measured in a functional assay described in “EXAMPLE 2: GLP1 Receptor Agonist Activity.”

[240] Provided herein is a polypeptide that agonizes a GCGR, wherein:the polypeptide comprises at least 28 amino acids, wherein the polypeptide comprises 2aminoisobutyric acid at position 16, leucine at position 27, and lysine at position 28; andthe polypeptide has at least 89% sequence identity to the amino acid sequence of SEQ ID NO: 1615.

[241] In some embodiments, the polypeptide is a linear polypeptide. In some embodiments, the polypeptide is a peptide. In some embodiments, the peptide is a linear peptide.

[242] In some embodiments, the polypeptide comprises 29 amino acids.

[243] In some embodiments, the polypeptide has at least 93% sequence identity to the amino acid sequence of SEQ ID NO: 1615. In some embodiments, the polypeptide has at least 96% sequence identity to the amino acid sequence of SEQ ID NO: 1615.

[244] In some embodiments, the polypeptide comprises an amino acid sequence having at most three (e.g., zero, one, two, three) amino acid modifications relative to SEQ ID NO: 1615. In some embodiments, the polypeptide comprises an amino acid sequence having at most two amino acid modifications relative to SEQ ID NO: 1615. In some embodiments, the polypeptide comprises an amino acid sequence having at most one amino acid modification relative to SEQ ID NO: 1615.

[245] In some embodiments, each amino acid modification, if any, is an amino acid substitution. In some embodiments, each amino acid modification, if any, is a conservative amino acid substitution. In some embodiments, each amino acid modification, if any, is a conservative amino acid substitution listed in Table 1.

[246] In some embodiments, the at most one amino acid modification is an amino acid deletion. In some embodiments, the at most one amino acid modification is an amino acid addition.

[247] In some embodiments, the polypeptide comprises d-serine at position 2.

[248] In some embodiments, the polypeptide comprises aspartic acid or glutamic acid at position 24. In some embodiments, the polypeptide comprises aspartic acid at position 24. In some embodiments, the polypeptide comprises glutamic acid at position 24.

[249] In some embodiments, the polypeptide comprises d-serine at position 2 and aspartic acid or glutamic acid at position 24. In some embodiments, the polypeptide comprises d-serine at position 2 and aspartic acid at position 24. In some embodiments, the polypeptide comprises dserine at position 2 and glutamic acid at position 24.

[250] In some embodiments, the polypeptide comprises lysine at position 17.

[251] In some embodiments, the polypeptide further comprises d-serine at position 2, lysine at position 17, and aspartic acid at position 24.

[252] In some embodiments, the polypeptide agonizes human GCGR (“hGCGR”). In some embodiments, the hGCGR comprises the amino acid sequence of SEQ ID NO: 1576.

[253] In some embodiments, the polypeptide has a hGCGR EC50 of less than or equal to 500 pM (e.g., less than or equal to 475 pM, less than or equal to 450 pM, less than or equal to 425 pM, less than or equal to 400 pM, less than or equal to 375 pM, less than or equal to 350 pM, less than or equal to 325 pM, less than or equal to 300 pM, less than or equal to 275 pM, less than or equal to 250 pM, less than or equal to 225 pM, less than or equal to 200 pM, less than or equal to 175 pM, less than or equal to 150 pM, less than or equal to 125 pM, less than or equal to 100 pM). In some embodiments, the hGCGR EC50 is measured in a functional assay described in “EXAMPLE 1: GCG Receptor Agonist Activity.”

[254] In some embodiments, the polypeptide has a hGCGR EC50 of 50 pM, 55 pM, 60 pM, 65 pM, 70 pM, 75 pM, 80 pM, 85 pM, 90 pM, 95 pM, 100 pM, 105 pM, 110 pM, 115 pM, 120 pM, 125 pM, 130 pM, 135 pM, 140 pM, 145 pM, 150 pM, 155 pM, 200 pM, 205 pM, 210 pM, 215 pM, 220 pM, 225 pM, 230 pM, 235 pM, 240 pM, 245 pM, 250 pM, 255 pM, 260 pM, 265 pM, 270 pM, 275 pM, 280 pM, 285 pM, 290 pM, 295 pM, 300 pM, 305 pM, 310 pM, 315 pM, 320 pM, 325 pM, 330 pM, 335 pM, 340 pM, 345 pM, 350 pM, 355 pM, 360 pM, 365 pM, 370 pM, 375 pM, 380 pM, 385 pM, 390 pM, 395 pM, 400 pM, 405 pM, 410 pM, 415 pM, 420 pM, 425 pM, 430 pM, 435 pM, 440 pM, 445 pM, 450 pM, 455 pM, 460 pM, 465 pM, 470 pM, 475 pM, 480 pM, 485 pM, 490 pM, 495 pM, or 500 pM. In some embodiments, the hGCGR EC50 is measured in a functional assay described in “EXAMPLE 1: GCG Receptor Agonist Activity.”

[255] In some embodiments, the polypeptide has a human glucagon-like peptide-1 receptor (“hGLP1R”) EC50:hGCGR EC50 ratio of at least 40:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 50:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 60:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 70:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 80:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 90:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 100:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 150:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 200:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 250:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 300:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 350:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 400:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 450:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 500:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 550:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 650:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 700:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 750:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 800:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 850:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 900:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 950:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 1000:1. In some embodiments, the hGCGR EC50 is measured in a functional assay described in “EXAMPLE 1: GCG Receptor Agonist Activity” and the hGLP1R EC50 is measured in a functional assay described in “EXAMPLE 2: GLP1 Receptor Agonist Activity.”

[256] In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of 40:1, 45:1, 50:1, 55:1, 60:1, 65:1, 70:1, 75:1, 80:1, 85:1, 90:1, 95:1, 100:1, 125:1, 150:1, 175:1, 200:1, 225:1, 250:1, 275:1, 300:1, 325:1, 350:1, 375:1, 400:1, 425:1, 450:1, 475:1, 500:1, 525:1, 550:1, 575:1, 600:1, 625:1, 650:1, 675:1, 700:1, 725:1, 750:1, 775:1, 800:1, 825:1, 850:1, 875:1, 900:1, 925:1, 950:1, 975:1, or 1000:1. In some embodiments, the hGCGR EC50 is measured in a functional assay described in “EXAMPLE 1: GCG Receptor Agonist Activity” and the hGLP1R EC50 is measured in a functional assay described in “EXAMPLE 2: GLP1 Receptor Agonist Activity.”

[257] Provided herein is a polypeptide that agonizes a GCGR, wherein:the polypeptide comprises at least 28 amino acids, wherein the polypeptide comprises 2-aminoisobutyric acid at position 16, aspartic acid at position 24, and lysine at position 28; andthe polypeptide has at least 89% sequence identity to the amino acid sequence of SEQ ID NO: 1626.

[258] In some embodiments, the polypeptide is a linear polypeptide. In some embodiments, the polypeptide is a peptide. In some embodiments, the peptide is a linear peptide.

[259] In some embodiments, the polypeptide comprises 29 amino acids.

[260] In some embodiments, the polypeptide has at least 93% sequence identity to the amino acid sequence of SEQ ID NO: 1626. In some embodiments, the polypeptide has at least 96% sequence identity to the amino acid sequence of SEQ ID NO: 1626.

[261] In some embodiments, the polypeptide comprises an amino acid sequence having at most three (e.g., zero, one, two, three) amino acid modifications relative to SEQ ID NO: 1626. In some embodiments, the polypeptide comprises an amino acid sequence having at most two amino acid modifications relative to SEQ ID NO: 1626. In some embodiments, the polypeptide comprises an amino acid sequence having at most one amino acid modification relative to SEQ ID NO: 1626.

[262] In some embodiments, each amino acid modification, if any, is an amino acid substitution. In some embodiments, each amino acid modification, if any, is a conservative amino acid substitution. In some embodiments, each amino acid modification, if any, is a conservative amino acid substitution listed in Table 1.

[263] In some embodiments, the at most one amino acid modification is an amino acid deletion. In some embodiments, the at most one amino acid modification is an amino acid addition.

[264] In some embodiments, the polypeptide comprises d-serine at position 2.

[265] In some embodiments, the polypeptide comprises lysine at position 17.

[266] In some embodiments, the polypeptide further comprises leucine at position 27.

[267] In some embodiments, the polypeptide agonizes human GCGR (“hGCGR”). In some embodiments, the hGCGR comprises the amino acid sequence of SEQ ID NO: 1576.

[268] In some embodiments, the polypeptide has a hGCGR EC50 of less than or equal to 500 pM (e.g., less than or equal to 475 pM, less than or equal to 450 pM, less than or equal to 425 pM, less than or equal to 400 pM, less than or equal to 375 pM, less than or equal to 350 pM, less than or equal to 325 pM, less than or equal to 300 pM, less than or equal to 275 pM, less than or equal to 250 pM, less than or equal to 225 pM, less than or equal to 200 pM, less than or equal to 175 pM, less than or equal to 150 pM, less than or equal to 125 pM, less than or equal to 100 pM). In some embodiments, the hGCGR EC50 is measured in a functional assay described in “EXAMPLE 1: GCG Receptor Agonist Activity.”

[269] In some embodiments, the polypeptide has a hGCGR EC50 of 50 pM, 55 pM, 60 pM, 65 pM, 70 pM, 75 pM, 80 pM, 85 pM, 90 pM, 95 pM, 100 pM, 105 pM, 110 pM, 115 pM, 120 pM, 125 pM, 130 pM, 135 pM, 140 pM, 145 pM, 150 pM, 155 pM, 200 pM, 205 pM, 210 pM, 215 pM, 220 pM, 225 pM, 230 pM, 235 pM, 240 pM, 245 pM, 250 pM, 255 pM, 260 pM, 265 pM, 270 pM, 275 pM, 280 pM, 285 pM, 290 pM, 295 pM, 300 pM, 305 pM, 310 pM, 315 pM, 320 pM, 325 pM, 330 pM, 335 pM, 340 pM, 345 pM, 350 pM, 355 pM, 360 pM, 365 pM, 370 pM, 375 pM, 380 pM, 385 pM, 390 pM, 395 pM, 400 pM, 405 pM, 410 pM, 415 pM, 420 pM, 425 pM, 430 pM, 435 pM, 440 pM, 445 pM, 450 pM, 455 pM, 460 pM, 465 pM, 470 pM, 475 pM, 480 pM, 485 pM, 490 pM, 495 pM, or 500 pM. In some embodiments, the hGCGR EC50 is measured in a functional assay described in “EXAMPLE 1: GCG Receptor Agonist Activity.”

[270] In some embodiments, the polypeptide has a human glucagon-like peptide-1 receptor (“hGLP1R”) EC50:hGCGR EC50 ratio of at least 40:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 50:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 60:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 70:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 80:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 90:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 100:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 150:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 200:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 250:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 300:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 350:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 400:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 450:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 500:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 550:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 650:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 700:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 750:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 800:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 850:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 900:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 950:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 1000:1. In some embodiments, the hGCGR EC50 is measured in a functional assay described in “EXAMPLE 1: GCG Receptor Agonist Activity” and the hGLP1R EC50 is measured in a functional assay described in “EXAMPLE 2: GLP1 Receptor Agonist Activity.”

[271] In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of 40:1, 45:1, 50:1, 55:1, 60:1, 65:1, 70:1, 75:1, 80:1, 85:1, 90:1, 95:1, 100:1, 125:1, 150:1, 175:1, 200:1, 225:1, 250:1, 275:1, 300:1, 325:1, 350:1, 375:1, 400:1, 425:1, 450:1, 475:1, 500:1, 525:1, 550:1, 575:1, 600:1, 625:1, 650:1, 675:1, 700:1, 725:1, 750:1, 775:1, 800:1, 825:1, 850:1, 875:1, 900:1, 925:1, 950:1, 975:1, or 1000:1. In some embodiments, the hGCGR EC50 is measured in a functional assay described in “EXAMPLE 1: GCG Receptor Agonist Activity” and the hGLP1R EC50 is measured in a functional assay described in “EXAMPLE 2: GLP1 Receptor Agonist Activity.

[272] Provided herein is a polypeptide that agonizes a GCGR comprising the amino acid sequence of any one of SEQ ID NOs: 15871627.

[273] In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1587. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1588. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1589. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1590. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1591. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1592. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1593. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1594. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1595. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1596. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1597. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1598. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1599. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1600. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1601. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1602. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1603. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1604. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1605. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1606. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1607. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1608. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1609. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1610. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1611. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1612. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1613. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1614. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1615. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1616. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1617. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1618. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1619. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1620. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1621. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1622. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1623. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1624. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1625. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1626. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1627.

[274] In some embodiments, the polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 1596, 1597, 1615, or 1626.

[275] In some embodiments, the polypeptide consists of the amino acid sequence of any one of SEQ ID NOs: 15871627.

[276] In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1587. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1588. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1589. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1590. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1591. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1592. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1593. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1594. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1595. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1596. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1597. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1598. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1599. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1600. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1601. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1602. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1603. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1604. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1605. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1606. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1607. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1608. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1609. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1610. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1611. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1612. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1613. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1614. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1615. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1616. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1617. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1618. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1619. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1620. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1621. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1622. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1623. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1624. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1625. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1626. In some embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1627.

[277] In some embodiments, the polypeptide consists of the amino acid sequence of any one of SEQ ID NOs: 1596, 1597, 1615, or 1626.

[278] In some embodiments, the polypeptide agonizes human GCGR (“hGCGR”). In some embodiments, the hGCGR comprises the amino acid sequence of SEQ ID NO: 1576.

[279] In some embodiments, the polypeptide has a hGCGR EC50 of less than or equal to 500 pM (e.g., less than or equal to 475 pM, less than or equal to 450 pM, less than or equal to 425 pM, less than or equal to 400 pM, less than or equal to 375 pM, less than or equal to 350 pM, less than or equal to 325 pM, less than or equal to 300 pM, less than or equal to 275 pM, less than or equal to 250 pM, less than or equal to 225 pM, less than or equal to 200 pM, less than or equal to 175 pM, less than or equal to 150 pM, less than or equal to 125 pM, less than or equal to 100 pM). In some embodiments, the hGCGR EC50 is measured in a functional assay described in “EXAMPLE 1: GCG Receptor Agonist Activity.”

[280] In some embodiments, the polypeptide has a hGCGR EC50 of 50 pM, 55 pM, 60 pM, 65 pM, 70 pM, 75 pM, 80 pM, 85 pM, 90 pM, 95 pM, 100 pM, 105 pM, 110 pM, 115 pM, 120 pM, 125 pM, 130 pM, 135 pM, 140 pM, 145 pM, 150 pM, 155 pM, 200 pM, 205 pM, 210 pM, 215 pM, 220 pM, 225 pM, 230 pM, 235 pM, 240 pM, 245 pM, 250 pM, 255 pM, 260 pM, 265 pM, 270 pM, 275 pM, 280 pM, 285 pM, 290 pM, 295 pM, 300 pM, 305 pM, 310 pM, 315 pM, 320 pM, 325 pM, 330 pM, 335 pM, 340 pM, 345 pM, 350 pM, 355 pM, 360 pM, 365 pM, 370 pM, 375 pM, 380 pM, 385 pM, 390 pM, 395 pM, 400 pM, 405 pM, 410 pM, 415 pM, 420 pM, 425 pM, 430 pM, 435 pM, 440 pM, 445 pM, 450 pM, 455 pM, 460 pM, 465 pM, 470 pM, 475 pM, 480 pM, 485 pM, 490 pM, 495 pM, or 500 pM. In some embodiments, the hGCGR EC50 is measured in a functional assay described in “EXAMPLE 1: GCG Receptor Agonist Activity.”

[281] In some embodiments, the polypeptide has a human glucagon-like peptide-1 receptor (“hGLP1R”) EC50:hGCGR EC50 ratio of at least 40:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 50:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 60:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 70:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 80:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 90:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 100:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 150:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 200:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 250:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 300:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 350:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 400:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 450:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 500:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 550:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 650:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 700:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 750:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 800:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 850:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 900:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 950:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 1000:1. In some embodiments, the hGCGR EC50 is measured in a functional assay described in “EXAMPLE 1: GCG Receptor Agonist Activity” and the hGLP1R EC50 is measured in a functional assay described in “EXAMPLE 2: GLP1 Receptor Agonist Activity.”

[282] In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of 40:1, 45:1, 50:1, 55:1, 60:1, 65:1, 70:1, 75:1, 80:1, 85:1, 90:1, 95:1, 100:1, 125:1, 150:1, 175:1, 200:1, 225:1, 250:1, 275:1, 300:1, 325:1, 350:1, 375:1, 400:1, 425:1, 450:1, 475:1, 500:1, 525:1, 550:1, 575:1, 600:1, 625:1, 650:1, 675:1, 700:1, 725:1, 750:1, 775:1, 800:1, 825:1, 850:1, 875:1, 900:1, 925:1, 950:1, 975:1, or 1000:1. In some embodiments, the hGCGR EC50 is measured in a functional assay described in “EXAMPLE 1: GCG Receptor Agonist Activity” and the hGLP1R EC50 is measured in a functional assay described in “EXAMPLE 2: GLP1 Receptor Agonist Activity.”

[283] The present disclosure further provides molecules in which a polypeptide agonist disclosed herein is conjugated to a linker moiety, such as, e.g., a linker polypeptide. Linker moieties, including linker polypeptides, are discussed in more detail below. If desired, such molecules can be further conjugated to another molecule via the linker moiety. To facilitate such conjugation reactions, the polypeptide agonist may be derivatized.

[284] For example, provided herein is a molecule comprising a first polypeptide that agonizes a glucagon receptor (“GCGR”) selected from the polypeptides provided herein; and a second polypeptide comprising the amino acid sequence of any one of SEQ ID NOs: 16281683, wherein the Cterminus of the second polypeptide is covalently linked to an εamino group of a lysine residue of the first polypeptide. For example, in some embodiments, a lysine residue of the first polypeptide and the C-terminus of the second polypeptide are covalently linked by an amide bond. Illustratively, in some embodiments, the first polypeptide and the second polypeptide are covalently linked by an amide bond formed by the condensation of an εamino group of a lysine residue of the first polypeptide and a carboxyl group of the Cterminus of the second polypeptide.

[285] In some embodiments, the molecule is a branched polypeptide. In some embodiments, the molecule is a branched peptide.

[286] In some embodiments, the C-terminus of the second polypeptide is covalently linked to the εamino group of a lysine at position 24 or position 28 of the first polypeptide (e.g., a lysine residue at position 24 or position 28 of the first polypeptide is covalently linked to the Cterminus of the second polypeptide by an amide bond, e.g., an amide bond formed by the condensation of an εamino group of a lysine residue of the first polypeptide and a carboxyl group of the Cterminus of the second polypeptide). In some embodiments, the C-terminus of the second polypeptide is covalently linked to the εamino group of a lysine at position 24 of the first polypeptide. In some embodiments, the C-terminus of the second polypeptide is covalently linked to the εamino group of a lysine at position 28 of the first polypeptide.

[287] In some embodiments, the first polypeptide comprises at least 25 amino acids, wherein: the first polypeptide comprises 5-bromo-tryptophan at position 25; and the first polypeptide has at least 79% (e.g., at least 82%, at least 86%, at least 89%, at least 93%, at least 96%) sequence identity to the amino acid sequence of SEQ ID NO: 1587. In some embodiments, the first polypeptide comprises SEQ ID NO: 1587. In some embodiments, the first polypeptide consists of SEQ ID NO: 1587.

[288] In some embodiments, the first polypeptide comprises at least 28 amino acids, wherein: the first polypeptide comprises 2-aminoisobutyric acid at position 16 and lysine, serine, or aspartic acid at position 28; and the first polypeptide has at least 89% (e.g., at least 93%, at least 96%) sequence identity to the amino acid sequence of SEQ ID NO: 1596. In some embodiments, the first polypeptide comprises SEQ ID NO: 1596. In some embodiments, the first polypeptide consists of SEQ ID NO: 1596.

[289] In some embodiments, the first polypeptide comprises at least 28 amino acids, wherein: the first polypeptide comprises 2-aminoisobutyric acid at position 16, leucine at position 27, and lysine at position 28; and the first polypeptide has at least 89% (e.g., at least 93%, at least 96%) sequence identity to the amino acid sequence of SEQ ID NO: 1615. In some embodiments, the first polypeptide comprises SEQ ID NO: 1615. In some embodiments, the first polypeptide consists of SEQ ID NO: 1615.

[290] In some embodiments, the first polypeptide comprises at least 28 amino acids, wherein: the first polypeptide comprises 2-aminoisobutyric acid at position 16, aspartic acid at position 24, and lysine at position 28; and the first polypeptide has at least 89% (e.g., at least 93%, at least 96%) sequence identity to the amino acid sequence of SEQ ID NO: 1626. In some embodiments, the first polypeptide comprises SEQ ID NO: 1626. In some embodiments, the first polypeptide consists of SEQ ID NO: 1626.

[291] In some embodiments, the first polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 15871627. In some embodiments, the first polypeptide consists of the amino acid sequence of any one of SEQ ID NOs: 15871627.

[292] In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1587. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1588. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1589. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1590. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1591. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1592. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1593. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1594. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1595. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1596. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1597. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1598. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1599. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1600. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1601. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1602. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1603. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1604. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1605. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1606. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1607. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1608. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1609. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1610. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1611. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1612. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1613. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1614. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1615. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1616. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1617. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1618. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1619. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1620. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1621. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1622. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1623. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1624. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1625. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1626. In some embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 1627.

[293] In some embodiments, the first polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 1596, 1597, 1615, or 1626.

[294] In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1587. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1588. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1589. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1590. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1591. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1592. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1593. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1594. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1595. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1596. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1597. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1598. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1599. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1600. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1601. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1602. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1603. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1604. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1605. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1606. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1607. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1608. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1609. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1610. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1611. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1612. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1613. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1614. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1615. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1616. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1617. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1618. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1619. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1620. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1621. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1622. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1623. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1624. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1625. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1626. In some embodiments, the first polypeptide consists of the amino acid sequence of SEQ ID NO: 1627.

[295] In some embodiments, the first polypeptide consists of the amino acid sequence of any one of SEQ ID NOs: 1596, 1597, 1615, or 1626.

[296] In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1628. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1629. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1630. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1631. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1632. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1633. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1634. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1635. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1636. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1637. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1638. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1639. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1640. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1641. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1642. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1643. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1644. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1645. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1646. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1647. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1648. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1649. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1650. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1651. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1652. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1653. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1654. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1655. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1656. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1657. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1658. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1659. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1660. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1661. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1662. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1663. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1664. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1665. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1666. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1667. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1668. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1669. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1670. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1671. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1672. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1673. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1674. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1675. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1676. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1677. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1678. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1679. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1680. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1681. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1682. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1683.

[297] In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 16281630. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1628. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1629. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1630.

[298] In some embodiments, the first polypeptide comprises at least 25 amino acids, wherein: the first polypeptide comprises 5-bromo-tryptophan at position 25; and the first polypeptide has at least 79% (e.g., at least 82%, at least 86%, at least 89%, at least 93%, at least 96%) sequence identity to the amino acid sequence of SEQ ID NO: 1587; and the second polypeptide comprises the amino acid sequence of SEQ ID NO: 16281630. In some embodiments, the first polypeptide comprises SEQ ID NO: 1587; and the second polypeptide comprises the amino acid sequence of SEQ ID NO: 16281630. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1628. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1629. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1630.

[299] In some embodiments, the first polypeptide comprises at least 28 amino acids, wherein: the first polypeptide comprises 2-aminoisobutyric acid at position 16 and lysine, serine, or aspartic acid at position 28; and the first polypeptide has at least 89% (e.g., at least 93%, at least 96%) sequence identity to the amino acid sequence of SEQ ID NO: 1596; and the second polypeptide comprises the amino acid sequence of SEQ ID NO: 16281630. In some embodiments, the first polypeptide comprises SEQ ID NO: 1596; and the second polypeptide comprises the amino acid sequence of SEQ ID NO: 16281630. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1628. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1629. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1630.

[300] In some embodiments, the first polypeptide comprises at least 28 amino acids, wherein: the first polypeptide comprises 2-aminoisobutyric acid at position 16, leucine at position 27, and lysine at position 28; and the first polypeptide has at least 89% (e.g., at least 93%, at least 96%) sequence identity to the amino acid sequence of SEQ ID NO: 1615; and the second polypeptide comprises the amino acid sequence of SEQ ID NO: 16281630. In some embodiments, the first polypeptide comprises SEQ ID NO: 1615; and the second polypeptide comprises the amino acid sequence of SEQ ID NO: 16281630. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1628. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1629. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1630.

[301] In some embodiments, the first polypeptide comprises at least 28 amino acids, wherein: the first polypeptide comprises 2-aminoisobutyric acid at position 16, aspartic acid at position 24, and lysine at position 28; and the first polypeptide has at least 89% (e.g., at least 93%, at least 96%) sequence identity to the amino acid sequence of SEQ ID NO: 1626; and the second polypeptide comprises the amino acid sequence of SEQ ID NO: 16281630. In some embodiments, the first polypeptide comprises SEQ ID NO: 1626; and the second polypeptide comprises the amino acid sequence of SEQ ID NO: 16281630. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1628. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1629. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1630.

[302] In some embodiments, the first polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 15871627; and the second polypeptide comprises the amino acid sequence of SEQ ID NO: 16281630. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1628. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1629. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1630.

[303] In some embodiments, the first polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 1587, 1592, 1596, 1615, or 1626; and the second polypeptide comprises the amino acid sequence of SEQ ID NO: 16281630. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1628. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1629. In some embodiments, the second polypeptide comprises the amino acid sequence of SEQ ID NO: 1630.

[304] In some embodiments, the molecule comprises,wherein the solid line between the lysine (K) residue and the glycine (G) residue represents an amide bond formed by condensation of the εamino group of the lysine residue and the Cterminal carboxylic acid group of the glycine residue. In some embodiments, the N-terminal glycine residue of the molecule is optionally derivatized to facilitate conjugation to another molecule. In some embodiments, the N-terminal glycine residue of the molecule is bromoacetylated to facilitate a thiol-bromoacetyl reaction with a thiol group (e.g., of a cysteine residue).

[305] In some embodiments, the molecule comprises,wherein the solid line between the lysine (K) residue and the glycine (G) residue represents an amide bond formed by condensation of the εamino group of the lysine residue and the Cterminal carboxylic acid group of the glycine residue.

[306] In some embodiments, the molecule comprises the structure depicted in FIG. 9.

[307] In some embodiments, the molecule has a hGCGR EC50 of less than or equal to 500 pM (e.g., less than or equal to 475 pM, less than or equal to 450 pM, less than or equal to 425 pM, less than or equal to 400 pM, less than or equal to 375 pM, less than or equal to 350 pM, less than or equal to 325 pM, less than or equal to 300 pM, less than or equal to 275 pM, less than or equal to 250 pM, less than or equal to 225 pM, less than or equal to 200 pM, less than or equal to 175 pM, less than or equal to 150 pM, less than or equal to 125 pM, less than or equal to 100 pM). In some embodiments, the hGCGR EC50 is measured in a functional assay described in “EXAMPLE 1: GCG Receptor Agonist Activity.”

[308] In some embodiments, the molecule has a hGCGR EC50 of 50 pM, 55 pM, 60 pM, 65 pM, 70 pM, 75 pM, 80 pM, 85 pM, 90 pM, 95 pM, 100 pM, 105 pM, 110 pM, 115 pM, 120 pM, 125 pM, 130 pM, 135 pM, 140 pM, 145 pM, 150 pM, 155 pM, 200 pM, 205 pM, 210 pM, 215 pM, 220 pM, 225 pM, 230 pM, 235 pM, 240 pM, 245 pM, 250 pM, 255 pM, 260 pM, 265 pM, 270 pM, 275 pM, 280 pM, 285 pM, 290 pM, 295 pM, 300 pM, 305 pM, 310 pM, 315 pM, 320 pM, 325 pM, 330 pM, 335 pM, 340 pM, 345 pM, 350 pM, 355 pM, 360 pM, 365 pM, 370 pM, 375 pM, 380 pM, 385 pM, 390 pM, 395 pM, 400 pM, 405 pM, 410 pM, 415 pM, 420 pM, 425 pM, 430 pM, 435 pM, 440 pM, 445 pM, 450 pM, 455 pM, 460 pM, 465 pM, 470 pM, 475 pM, 480 pM, 485 pM, 490 pM, 495 pM, or 500 pM. In some embodiments, the hGCGR EC50 is measured in a functional assay described in “EXAMPLE 1: GCG Receptor Agonist Activity.”

[309] In some embodiments, the polypeptide has a human glucagon-like peptide-1 receptor (“hGLP1R”) EC50:hGCGR EC50 ratio of at least 40:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 50:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 60:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 70:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 80:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 90:1. In some embodiments, the polypeptide has a hGLP-1R EC50:hGCGR EC50 ratio of at least 100:1. In some embodiments, the molecule has a hGLP-1R EC50:hGCGR EC50 ratio of at least 150:1. In some embodiments, the molecule has a hGLP-1R EC50:hGCGR EC50 ratio of at least 200:1. In some embodiments, the molecule has a hGLP-1R EC50:hGCGR EC50 ratio of at least 250:1. In some embodiments, the molecule has a hGLP-1R EC50:hGCGR EC50 ratio of at least 300:1. In some embodiments, the molecule has a hGLP-1R EC50:hGCGR EC50 ratio of at least 350:1. In some embodiments, the molecule has a hGLP-1R EC50:hGCGR EC50 ratio of at least 400:1. In some embodiments, the molecule has a hGLP-1R EC50:hGCGR EC50 ratio of at least 450:1. In some embodiments, the molecule has a hGLP-1R EC50:hGCGR EC50 ratio of at least 500:1. In some embodiments, the molecule has a hGLP-1R EC50:hGCGR EC50 ratio of at least 550:1. In some embodiments, the molecule has a hGLP-1R EC50:hGCGR EC50 ratio of at least 650:1. In some embodiments, the molecule has a hGLP-1R EC50:hGCGR EC50 ratio of at least 700:1. In some embodiments, the molecule has a hGLP-1R EC50:hGCGR EC50 ratio of at least 750:1. In some embodiments, the molecule has a hGLP-1R EC50:hGCGR EC50 ratio of at least 800:1. In some embodiments, the molecule has a hGLP-1R EC50:hGCGR EC50 ratio of at least 850:1. In some embodiments, the molecule has a hGLP-1R EC50:hGCGR EC50 ratio of at least 900:1. In some embodiments, the molecule has a hGLP-1R EC50:hGCGR EC50 ratio of at least 950:1. In some embodiments, the molecule has a hGLP-1R EC50:hGCGR EC50 ratio of at least 1000:1. In some...

Claims

1. A polypeptide that agonizes a glucagon receptor (“GCGR”), wherein: the polypeptide comprises at least 25 amino acids, wherein the polypeptide comprises 5bromotryptophan at position 25; andthe polypeptide has at least 79% sequence identity to the amino acid sequence of SEQ ID NO: 1587.

2. The polypeptide of claim 1, wherein the polypeptide has at least 82%, at least 86%, at least 89%, at least 93%, or at least 96% sequence identity to the amino acid sequence of SEQ ID NO: 1587.

3. The polypeptide of claim 1 or claim 2, comprising at least 27 amino acids, wherein the polypeptide further comprises one or more of:d-serine at position 2;2-aminoisobutyric acid at position 16;lysine at position 17;β-(2-naphthyl)-L-alanine at position 18;aspartic acid, lysine, alanine, or glutamic acid at position 24; andleucine at position 27.

4. The polypeptide of claim 1 or claim 2, wherein the polypeptide further comprises one or more of:dserine at position 2.2aminoisobutyric acid at position 16; lysine at position 17;aspartic acid at position 24; and leucine at position 27.

5. The polypeptide of any one of claims 14, comprising at least 28 amino acids, wherein the polypeptide further comprises lysine at position 28.

6. The polypeptide of any one of claims 15, wherein the polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 15871595.

7. The polypeptide of claim 6, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1587 or SEQ ID NO: 1592.

8. A polypeptide that agonizes a glucagon receptor (“GCGR”), wherein: the polypeptide comprises at least 28 amino acids, wherein the polypeptide comprises 2aminoisobutyric acid at position 16 and lysine, serine, or aspartic acid at position 28; andthe polypeptide has at least 89% sequence identity to the amino acid sequence of SEQ ID NO: 1596.

9. The polypeptide of claim 9, wherein the polypeptide has at least 93% or at least 96% sequence identity to the amino acid sequence of SEQ ID NO: 1596.

10. The polypeptide of claim 8 or claim 9, wherein the polypeptide further comprises one or more of:tyrosine at position 1;dserine, d-threonine, or 2-aminoisobutyric acid at position 2;histidine at position 7;lysine, citrulline, or glutamine at position 17;β-(2-naphthyl)-L-alanine or β-(4,4'-biphenyl)alanine at position 18;lysine, alanine, asparagine, glutamic acid, glycine, aspartic acid, histidine, threonine, or 2aminoisobutyric acid at position 24;tyrosine, 5-bromo-tryptophan, or 2-bromo-5-hydroxytryptophan at position 25; andleucine, glutamic acid, or αaminoadipic acid at position 27.

11. The polypeptide of any one of claims 810, comprising at least 29 amino acids, wherein the polypeptide further comprises alanine, aspartic acid, glutamic acid, or serine at position 29.

12. The polypeptide of any one of claims 810, wherein the polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 15961627.

13. The polypeptide of claim 12, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1596, SEQ ID NO: 1615, or SEQ ID NO: 1626.

14. The polypeptide of any one of claims 113, wherein the polypeptide agonizes human GCGR (“hGCGR”).

15. The polypeptide of any one of claims 114, wherein: the polypeptide has a hGCGR EC50 of less than or equal to 500 pM; andthe polypeptide has a human glucagon-like peptide-1 receptor (“hGLP-1R”) EC50:hGCGR EC50 ratio of at least 40:1.

16. A molecule comprising: a polypeptide that agonizes a glucagon receptor (“GCGR”), wherein the polypeptide is selected from the polypeptides of any one of claims 115; and a half-life extending domain.

17. The molecule of claim 16, wherein: the half-life extending domain is an Fc-containing polypeptide;an εamino group of a lysine residue of the polypeptide is covalently linked to a Cterminus of a linker polypeptide; andan N-terminus of the linker polypeptide is conjugated to a cysteine residue of the Fccontaining polypeptide.

18. The molecule of claim 17, wherein the linker polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 16281683.

19. The molecule of claim 17 or claim 18, wherein the linker polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 16281630.

20. The molecule of any one of claims 1619, wherein the polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 1587, 1592, 1596, 1615, or 1626.

21. The molecule of any one of claims 1620, wherein the half-life extending domain is an antibody.

22. A molecule comprising:a first polypeptide that agonizes a glucagon receptor (“GCGR”); andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”).

23. The molecule of claim 22, wherein: an εamino group of a lysine residue of the first polypeptide is covalently linked to a Cterminus of a first linker polypeptide; andan N-terminus of the first linker polypeptide is conjugated to a cysteine residue of the antibody.

24. The molecule of claim 22 or claim 23, wherein the first polypeptide is selected from the polypeptides of any one of claims 115.

25. The molecule of any one of claims 2224, wherein the first polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 1587, 1592, 1596, 1615, or 1626.

26. The molecule of any one of claims 2325, wherein the first linker polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 16281683.

27. The molecule of any one of claims 2326, wherein the first linker polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 16281630.

28. The molecule of any one of claims 2327, wherein the cysteine residue of the antibody that is conjugated to the N-terminus of the first linker polypeptide is at a position selected from the group consisting of 88 of a light chain, 384 of a heavy chain, and 487 of a heavy chain, according to AHo numbering.

29. The molecule of any one of claims 2228, further comprising a second polypeptide that agonizes a GCGR.

30. The molecule of claim 29, wherein: an εamino group of a lysine residue of the second polypeptide is covalently linked to a Cterminus of a second linker polypeptide; andan N-terminus of the second linker polypeptide is conjugated to a cysteine residue of the antibody.

31. The molecule of claim 29 or claim 30, wherein the second polypeptide is selected from the polypeptides of any one of claims 115.

32. The molecule of any one of claims 2931, wherein the second polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 1587, 1592, 1596, 1615, or 1626.

33. The molecule of any one of claims 2932, wherein the first polypeptide has the same amino acid sequence as the second polypeptide.

34. The molecule of any one of claims 3033, wherein the second linker polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 16281683.

35. The molecule of any one of claims 3034, wherein the second linker polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 16281630.

36. The molecule of any one of claims 3035, wherein the first linker polypeptide has the same amino acid sequence as the second linker polypeptide.

37. The molecule of any one of claims 3036, wherein the cysteine residue of the antibody that is conjugated to the N-terminus of the second linker polypeptide is at a position selected from the group consisting of 88 of a light chain, 384 of a heavy chain, and 487 of a heavy chain, according to AHo numbering.

38. The molecule of any one of claims 2237, wherein the antibody comprises a CDRL1, a CDRL2, a CDRL3, a CDRH1, a CDRH2, and a CDRH3, wherein the CDRL1, the CDRL2, the CDRL3, the CDRH1, the CDRH2, and the CDRH3 comprise amino acid sequences selected from:i. SEQ ID NO: 629, SEQ ID NO: 786, SEQ ID NO: 943, SEQ ID NO: 1100, SEQ ID NO: 1257, and SEQ ID NO: 1414, respectively; ii. SEQ ID NO: 630, SEQ ID NO: 787, SEQ ID NO: 944, SEQ ID NO: 1101, SEQ ID NO: 1258, and SEQ ID NO: 1415, respectively; iii. SEQ ID NO: 631, SEQ ID NO: 788, SEQ ID NO: 945, SEQ ID NO: 1102, SEQ ID NO: 1259, and SEQ ID NO: 1416, respectively; iv. SEQ ID NO: 632, SEQ ID NO: 789, SEQ ID NO: 946, SEQ ID NO: 1103, SEQ ID NO: 1260, and SEQ ID NO: 1417, respectively; v. SEQ ID NO: 633, SEQ ID NO: 790, SEQ ID NO: 947, SEQ ID NO: 1104, SEQ ID NO: 1261, and SEQ ID NO: 1418, respectively; vi. SEQ ID NO: 634, SEQ ID NO: 791, SEQ ID NO: 948, SEQ ID NO: 1105, SEQ ID NO: 1262, and SEQ ID NO: 1419, respectively; vii. SEQ ID NO: 635, SEQ ID NO: 792, SEQ ID NO: 949, SEQ ID NO: 1106, SEQ ID NO: 1263, and SEQ ID NO: 1420, respectively; viii. SEQ ID NO: 636, SEQ ID NO: 793, SEQ ID NO: 950, SEQ ID NO: 1107, SEQ ID NO: 1264, and SEQ ID NO: 1421, respectively; ix. SEQ ID NO: 637, SEQ ID NO: 794, SEQ ID NO: 951, SEQ ID NO: 1108, SEQ ID NO: 1265, and SEQ ID NO: 1422, respectively; x. SEQ ID NO: 638, SEQ ID NO: 795, SEQ ID NO: 952, SEQ ID NO: 1109, SEQ ID NO: 1266, and SEQ ID NO: 1423, respectively; xi. SEQ ID NO: 639, SEQ ID NO: 796, SEQ ID NO: 953, SEQ ID NO: 1110, SEQ ID NO: 1267, and SEQ ID NO: 1424, respectively; xii. SEQ ID NO: 640, SEQ ID NO: 797, SEQ ID NO: 954, SEQ ID NO: 1111, SEQ ID NO: 1268, and SEQ ID NO: 1425, respectively; xiii. SEQ ID NO: 641, SEQ ID NO: 798, SEQ ID NO: 955, SEQ ID NO: 1112, SEQ ID NO: 1269, and SEQ ID NO: 1426, respectively; xiv. SEQ ID NO: 642, SEQ ID NO: 799, SEQ ID NO: 956, SEQ ID NO: 1113, SEQ ID NO: 1270, and SEQ ID NO: 1427, respectively; xv. SEQ ID NO: 643, SEQ ID NO: 800, SEQ ID NO: 957, SEQ ID NO: 1114, SEQ ID NO: 1271, and SEQ ID NO: 1428, respectively; xvi. SEQ ID NO: 644, SEQ ID NO: 801, SEQ ID NO: 958, SEQ ID NO: 1115, SEQ ID NO: 1272, and SEQ ID NO: 1429, respectively; xvii. SEQ ID NO: 645, SEQ ID NO: 802, SEQ ID NO: 959, SEQ ID NO: 1116, SEQ ID NO: 1273, and SEQ ID NO: 1430, respectively; xviii. SEQ ID NO: 646, SEQ ID NO: 803, SEQ ID NO: 960, SEQ ID NO: 1117, SEQ ID NO: 1274, and SEQ ID NO: 1431, respectively; xix. SEQ ID NO: 647, SEQ ID NO: 804, SEQ ID NO: 961, SEQ ID NO: 1118, SEQ ID NO: 1275, and SEQ ID NO: 1432, respectively; xx. SEQ ID NO: 648, SEQ ID NO: 805, SEQ ID NO: 962, SEQ ID NO: 1119, SEQ ID NO: 1276, and SEQ ID NO: 1433, respectively; xxi. SEQ ID NO: 649, SEQ ID NO: 806, SEQ ID NO: 963, SEQ ID NO: 1120, SEQ ID NO: 1277, and SEQ ID NO: 1434, respectively; xxii. SEQ ID NO: 650, SEQ ID NO: 807, SEQ ID NO: 964, SEQ ID NO: 1121, SEQ ID NO: 1278, and SEQ ID NO: 1435, respectively; xxiii. SEQ ID NO: 651, SEQ ID NO: 808, SEQ ID NO: 965, SEQ ID NO: 1122, SEQ ID NO: 1279, and SEQ ID NO: 1436, respectively; xxiv. SEQ ID NO: 652, SEQ ID NO: 809, SEQ ID NO: 966, SEQ ID NO: 1123, SEQ ID NO: 1280, and SEQ ID NO: 1437, respectively; xxv. SEQ ID NO: 653, SEQ ID NO: 810, SEQ ID NO: 967, SEQ ID NO: 1124, SEQ ID NO: 1281, and SEQ ID NO: 1438, respectively; xxvi. SEQ ID NO: 654, SEQ ID NO: 811, SEQ ID NO: 968, SEQ ID NO: 1125, SEQ ID NO: 1282, and SEQ ID NO: 1439, respectively; xxvii. SEQ ID NO: 655, SEQ ID NO: 812, SEQ ID NO: 969, SEQ ID NO: 1126, SEQ ID NO: 1283, and SEQ ID NO: 1440, respectively; xxviii. SEQ ID NO: 656, SEQ ID NO: 813, SEQ ID NO: 970, SEQ ID NO: 1127, SEQ ID NO: 1284, and SEQ ID NO: 1441, respectively; xxix. SEQ ID NO: 657, SEQ ID NO: 814, SEQ ID NO: 971, SEQ ID NO: 1128, SEQ ID NO: 1285, and SEQ ID NO: 1442, respectively; xxx. SEQ ID NO: 658, SEQ ID NO: 815, SEQ ID NO: 972, SEQ ID NO: 1129, SEQ ID NO: 1286, and SEQ ID NO: 1443, respectively; xxxi. SEQ ID NO: 659, SEQ ID NO: 816, SEQ ID NO: 973, SEQ ID NO: 1130, SEQ ID NO: 1287, and SEQ ID NO: 1444, respectively; xxxii. SEQ ID NO: 660, SEQ ID NO: 817, SEQ ID NO: 974, SEQ ID NO: 1131, SEQ ID NO: 1288, and SEQ ID NO: 1445, respectively; xxxiii. SEQ ID NO: 661, SEQ ID NO: 818, SEQ ID NO: 975, SEQ ID NO: 1132, SEQ ID NO: 1289, and SEQ ID NO: 1446, respectively; xxxiv. SEQ ID NO: 662, SEQ ID NO: 819, SEQ ID NO: 976, SEQ ID NO: 1133, SEQ ID NO: 1290, and SEQ ID NO: 1447, respectively; xxxv. SEQ ID NO: 663, SEQ ID NO: 820, SEQ ID NO: 977, SEQ ID NO: 1134, SEQ ID NO: 1291, and SEQ ID NO: 1448, respectively; xxxvi. SEQ ID NO: 664, SEQ ID NO: 821, SEQ ID NO: 978, SEQ ID NO: 1135, SEQ ID NO: 1292, and SEQ ID NO: 1449, respectively; xxxvii. SEQ ID NO: 665, SEQ ID NO: 822, SEQ ID NO: 979, SEQ ID NO: 1136, SEQ ID NO: 1293, and SEQ ID NO: 1450, respectively; xxxviii. SEQ ID NO: 666, SEQ ID NO: 823, SEQ ID NO: 980, SEQ ID NO: 1137, SEQ ID NO: 1294, and SEQ ID NO: 1451, respectively; xxxix. SEQ ID NO: 667, SEQ ID NO: 824, SEQ ID NO: 981, SEQ ID NO: 1138, SEQ ID NO: 1295, and SEQ ID NO: 1452, respectively; xl. SEQ ID NO: 668, SEQ ID NO: 825, SEQ ID NO: 982, SEQ ID NO: 1139, SEQ ID NO: 1296, and SEQ ID NO: 1453, respectively; xli. SEQ ID NO: 669, SEQ ID NO: 826, SEQ ID NO: 983, SEQ ID NO: 1140, SEQ ID NO: 1297, and SEQ ID NO: 1454, respectively; xlii. SEQ ID NO: 670, SEQ ID NO: 827, SEQ ID NO: 984, SEQ ID NO: 1141, SEQ ID NO: 1298, and SEQ ID NO: 1455, respectively; xliii. SEQ ID NO: 671, SEQ ID NO: 828, SEQ ID NO: 985, SEQ ID NO: 1142, SEQ ID NO: 1299, and SEQ ID NO: 1456, respectively; xliv. SEQ ID NO: 672, SEQ ID NO: 829, SEQ ID NO: 986, SEQ ID NO: 1143, SEQ ID NO: 1300, and SEQ ID NO: 1457, respectively; xlv. SEQ ID NO: 673, SEQ ID NO: 830, SEQ ID NO: 987, SEQ ID NO: 1144, SEQ ID NO: 1301, and SEQ ID NO: 1458, respectively; xlvi. SEQ ID NO: 674, SEQ ID NO: 831, SEQ ID NO: 988, SEQ ID NO: 1145, SEQ ID NO: 1302, and SEQ ID NO: 1459, respectively; xlvii. SEQ ID NO: 675, SEQ ID NO: 832, SEQ ID NO: 989, SEQ ID NO: 1146, SEQ ID NO: 1303, and SEQ ID NO: 1460, respectively; xlviii. SEQ ID NO: 676, SEQ ID NO: 833, SEQ ID NO: 990, SEQ ID NO: 1147, SEQ ID NO: 1304, and SEQ ID NO: 1461, respectively; xlix. SEQ ID NO: 677, SEQ ID NO: 834, SEQ ID NO: 991, SEQ ID NO: 1148, SEQ ID NO: 1305, and SEQ ID NO: 1462, respectively; l. SEQ ID NO: 678, SEQ ID NO: 835, SEQ ID NO: 992, SEQ ID NO: 1149, SEQ ID NO: 1306, and SEQ ID NO: 1463, respectively; li. SEQ ID NO: 679, SEQ ID NO: 836, SEQ ID NO: 993, SEQ ID NO: 1150, SEQ ID NO: 1307, and SEQ ID NO: 1464, respectively; lii. SEQ ID NO: 680, SEQ ID NO: 837, SEQ ID NO: 994, SEQ ID NO: 1151, SEQ ID NO: 1308, and SEQ ID NO: 1465, respectively; liii. SEQ ID NO: 681, SEQ ID NO: 838, SEQ ID NO: 995, SEQ ID NO: 1152, SEQ ID NO: 1309, and SEQ ID NO: 1466, respectively; liv. SEQ ID NO: 682, SEQ ID NO: 839, SEQ ID NO: 996, SEQ ID NO: 1153, SEQ ID NO: 1310, and SEQ ID NO: 1467, respectively; lv. SEQ ID NO: 683, SEQ ID NO: 840, SEQ ID NO: 997, SEQ ID NO: 1154, SEQ ID NO: 1311, and SEQ ID NO: 1468, respectively; lvi. SEQ ID NO: 684, SEQ ID NO: 841, SEQ ID NO: 998, SEQ ID NO: 1155, SEQ ID NO: 1312, and SEQ ID NO: 1469, respectively; lvii. SEQ ID NO: 685, SEQ ID NO: 842, SEQ ID NO: 999, SEQ ID NO: 1156, SEQ ID NO: 1313, and SEQ ID NO: 1470, respectively; lviii. SEQ ID NO: 686, SEQ ID NO: 843, SEQ ID NO: 1000, SEQ ID NO: 1157, SEQ ID NO: 1314, and SEQ ID NO: 1471, respectively; lix. SEQ ID NO: 687, SEQ ID NO: 844, SEQ ID NO: 1001, SEQ ID NO: 1158, SEQ ID NO: 1315, and SEQ ID NO: 1472, respectively; lx. SEQ ID NO: 688, SEQ ID NO: 845, SEQ ID NO: 1002, SEQ ID NO: 1159, SEQ ID NO: 1316, and SEQ ID NO: 1473, respectively; lxi. SEQ ID NO: 689, SEQ ID NO: 846, SEQ ID NO: 1003, SEQ ID NO: 1160, SEQ ID NO: 1317, and SEQ ID NO: 1474, respectively; lxii. SEQ ID NO: 690, SEQ ID NO: 847, SEQ ID NO: 1004, SEQ ID NO: 1161, SEQ ID NO: 1318, and SEQ ID NO: 1475, respectively; lxiii. SEQ ID NO: 691, SEQ ID NO: 848, SEQ ID NO: 1005, SEQ ID NO: 1162, SEQ ID NO: 1319, and SEQ ID NO: 1476, respectively; lxiv. SEQ ID NO: 692, SEQ ID NO: 849, SEQ ID NO: 1006, SEQ ID NO: 1163, SEQ ID NO: 1320, and SEQ ID NO: 1477, respectively; lxv. SEQ ID NO: 693, SEQ ID NO: 850, SEQ ID NO: 1007, SEQ ID NO: 1164, SEQ ID NO: 1321, and SEQ ID NO: 1478, respectively; lxvi. SEQ ID NO: 694, SEQ ID NO: 851, SEQ ID NO: 1008, SEQ ID NO: 1165, SEQ ID NO: 1322, and SEQ ID NO: 1479, respectively; lxvii. SEQ ID NO: 695, SEQ ID NO: 852, SEQ ID NO: 1009, SEQ ID NO: 1166, SEQ ID NO: 1323, and SEQ ID NO: 1480, respectively; lxviii. SEQ ID NO: 696, SEQ ID NO: 853, SEQ ID NO: 1010, SEQ ID NO: 1167, SEQ ID NO: 1324, and SEQ ID NO: 1481, respectively; lxix. SEQ ID NO: 697, SEQ ID NO: 854, SEQ ID NO: 1011, SEQ ID NO: 1168, SEQ ID NO: 1325, and SEQ ID NO: 1482, respectively; lxx. SEQ ID NO: 698, SEQ ID NO: 855, SEQ ID NO: 1012, SEQ ID NO: 1169, SEQ ID NO: 1326, and SEQ ID NO: 1483, respectively; lxxi. SEQ ID NO: 699, SEQ ID NO: 856, SEQ ID NO: 1013, SEQ ID NO: 1170, SEQ ID NO: 1327, and SEQ ID NO: 1484, respectively; lxxii. SEQ ID NO: 700, SEQ ID NO: 857, SEQ ID NO: 1014, SEQ ID NO: 1171, SEQ ID NO: 1328, and SEQ ID NO: 1485, respectively; lxxiii. SEQ ID NO: 701, SEQ ID NO: 858, SEQ ID NO: 1015, SEQ ID NO: 1172, SEQ ID NO: 1329, and SEQ ID NO: 1486, respectively; lxxiv. SEQ ID NO: 702, SEQ ID NO: 859, SEQ ID NO: 1016, SEQ ID NO: 1173, SEQ ID NO: 1330, and SEQ ID NO: 1487, respectively; lxxv. SEQ ID NO: 703, SEQ ID NO: 860, SEQ ID NO: 1017, SEQ ID NO: 1174, SEQ ID NO: 1331, and SEQ ID NO: 1488, respectively; lxxvi. SEQ ID NO: 704, SEQ ID NO: 861, SEQ ID NO: 1018, SEQ ID NO: 1175, SEQ ID NO: 1332, and SEQ ID NO: 1489, respectively; lxxvii. SEQ ID NO: 705, SEQ ID NO: 862, SEQ ID NO: 1019, SEQ ID NO: 1176, SEQ ID NO: 1333, and SEQ ID NO: 1490, respectively; lxxviii. SEQ ID NO: 706, SEQ ID NO: 863, SEQ ID NO: 1020, SEQ ID NO: 1177, SEQ ID NO: 1334, and SEQ ID NO: 1491, respectively; lxxix. SEQ ID NO: 707, SEQ ID NO: 864, SEQ ID NO: 1021, SEQ ID NO: 1178, SEQ ID NO: 1335, and SEQ ID NO: 1492, respectively; lxxx. SEQ ID NO: 708, SEQ ID NO: 865, SEQ ID NO: 1022, SEQ ID NO: 1179, SEQ ID NO: 1336, and SEQ ID NO: 1493, respectively; lxxxi. SEQ ID NO: 709, SEQ ID NO: 866, SEQ ID NO: 1023, SEQ ID NO: 1180, SEQ ID NO: 1337, and SEQ ID NO: 1494, respectively; lxxxii. SEQ ID NO: 710, SEQ ID NO: 867, SEQ ID NO: 1024, SEQ ID NO: 1181, SEQ ID NO: 1338, and SEQ ID NO: 1495, respectively; lxxxiii. SEQ ID NO: 711, SEQ ID NO: 868, SEQ ID NO: 1025, SEQ ID NO: 1182, SEQ ID NO: 1339, and SEQ ID NO: 1496, respectively; lxxxiv. SEQ ID NO: 712, SEQ ID NO: 869, SEQ ID NO: 1026, SEQ ID NO: 1183, SEQ ID NO: 1340, and SEQ ID NO: 1497, respectively; lxxxv. SEQ ID NO: 713, SEQ ID NO: 870, SEQ ID NO: 1027, SEQ ID NO: 1184, SEQ ID NO: 1341, and SEQ ID NO: 1498, respectively; lxxxvi. SEQ ID NO: 714, SEQ ID NO: 871, SEQ ID NO: 1028, SEQ ID NO: 1185, SEQ ID NO: 1342, and SEQ ID NO: 1499, respectively; lxxxvii. SEQ ID NO: 715, SEQ ID NO: 872, SEQ ID NO: 1029, SEQ ID NO: 1186, SEQ ID NO: 1343, and SEQ ID NO: 1500, respectively; lxxxviii. SEQ ID NO: 716, SEQ ID NO: 873, SEQ ID NO: 1030, SEQ ID NO: 1187, SEQ ID NO: 1344, and SEQ ID NO: 1501, respectively; lxxxix. SEQ ID NO: 717, SEQ ID NO: 874, SEQ ID NO: 1031, SEQ ID NO: 1188, SEQ ID NO: 1345, and SEQ ID NO: 1502, respectively; xc. SEQ ID NO: 718, SEQ ID NO: 875, SEQ ID NO: 1032, SEQ ID NO: 1189, SEQ ID NO: 1346, and SEQ ID NO: 1503, respectively; xci. SEQ ID NO: 719, SEQ ID NO: 876, SEQ ID NO: 1033, SEQ ID NO: 1190, SEQ ID NO: 1347, and SEQ ID NO: 1504, respectively; xcii. SEQ ID NO: 720, SEQ ID NO: 877, SEQ ID NO: 1034, SEQ ID NO: 1191, SEQ ID NO: 1348, and SEQ ID NO: 1505, respectively; xciii. SEQ ID NO: 721, SEQ ID NO: 878, SEQ ID NO: 1035, SEQ ID NO: 1192, SEQ ID NO: 1349, and SEQ ID NO: 1506, respectively; xciv. SEQ ID NO: 722, SEQ ID NO: 879, SEQ ID NO: 1036, SEQ ID NO: 1193, SEQ ID NO: 1350, and SEQ ID NO: 1507, respectively; xcv. SEQ ID NO: 723, SEQ ID NO: 880, SEQ ID NO: 1037, SEQ ID NO: 1194, SEQ ID NO: 1351, and SEQ ID NO: 1508, respectively; xcvi. SEQ ID NO: 724, SEQ ID NO: 881, SEQ ID NO: 1038, SEQ ID NO: 1195, SEQ ID NO: 1352, and SEQ ID NO: 1509, respectively; xcvii. SEQ ID NO: 725, SEQ ID NO: 882, SEQ ID NO: 1039, SEQ ID NO: 1196, SEQ ID NO: 1353, and SEQ ID NO: 1510, respectively; xcviii. SEQ ID NO: 726, SEQ ID NO: 883, SEQ ID NO: 1040, SEQ ID NO: 1197, SEQ ID NO: 1354, and SEQ ID NO: 1511, respectively; xcix. SEQ ID NO: 727, SEQ ID NO: 884, SEQ ID NO: 1041, SEQ ID NO: 1198, SEQ ID NO: 1355, and SEQ ID NO: 1512, respectively; c. SEQ ID NO: 728, SEQ ID NO: 885, SEQ ID NO: 1042, SEQ ID NO: 1199, SEQ ID NO: 1356, and SEQ ID NO: 1513, respectively; ci. SEQ ID NO: 729, SEQ ID NO: 886, SEQ ID NO: 1043, SEQ ID NO: 1200, SEQ ID NO: 1357, and SEQ ID NO: 1514, respectively; cii. SEQ ID NO: 730, SEQ ID NO: 887, SEQ ID NO: 1044, SEQ ID NO: 1201, SEQ ID NO: 1358, and SEQ ID NO: 1515, respectively; ciii. SEQ ID NO: 731, SEQ ID NO: 888, SEQ ID NO: 1045, SEQ ID NO: 1202, SEQ ID NO: 1359, and SEQ ID NO: 1516, respectively; civ. SEQ ID NO: 732, SEQ ID NO: 889, SEQ ID NO: 1046, SEQ ID NO: 1203, SEQ ID NO: 1360, and SEQ ID NO: 1517, respectively; cv. SEQ ID NO: 733, SEQ ID NO: 890, SEQ ID NO: 1047, SEQ ID NO: 1204, SEQ ID NO: 1361, and SEQ ID NO: 1518, respectively; cvi. SEQ ID NO: 734, SEQ ID NO: 891, SEQ ID NO: 1048, SEQ ID NO: 1205, SEQ ID NO: 1362, and SEQ ID NO: 1519, respectively; cvii. SEQ ID NO: 735, SEQ ID NO: 892, SEQ ID NO: 1049, SEQ ID NO: 1206, SEQ ID NO: 1363, and SEQ ID NO: 1520, respectively; cviii. SEQ ID NO: 736, SEQ ID NO: 893, SEQ ID NO: 1050, SEQ ID NO: 1207, SEQ ID NO: 1364, and SEQ ID NO: 1521, respectively; cix. SEQ ID NO: 737, SEQ ID NO: 894, SEQ ID NO: 1051, SEQ ID NO: 1208, SEQ ID NO: 1365, and SEQ ID NO: 1522, respectively; cx. SEQ ID NO: 738, SEQ ID NO: 895, SEQ ID NO: 1052, SEQ ID NO: 1209, SEQ ID NO: 1366, and SEQ ID NO: 1523, respectively; cxi. SEQ ID NO: 739, SEQ ID NO: 896, SEQ ID NO: 1053, SEQ ID NO: 1210, SEQ ID NO: 1367, and SEQ ID NO: 1524, respectively; cxii. SEQ ID NO: 740, SEQ ID NO: 897, SEQ ID NO: 1054, SEQ ID NO: 1211, SEQ ID NO: 1368, and SEQ ID NO: 1525, respectively; cxiii. SEQ ID NO: 741, SEQ ID NO: 898, SEQ ID NO: 1055, SEQ ID NO: 1212, SEQ ID NO: 1369, and SEQ ID NO: 1526, respectively; cxiv. SEQ ID NO: 742, SEQ ID NO: 899, SEQ ID NO: 1056, SEQ ID NO: 1213, SEQ ID NO: 1370, and SEQ ID NO: 1527, respectively; cxv. SEQ ID NO: 743, SEQ ID NO: 900, SEQ ID NO: 1057, SEQ ID NO: 1214, SEQ ID NO: 1371, and SEQ ID NO: 1528, respectively; cxvi. SEQ ID NO: 744, SEQ ID NO: 901, SEQ ID NO: 1058, SEQ ID NO: 1215, SEQ ID NO: 1372, and SEQ ID NO: 1529, respectively; cxvii. SEQ ID NO: 745, SEQ ID NO: 902, SEQ ID NO: 1059, SEQ ID NO: 1216, SEQ ID NO: 1373, and SEQ ID NO: 1530, respectively; cxviii. SEQ ID NO: 746, SEQ ID NO: 903, SEQ ID NO: 1060, SEQ ID NO: 1217, SEQ ID NO: 1374, and SEQ ID NO: 1531, respectively; cxix. SEQ ID NO: 747, SEQ ID NO: 904, SEQ ID NO: 1061, SEQ ID NO: 1218, SEQ ID NO: 1375, and SEQ ID NO: 1532, respectively; cxx. SEQ ID NO: 748, SEQ ID NO: 905, SEQ ID NO: 1062, SEQ ID NO: 1219, SEQ ID NO: 1376, and SEQ ID NO: 1533, respectively; cxxi. SEQ ID NO: 749, SEQ ID NO: 906, SEQ ID NO: 1063, SEQ ID NO: 1220, SEQ ID NO: 1377, and SEQ ID NO: 1534, respectively; cxxii. SEQ ID NO: 750, SEQ ID NO: 907, SEQ ID NO: 1064, SEQ ID NO: 1221, SEQ ID NO: 1378, and SEQ ID NO: 1535, respectively; cxxiii. SEQ ID NO: 751, SEQ ID NO: 908, SEQ ID NO: 1065, SEQ ID NO: 1222, SEQ ID NO: 1379, and SEQ ID NO: 1536, respectively; cxxiv. SEQ ID NO: 752, SEQ ID NO: 909, SEQ ID NO: 1066, SEQ ID NO: 1223, SEQ ID NO: 1380, and SEQ ID NO: 1537, respectively; cxxv. SEQ ID NO: 753, SEQ ID NO: 910, SEQ ID NO: 1067, SEQ ID NO: 1224, SEQ ID NO: 1381, and SEQ ID NO: 1538, respectively; cxxvi. SEQ ID NO: 754, SEQ ID NO: 911, SEQ ID NO: 1068, SEQ ID NO: 1225, SEQ ID NO: 1382, and SEQ ID NO: 1539, respectively; cxxvii. SEQ ID NO: 755, SEQ ID NO: 912, SEQ ID NO: 1069, SEQ ID NO: 1226, SEQ ID NO: 1383, and SEQ ID NO: 1540, respectively; cxxviii. SEQ ID NO: 756, SEQ ID NO: 913, SEQ ID NO: 1070, SEQ ID NO: 1227, SEQ ID NO: 1384, and SEQ ID NO: 1541, respectively; cxxix. SEQ ID NO: 757, SEQ ID NO: 914, SEQ ID NO: 1071, SEQ ID NO: 1228, SEQ ID NO: 1385, and SEQ ID NO: 1542, respectively; cxxx. SEQ ID NO: 758, SEQ ID NO: 915, SEQ ID NO: 1072, SEQ ID NO: 1229, SEQ ID NO: 1386, and SEQ ID NO: 1543, respectively; cxxxi. SEQ ID NO: 759, SEQ ID NO: 916, SEQ ID NO: 1073, SEQ ID NO: 1230, SEQ ID NO: 1387, and SEQ ID NO: 1544, respectively; cxxxii. SEQ ID NO: 760, SEQ ID NO: 917, SEQ ID NO: 1074, SEQ ID NO: 1231, SEQ ID NO: 1388, and SEQ ID NO: 1545, respectively; cxxxiii. SEQ ID NO: 761, SEQ ID NO: 918, SEQ ID NO: 1075, SEQ ID NO: 1232, SEQ ID NO: 1389, and SEQ ID NO: 1546, respectively; cxxxiv. SEQ ID NO: 762, SEQ ID NO: 919, SEQ ID NO: 1076, SEQ ID NO: 1233, SEQ ID NO: 1390, and SEQ ID NO: 1547, respectively; cxxxv. SEQ ID NO: 763, SEQ ID NO: 920, SEQ ID NO: 1077, SEQ ID NO: 1234, SEQ ID NO: 1391, and SEQ ID NO: 1548, respectively; cxxxvi. SEQ ID NO: 764, SEQ ID NO: 921, SEQ ID NO: 1078, SEQ ID NO: 1235, SEQ ID NO: 1392, and SEQ ID NO: 1549, respectively; cxxxvii. SEQ ID NO: 765, SEQ ID NO: 922, SEQ ID NO: 1079, SEQ ID NO: 1236, SEQ ID NO: 1393, and SEQ ID NO: 1550, respectively; cxxxviii. SEQ ID NO: 766, SEQ ID NO: 923, SEQ ID NO: 1080, SEQ ID NO: 1237, SEQ ID NO: 1394, and SEQ ID NO: 1551, respectively; cxxxix. SEQ ID NO: 767, SEQ ID NO: 924, SEQ ID NO: 1081, SEQ ID NO: 1238, SEQ ID NO: 1395, and SEQ ID NO: 1552, respectively; cxl. SEQ ID NO: 768, SEQ ID NO: 925, SEQ ID NO: 1082, SEQ ID NO: 1239, SEQ ID NO: 1396, and SEQ ID NO: 1553, respectively; cxli. SEQ ID NO: 769, SEQ ID NO: 926, SEQ ID NO: 1083, SEQ ID NO: 1240, SEQ ID NO: 1397, and SEQ ID NO: 1554, respectively; cxlii. SEQ ID NO: 770, SEQ ID NO: 927, SEQ ID NO: 1084, SEQ ID NO: 1241, SEQ ID NO: 1398, and SEQ ID NO: 1555, respectively; cxliii. SEQ ID NO: 771, SEQ ID NO: 928, SEQ ID NO: 1085, SEQ ID NO: 1242, SEQ ID NO: 1399, and SEQ ID NO: 1556, respectively; cxliv. SEQ ID NO: 772, SEQ ID NO: 929, SEQ ID NO: 1086, SEQ ID NO: 1243, SEQ ID NO: 1400, and SEQ ID NO: 1557, respectively; cxlv. SEQ ID NO: 773, SEQ ID NO: 930, SEQ ID NO: 1087, SEQ ID NO: 1244, SEQ ID NO: 1401, and SEQ ID NO: 1558, respectively; cxlvi. SEQ ID NO: 774, SEQ ID NO: 931, SEQ ID NO: 1088, SEQ ID NO: 1245, SEQ ID NO: 1402, and SEQ ID NO: 1559, respectively; cxlvii. SEQ ID NO: 775, SEQ ID NO: 932, SEQ ID NO: 1089, SEQ ID NO: 1246, SEQ ID NO: 1403, and SEQ ID NO: 1560, respectively; cxlviii. SEQ ID NO: 776, SEQ ID NO: 933, SEQ ID NO: 1090, SEQ ID NO: 1247, SEQ ID NO: 1404, and SEQ ID NO: 1561, respectively; cxlix. SEQ ID NO: 777, SEQ ID NO: 934, SEQ ID NO: 1091, SEQ ID NO: 1248, SEQ ID NO: 1405, and SEQ ID NO: 1562, respectively; cl. SEQ ID NO: 778, SEQ ID NO: 935, SEQ ID NO: 1092, SEQ ID NO: 1249, SEQ ID NO: 1406, and SEQ ID NO: 1563, respectively; cli. SEQ ID NO: 779, SEQ ID NO: 936, SEQ ID NO: 1093, SEQ ID NO: 1250, SEQ ID NO: 1407, and SEQ ID NO: 1564, respectively; clii. SEQ ID NO: 780, SEQ ID NO: 937, SEQ ID NO: 1094, SEQ ID NO: 1251, SEQ ID NO: 1408, and SEQ ID NO: 1565, respectively; cliii. SEQ ID NO: 781, SEQ ID NO: 938, SEQ ID NO: 1095, SEQ ID NO: 1252, SEQ ID NO: 1409, and SEQ ID NO: 1566, respectively; cliv. SEQ ID NO: 782, SEQ ID NO: 939, SEQ ID NO: 1096, SEQ ID NO: 1253, SEQ ID NO: 1410, and SEQ ID NO: 1567, respectively; clv. SEQ ID NO: 783, SEQ ID NO: 940, SEQ ID NO: 1097, SEQ ID NO: 1254, SEQ ID NO: 1411, and SEQ ID NO: 1568, respectively; clvi. SEQ ID NO: 784, SEQ ID NO: 941, SEQ ID NO: 1098, SEQ ID NO: 1255, SEQ ID NO: 1412, and SEQ ID NO: 1569, respectively; and clvii. SEQ ID NO: 785, SEQ ID NO: 942, SEQ ID NO: 1099, SEQ ID NO: 1256, SEQ ID NO: 1413, and SEQ ID NO: 1570, respectively.

39. The molecule of any one of claims 2238, wherein the antibody comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region and the heavy chain variable region comprise amino acid sequences selected from:i. SEQ ID NO: 1 and SEQ ID NO: 158, respectively; ii. SEQ ID NO: 2 and SEQ ID NO: 159, respectively; iii. SEQ ID NO: 3 and SEQ ID NO: 160, respectively; iv. SEQ ID NO: 4 and SEQ ID NO: 161, respectively; v. SEQ ID NO: 5 and SEQ ID NO: 162, respectively; vi. SEQ ID NO: 6 and SEQ ID NO: 163, respectively; vii. SEQ ID NO: 7 and SEQ ID NO: 164, respectively; viii. SEQ ID NO: 8 and SEQ ID NO: 165, respectively; ix. SEQ ID NO: 9 and SEQ ID NO: 166, respectively; x. SEQ ID NO: 10 and SEQ ID NO: 167, respectively; xi. SEQ ID NO: 11 and SEQ ID NO: 168, respectively; xii. SEQ ID NO: 12 and SEQ ID NO: 169, respectively; xiii. SEQ ID NO: 13 and SEQ ID NO: 170, respectively; xiv. SEQ ID NO: 14 and SEQ ID NO: 171, respectively; xv. SEQ ID NO: 15 and SEQ ID NO: 172, respectively; xvi. SEQ ID NO: 16 and SEQ ID NO: 173, respectively; xvii. SEQ ID NO: 17 and SEQ ID NO: 174, respectively; xviii. SEQ ID NO: 18 and SEQ ID NO: 175, respectively; xix. SEQ ID NO: 19 and SEQ ID NO: 176, respectively; xx. SEQ ID NO: 20 and SEQ ID NO: 177, respectively; xxi. SEQ ID NO: 21 and SEQ ID NO: 178, respectively; xxii. SEQ ID NO: 22 and SEQ ID NO: 179, respectively; xxiii. SEQ ID NO: 23 and SEQ ID NO: 180, respectively; xxiv. SEQ ID NO: 24 and SEQ ID NO: 181, respectively; xxv. SEQ ID NO: 25 and SEQ ID NO: 182, respectively; xxvi. SEQ ID NO: 26 and SEQ ID NO: 183, respectively; xxvii. SEQ ID NO: 27 and SEQ ID NO: 184, respectively; xxviii. SEQ ID NO: 28 and SEQ ID NO: 185, respectively; xxix. SEQ ID NO: 29 and SEQ ID NO: 186, respectively; xxx. SEQ ID NO: 30 and SEQ ID NO: 187, respectively; xxxi. SEQ ID NO: 31 and SEQ ID NO: 188, respectively; xxxii. SEQ ID NO: 32 and SEQ ID NO: 189, respectively; xxxiii. SEQ ID NO: 33 and SEQ ID NO: 190, respectively; xxxiv. SEQ ID NO: 34 and SEQ ID NO: 191, respectively; xxxv. SEQ ID NO: 35 and SEQ ID NO: 192, respectively; xxxvi. SEQ ID NO: 36 and SEQ ID NO: 193, respectively; xxxvii. SEQ ID NO: 37 and SEQ ID NO: 194, respectively; xxxviii. SEQ ID NO: 38 and SEQ ID NO: 195, respectively; xxxix. SEQ ID NO: 39 and SEQ ID NO: 196, respectively; xl. SEQ ID NO: 40 and SEQ ID NO: 197, respectively; xli. SEQ ID NO: 41 and SEQ ID NO: 198, respectively; xlii. SEQ ID NO: 42 and SEQ ID NO: 199, respectively; xliii. SEQ ID NO: 43 and SEQ ID NO: 200, respectively; xliv. SEQ ID NO: 44 and SEQ ID NO: 201, respectively; xlv. SEQ ID NO: 45 and SEQ ID NO: 202, respectively; xlvi. SEQ ID NO: 46 and SEQ ID NO: 203, respectively; xlvii. SEQ ID NO: 47 and SEQ ID NO: 204, respectively; xlviii. SEQ ID NO: 48 and SEQ ID NO: 205, respectively; xlix. SEQ ID NO: 49 and SEQ ID NO: 206, respectively; l. SEQ ID NO: 50 and SEQ ID NO: 207, respectively; li. SEQ ID NO: 51 and SEQ ID NO: 208, respectively; lii. SEQ ID NO: 52 and SEQ ID NO: 209, respectively; liii. SEQ ID NO: 53 and SEQ ID NO: 210, respectively; liv. SEQ ID NO: 54 and SEQ ID NO: 211, respectively; lv. SEQ ID NO: 55 and SEQ ID NO: 212, respectively; lvi. SEQ ID NO: 56 and SEQ ID NO: 213, respectively; lvii. SEQ ID NO: 57 and SEQ ID NO: 214, respectively; lviii. SEQ ID NO: 58 and SEQ ID NO: 215, respectively; lix. SEQ ID NO: 59 and SEQ ID NO: 216, respectively; lx. SEQ ID NO: 60 and SEQ ID NO: 217, respectively; lxi. SEQ ID NO: 61 and SEQ ID NO: 218, respectively; lxii. SEQ ID NO: 62 and SEQ ID NO: 219, respectively; lxiii. SEQ ID NO: 63 and SEQ ID NO: 220, respectively; lxiv. SEQ ID NO: 64 and SEQ ID NO: 221, respectively; lxv. SEQ ID NO: 65 and SEQ ID NO: 222, respectively; lxvi. SEQ ID NO: 66 and SEQ ID NO: 223, respectively; lxvii. SEQ ID NO: 67 and SEQ ID NO: 224, respectively; lxviii. SEQ ID NO: 68 and SEQ ID NO: 225, respectively; lxix. SEQ ID NO: 69 and SEQ ID NO: 226, respectively; lxx. SEQ ID NO: 70 and SEQ ID NO: 227, respectively; lxxi. SEQ ID NO: 71 and SEQ ID NO: 228, respectively; lxxii. SEQ ID NO: 72 and SEQ ID NO: 229, respectively; lxxiii. SEQ ID NO: 73 and SEQ ID NO: 230, respectively; lxxiv. SEQ ID NO: 74 and SEQ ID NO: 231, respectively; lxxv. SEQ ID NO: 75 and SEQ ID NO: 232, respectively; lxxvi. SEQ ID NO: 76 and SEQ ID NO: 233, respectively; lxxvii. SEQ ID NO: 77 and SEQ ID NO: 234, respectively; lxxviii. SEQ ID NO: 78 and SEQ ID NO: 235, respectively; lxxix. SEQ ID NO: 79 and SEQ ID NO: 236, respectively; lxxx. SEQ ID NO: 80 and SEQ ID NO: 237, respectively; lxxxi. SEQ ID NO: 81 and SEQ ID NO: 238, respectively; lxxxii. SEQ ID NO: 82 and SEQ ID NO: 239, respectively; lxxxiii. SEQ ID NO: 83 and SEQ ID NO: 240, respectively; lxxxiv. SEQ ID NO: 84 and SEQ ID NO: 241, respectively; lxxxv. SEQ ID NO: 85 and SEQ ID NO: 242, respectively; lxxxvi. SEQ ID NO: 86 and SEQ ID NO: 243, respectively; lxxxvii. SEQ ID NO: 87 and SEQ ID NO: 244, respectively; lxxxviii. SEQ ID NO: 88 and SEQ ID NO: 245, respectively; lxxxix. SEQ ID NO: 89 and SEQ ID NO: 246, respectively; xc. SEQ ID NO: 90 and SEQ ID NO: 247, respectively; xci. SEQ ID NO: 91 and SEQ ID NO: 248, respectively; xcii. SEQ ID NO: 92 and SEQ ID NO: 249, respectively; xciii. SEQ ID NO: 93 and SEQ ID NO: 250, respectively; xciv. SEQ ID NO: 94 and SEQ ID NO: 251, respectively; xcv. SEQ ID NO: 95 and SEQ ID NO: 252, respectively; xcvi. SEQ ID NO: 96 and SEQ ID NO: 253, respectively; xcvii. SEQ ID NO: 97 and SEQ ID NO: 254, respectively; xcviii. SEQ ID NO: 98 and SEQ ID NO: 255, respectively; xcix. SEQ ID NO: 99 and SEQ ID NO: 256, respectively; c. SEQ ID NO: 100 and SEQ ID NO: 257, respectively; ci. SEQ ID NO: 101 and SEQ ID NO: 258, respectively; cii. SEQ ID NO: 102 and SEQ ID NO: 259, respectively; ciii. SEQ ID NO: 103 and SEQ ID NO: 260, respectively; civ. SEQ ID NO: 104 and SEQ ID NO: 261, respectively; cv. SEQ ID NO: 105 and SEQ ID NO: 262, respectively; cvi. SEQ ID NO: 106 and SEQ ID NO: 263, respectively; cvii. SEQ ID NO: 107 and SEQ ID NO: 264, respectively; cviii. SEQ ID NO: 108 and SEQ ID NO: 265, respectively; cix. SEQ ID NO: 109 and SEQ ID NO: 266, respectively; cx. SEQ ID NO: 110 and SEQ ID NO: 267, respectively; cxi. SEQ ID NO: 111 and SEQ ID NO: 268, respectively; cxii. SEQ ID NO: 112 and SEQ ID NO: 269, respectively; cxiii. SEQ ID NO: 113 and SEQ ID NO: 270, respectively; cxiv. SEQ ID NO: 114 and SEQ ID NO: 271, respectively; cxv. SEQ ID NO: 115 and SEQ ID NO: 272, respectively; cxvi. SEQ ID NO: 116 and SEQ ID NO: 273, respectively; cxvii. SEQ ID NO: 117 and SEQ ID NO: 274, respectively; cxviii. SEQ ID NO: 118 and SEQ ID NO: 275, respectively; cxix. SEQ ID NO: 119 and SEQ ID NO: 276, respectively; cxx. SEQ ID NO: 120 and SEQ ID NO: 277, respectively; cxxi. SEQ ID NO: 121 and SEQ ID NO: 278, respectively; cxxii. SEQ ID NO: 122 and SEQ ID NO: 279, respectively; cxxiii. SEQ ID NO: 123 and SEQ ID NO: 280, respectively; cxxiv. SEQ ID NO: 124 and SEQ ID NO: 281, respectively; cxxv. SEQ ID NO: 125 and SEQ ID NO: 282, respectively; cxxvi. SEQ ID NO: 126 and SEQ ID NO: 283, respectively; cxxvii. SEQ ID NO: 127 and SEQ ID NO: 284, respectively; cxxviii. SEQ ID NO: 128 and SEQ ID NO: 285, respectively; cxxix. SEQ ID NO: 129 and SEQ ID NO: 286, respectively; cxxx. SEQ ID NO: 130 and SEQ ID NO: 287, respectively; cxxxi. SEQ ID NO: 131 and SEQ ID NO: 288, respectively; cxxxii. SEQ ID NO: 132 and SEQ ID NO: 289, respectively; cxxxiii. SEQ ID NO: 133 and SEQ ID NO: 290, respectively; cxxxiv. SEQ ID NO: 134 and SEQ ID NO: 291, respectively; cxxxv. SEQ ID NO: 135 and SEQ ID NO: 292, respectively; cxxxvi. SEQ ID NO: 136 and SEQ ID NO: 293, respectively; cxxxvii. SEQ ID NO: 137 and SEQ ID NO: 294, respectively; cxxxviii. SEQ ID NO: 138 and SEQ ID NO: 295, respectively; cxxxix. SEQ ID NO: 139 and SEQ ID NO: 296, respectively; cxl. SEQ ID NO: 140 and SEQ ID NO: 297, respectively; cxli. SEQ ID NO: 141 and SEQ ID NO: 298, respectively; cxlii. SEQ ID NO: 142 and SEQ ID NO: 299, respectively; cxliii. SEQ ID NO: 143 and SEQ ID NO: 300, respectively; cxliv. SEQ ID NO: 144 and SEQ ID NO: 301, respectively; cxlv. SEQ ID NO: 145 and SEQ ID NO: 302, respectively; cxlvi. SEQ ID NO: 146 and SEQ ID NO: 303, respectively; cxlvii. SEQ ID NO: 147 and SEQ ID NO: 304, respectively; cxlviii. SEQ ID NO: 148 and SEQ ID NO: 305, respectively; cxlix. SEQ ID NO: 149 and SEQ ID NO: 306, respectively; cl. SEQ ID NO: 150 and SEQ ID NO: 307, respectively; cli. SEQ ID NO: 151 and SEQ ID NO: 308, respectively; clii. SEQ ID NO: 152 and SEQ ID NO: 309, respectively; cliii. SEQ ID NO: 153 and SEQ ID NO: 310, respectively; cliv. SEQ ID NO: 154 and SEQ ID NO: 311, respectively; clv. SEQ ID NO: 155 and SEQ ID NO: 312, respectively; clvi. SEQ ID NO: 156 and SEQ ID NO: 313, respectively; and clvii. SEQ ID NO: 157 and SEQ ID NO: 314, respectively.

40. The molecule of any one of claims 2239, wherein the antibody comprises a light chain and a heavy chain, wherein the light chain and heavy chain comprise amino acid sequences selected from:i. SEQ ID NO: 315 and SEQ ID NO: 472, respectively; ii. SEQ ID NO: 316 and SEQ ID NO: 473, respectively; iii. SEQ ID NO: 317 and SEQ ID NO: 474, respectively; iv. SEQ ID NO: 318 and SEQ ID NO: 475, respectively; v. SEQ ID NO: 319 and SEQ ID NO: 476, respectively; vi. SEQ ID NO: 320 and SEQ ID NO: 477, respectively; vii. SEQ ID NO: 321 and SEQ ID NO: 478, respectively; viii. SEQ ID NO: 322 and SEQ ID NO: 479, respectively; ix. SEQ ID NO: 323 and SEQ ID NO: 480, respectively; x. SEQ ID NO: 324 and SEQ ID NO: 481, respectively; xi. SEQ ID NO: 325 and SEQ ID NO: 482, respectively; xii. SEQ ID NO: 326 and SEQ ID NO: 483, respectively; xiii. SEQ ID NO: 327 and SEQ ID NO: 484, respectively; xiv. SEQ ID NO: 328 and SEQ ID NO: 485, respectively; xv. SEQ ID NO: 329 and SEQ ID NO: 486, respectively; xvi. SEQ ID NO: 330 and SEQ ID NO: 487, respectively; xvii. SEQ ID NO: 331 and SEQ ID NO: 488, respectively; xviii. SEQ ID NO: 332 and SEQ ID NO: 489, respectively; xix. SEQ ID NO: 333 and SEQ ID NO: 490, respectively; xx. SEQ ID NO: 334 and SEQ ID NO: 491, respectively; xxi. SEQ ID NO: 335 and SEQ ID NO: 492, respectively; xxii. SEQ ID NO: 336 and SEQ ID NO: 493, respectively; xxiii. SEQ ID NO: 337 and SEQ ID NO: 494, respectively; xxiv. SEQ ID NO: 338 and SEQ ID NO: 495, respectively; xxv. SEQ ID NO: 339 and SEQ ID NO: 496, respectively; xxvi. SEQ ID NO: 340 and SEQ ID NO: 497, respectively; xxvii. SEQ ID NO: 341 and SEQ ID NO: 498, respectively; xxviii. SEQ ID NO: 342 and SEQ ID NO: 499, respectively; xxix. SEQ ID NO: 343 and SEQ ID NO: 500, respectively; xxx. SEQ ID NO: 344 and SEQ ID NO: 501, respectively; xxxi. SEQ ID NO: 345 and SEQ ID NO: 502, respectively; xxxii. SEQ ID NO: 346 and SEQ ID NO: 503, respectively; xxxiii. SEQ ID NO: 347 and SEQ ID NO: 504, respectively; xxxiv. SEQ ID NO: 348 and SEQ ID NO: 505, respectively; xxxv. SEQ ID NO: 349 and SEQ ID NO: 506, respectively; xxxvi. SEQ ID NO: 350 and SEQ ID NO: 507, respectively; xxxvii. SEQ ID NO: 351 and SEQ ID NO: 508, respectively; xxxviii. SEQ ID NO: 352 and SEQ ID NO: 509, respectively; xxxix. SEQ ID NO: 353 and SEQ ID NO: 510, respectively; xl. SEQ ID NO: 354 and SEQ ID NO: 511, respectively; xli. SEQ ID NO: 355 and SEQ ID NO: 512, respectively; xlii. SEQ ID NO: 356 and SEQ ID NO: 513, respectively; xliii. SEQ ID NO: 357 and SEQ ID NO: 514, respectively; xliv. SEQ ID NO: 358 and SEQ ID NO: 515, respectively; xlv. SEQ ID NO: 359 and SEQ ID NO: 516, respectively; xlvi. SEQ ID NO: 360 and SEQ ID NO: 517, respectively; xlvii. SEQ ID NO: 361 and SEQ ID NO: 518, respectively; xlviii. SEQ ID NO: 362 and SEQ ID NO: 519, respectively; xlix. SEQ ID NO: 363 and SEQ ID NO: 520, respectively; l. SEQ ID NO: 364 and SEQ ID NO: 521, respectively; li. SEQ ID NO: 365 and SEQ ID NO: 522, respectively; lii. SEQ ID NO: 366 and SEQ ID NO: 523, respectively; liii. SEQ ID NO: 367 and SEQ ID NO: 524, respectively; liv. SEQ ID NO: 368 and SEQ ID NO: 525, respectively; lv. SEQ ID NO: 369 and SEQ ID NO: 526, respectively; lvi. SEQ ID NO: 370 and SEQ ID NO: 527, respectively; lvii. SEQ ID NO: 371 and SEQ ID NO: 528, respectively; lviii. SEQ ID NO: 372 and SEQ ID NO: 529, respectively;lix. SEQ ID NO: 373 and SEQ ID NO: 530, respectively; lx. SEQ ID NO: 374 and SEQ ID NO: 531, respectively; lxi. SEQ ID NO: 375 and SEQ ID NO: 532, respectively; lxii. SEQ ID NO: 376 and SEQ ID NO: 533, respectively; lxiii. SEQ ID NO: 377 and SEQ ID NO: 534, respectively; lxiv. SEQ ID NO: 378 and SEQ ID NO: 535, respectively; lxv. SEQ ID NO: 379 and SEQ ID NO: 536, respectively; lxvi. SEQ ID NO: 380 and SEQ ID NO: 537, respectively; lxvii. SEQ ID NO: 381 and SEQ ID NO: 538, respectively; lxviii. SEQ ID NO: 382 and SEQ ID NO: 539, respectively; lxix. SEQ ID NO: 383 and SEQ ID NO: 540, respectively; lxx. SEQ ID NO: 384 and SEQ ID NO: 541, respectively; lxxi. SEQ ID NO: 385 and SEQ ID NO: 542, respectively; lxxii. SEQ ID NO: 386 and SEQ ID NO: 543, respectively; lxxiii. SEQ ID NO: 387 and SEQ ID NO: 544, respectively; lxxiv. SEQ ID NO: 388 and SEQ ID NO: 545, respectively; lxxv. SEQ ID NO: 389 and SEQ ID NO: 546, respectively; lxxvi. SEQ ID NO: 390 and SEQ ID NO: 547, respectively; lxxvii. SEQ ID NO: 391 and SEQ ID NO: 548, respectively; lxxviii. SEQ ID NO: 392 and SEQ ID NO: 549, respectively; lxxix. SEQ ID NO: 393 and SEQ ID NO: 550, respectively; lxxx. SEQ ID NO: 394 and SEQ ID NO: 551, respectively; lxxxi. SEQ ID NO: 395 and SEQ ID NO: 552, respectively; lxxxii. SEQ ID NO: 396 and SEQ ID NO: 553, respectively; lxxxiii. SEQ ID NO: 397 and SEQ ID NO: 554, respectively; lxxxiv. SEQ ID NO: 398 and SEQ ID NO: 555, respectively; lxxxv. SEQ ID NO: 399 and SEQ ID NO: 556, respectively; lxxxvi. SEQ ID NO: 400 and SEQ ID NO: 557, respectively; lxxxvii. SEQ ID NO: 401 and SEQ ID NO: 558, respectively; lxxxviii. SEQ ID NO: 402 and SEQ ID NO: 559, respectively; lxxxix. SEQ ID NO: 403 and SEQ ID NO: 560, respectively; xc. SEQ ID NO: 404 and SEQ ID NO: 561, respectively; xci. SEQ ID NO: 405 and SEQ ID NO: 562, respectively; xcii. SEQ ID NO: 406 and SEQ ID NO: 563, respectively; xciii. SEQ ID NO: 407 and SEQ ID NO: 564, respectively; xciv. SEQ ID NO: 408 and SEQ ID NO: 565, respectively; xcv. SEQ ID NO: 409 and SEQ ID NO: 566, respectively; xcvi. SEQ ID NO: 410 and SEQ ID NO: 567, respectively; xcvii. SEQ ID NO: 411 and SEQ ID NO: 568, respectively; xcviii. SEQ ID NO: 412 and SEQ ID NO: 569, respectively; xcix. SEQ ID NO: 413 and SEQ ID NO: 570, respectively; c. SEQ ID NO: 414 and SEQ ID NO: 571, respectively; ci. SEQ ID NO: 415 and SEQ ID NO: 572, respectively; cii. SEQ ID NO: 416 and SEQ ID NO: 573, respectively; ciii. SEQ ID NO: 417 and SEQ ID NO: 574, respectively; civ. SEQ ID NO: 418 and SEQ ID NO: 575, respectively; cv. SEQ ID NO: 419 and SEQ ID NO: 576, respectively; cvi. SEQ ID NO: 420 and SEQ ID NO: 577, respectively; cvii. SEQ ID NO: 421 and SEQ ID NO: 578, respectively; cviii. SEQ ID NO: 422 and SEQ ID NO: 579, respectively; cix. SEQ ID NO: 423 and SEQ ID NO: 580, respectively; cx. SEQ ID NO: 424 and SEQ ID NO: 581, respectively; cxi. SEQ ID NO: 425 and SEQ ID NO: 582, respectively; cxii. SEQ ID NO: 426 and SEQ ID NO: 583, respectively; cxiii. SEQ ID NO: 427 and SEQ ID NO: 584, respectively; cxiv. SEQ ID NO: 428 and SEQ ID NO: 585, respectively; cxv. SEQ ID NO: 429 and SEQ ID NO: 586, respectively; cxvi. SEQ ID NO: 430 and SEQ ID NO: 587, respectively; cxvii. SEQ ID NO: 431 and SEQ ID NO: 588, respectively; cxviii. SEQ ID NO: 432 and SEQ ID NO: 589, respectively; cxix. SEQ ID NO: 433 and SEQ ID NO: 590, respectively; cxx. SEQ ID NO: 434 and SEQ ID NO: 591, respectively; cxxi. SEQ ID NO: 435 and SEQ ID NO: 592, respectively; cxxii. SEQ ID NO: 436 and SEQ ID NO: 593, respectively; cxxiii. SEQ ID NO: 437 and SEQ ID NO: 594, respectively; cxxiv. SEQ ID NO: 438 and SEQ ID NO: 595, respectively; cxxv. SEQ ID NO: 439 and SEQ ID NO: 596, respectively; cxxvi. SEQ ID NO: 440 and SEQ ID NO: 597, respectively; cxxvii. SEQ ID NO: 441 and SEQ ID NO: 598, respectively; cxxviii. SEQ ID NO: 442 and SEQ ID NO: 599, respectively; cxxix. SEQ ID NO: 443 and SEQ ID NO: 600, respectively; cxxx. SEQ ID NO: 444 and SEQ ID NO: 601, respectively; cxxxi. SEQ ID NO: 445 and SEQ ID NO: 602, respectively; cxxxii. SEQ ID NO: 446 and SEQ ID NO: 603, respectively; cxxxiii. SEQ ID NO: 447 and SEQ ID NO: 604, respectively; cxxxiv. SEQ ID NO: 448 and SEQ ID NO: 605, respectively; cxxxv. SEQ ID NO: 449 and SEQ ID NO: 606, respectively; cxxxvi. SEQ ID NO: 450 and SEQ ID NO: 607, respectively; cxxxvii. SEQ ID NO: 451 and SEQ ID NO: 608, respectively;cxxxviii. SEQ ID NO: 452 and SEQ ID NO: 609, respectively; cxxxix. SEQ ID NO: 453 and SEQ ID NO: 610, respectively; cxl. SEQ ID NO: 454 and SEQ ID NO: 611, respectively; cxli. SEQ ID NO: 455 and SEQ ID NO: 612, respectively; cxlii. SEQ ID NO: 456 and SEQ ID NO: 613, respectively; cxliii. SEQ ID NO: 457 and SEQ ID NO: 614, respectively; cxliv. SEQ ID NO: 458 and SEQ ID NO: 615, respectively; cxlv. SEQ ID NO: 459 and SEQ ID NO: 616, respectively; cxlvi. SEQ ID NO: 460 and SEQ ID NO: 617, respectively; cxlvii. SEQ ID NO: 461 and SEQ ID NO: 618, respectively; cxlviii. SEQ ID NO: 462 and SEQ ID NO: 619, respectively; cxlix. SEQ ID NO: 463 and SEQ ID NO: 620, respectively; cl. SEQ ID NO: 464 and SEQ ID NO: 621, respectively; cli. SEQ ID NO: 465 and SEQ ID NO: 622, respectively; clii. SEQ ID NO: 466 and SEQ ID NO: 623, respectively; cliii. SEQ ID NO: 467 and SEQ ID NO: 624, respectively; cliv. SEQ ID NO: 468 and SEQ ID NO: 625, respectively; clv. SEQ ID NO: 469 and SEQ ID NO: 626, respectively; clvi. SEQ ID NO: 470 and SEQ ID NO: 627, respectively; and clvii. SEQ ID NO: 471 and SEQ ID NO: 628, respectively,wherein the antibody comprises one or more cysteine amino acid substitution(s) at one or more position(s) selected from 88 of the light chain, 384 of the heavy chain, or 487 of the heavy chain, according to AHo numbering.

41. A molecule comprising:a first polypeptide and a second polypeptide that agonize a glucagon receptor (“GCGR”), wherein the first polypeptide and the second polypeptide each comprise the amino acid sequence of SEQ ID NO: 1615;a first linker polypeptide and a second linker polypeptide, wherein the first linker polypeptide and the second linker polypeptide each comprise the amino acid sequence of SEQ ID NO: 1629; andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a first light chain and a second light chain, wherein the first light chain and the second light chain each comprise the amino acid sequence of SEQ ID NO: 388, and a first heavy chain and a second heavy chain, wherein the first heavy chain and the second heavy chain each comprise the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 28 of the first polypeptide is covalently linked to a Cterminus of the first linker polypeptide; an N-terminus of the first linker polypeptide is conjugated to a cysteine residue at position 275 of the first heavy chain of the antibody;an εamino group of a lysine residue at position 28 of the second polypeptide is covalently linked to a Cterminus of the second linker polypeptide; andan N-terminus of the second linker polypeptide is conjugated to a cysteine residue at position 275 of the second heavy chain of the antibody.

42. A molecule comprising:a first polypeptide and a second polypeptide that agonize a glucagon receptor (“GCGR”), wherein the first polypeptide and the second polypeptide each comprise the amino acid sequence of SEQ ID NO: 1626;a first linker polypeptide and a second linker polypeptide, wherein the first linker polypeptide and the second linker polypeptide each comprise the amino acid sequence of SEQ ID NO: 1628; andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a first light chain and a second light chain, wherein the first light chain and the second light chain each comprise the amino acid sequence of SEQ ID NO: 388, and a first heavy chain and a second heavy chain, wherein the first heavy chain and the second heavy chain each comprise the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 28 of the first polypeptide is covalently linked to a Cterminus of the first linker polypeptide; an N-terminus of the first linker polypeptide is conjugated to a cysteine residue at position 275 of the first heavy chain of the antibody;an εamino group of a lysine residue at position 28 of the second polypeptide is covalently linked to a Cterminus of the second linker polypeptide; andan N-terminus of the second linker polypeptide is conjugated to a cysteine residue at position 275 of the second heavy chain of the antibody.

43. A molecule comprising:a first polypeptide and a second polypeptide that agonize a glucagon receptor (“GCGR”), wherein the first polypeptide and the second polypeptide each comprise the amino acid sequence of SEQ ID NO: 1592;a first linker polypeptide and a second linker polypeptide, wherein the first linker polypeptide and the second linker polypeptide each comprise the amino acid sequence of SEQ ID NO: 1628; andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a first light chain and a second light chain, wherein the first light chain and the second light chain each comprise the amino acid sequence of SEQ ID NO: 388, and a first heavy chain and a second heavy chain, wherein the first heavy chain and the second heavy chain each comprise the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 24 of the first polypeptide is covalently linked to a Cterminus of the first linker polypeptide; an N-terminus of the first linker polypeptide is conjugated to a cysteine residue at position 275 of the first heavy chain of the antibody;an εamino group of a lysine residue at position 24 of the second polypeptide is covalently linked to a Cterminus of the second linker polypeptide; andan N-terminus of the second linker polypeptide is conjugated to a cysteine residue at position 275 of the second heavy chain of the antibody.

44. A molecule comprising:a first polypeptide and a second polypeptide that agonize a glucagon receptor (“GCGR”), wherein the first polypeptide and the second polypeptide each comprise the amino acid sequence of SEQ ID NO: 1626;a first linker polypeptide and a second linker polypeptide, wherein the first linker polypeptide and the second linker polypeptide each comprise the amino acid sequence of SEQ ID NO: 1629; andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a first light chain and a second light chain, wherein the first light chain and the second light chain each comprise the amino acid sequence of SEQ ID NO: 388, and a first heavy chain and a second heavy chain, wherein the first heavy chain and the second heavy chain each comprise the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 28 of the first polypeptide is covalently linked to a Cterminus of the first linker polypeptide; an N-terminus of the first linker polypeptide is conjugated to a cysteine residue at position 275 of the first heavy chain of the antibody;an εamino group of a lysine residue at position 28 of the second polypeptide is covalently linked to a Cterminus of the second linker polypeptide; andan N-terminus of the second linker polypeptide is conjugated to a cysteine residue at position 275 of the second heavy chain of the antibody.

45. A molecule comprising:a first polypeptide and a second polypeptide that agonize a glucagon receptor (“GCGR”), wherein the first polypeptide and the second polypeptide each comprise the amino acid sequence of SEQ ID NO: 1587;a first linker polypeptide and a second linker polypeptide, wherein the first linker polypeptide and the second linker polypeptide each comprise the amino acid sequence of SEQ ID NO: 1628; andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a first light chain and a second light chain, wherein the first light chain and the second light chain each comprise the amino acid sequence of SEQ ID NO: 388, and a first heavy chain and a second heavy chain, wherein the first heavy chain and the second heavy chain each comprise the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 28 of the first polypeptide is covalently linked to a Cterminus of the first linker polypeptide; an N-terminus of the first linker polypeptide is conjugated to a cysteine residue at position 275 of the first heavy chain of the antibody;an εamino group of a lysine residue at position 28 of the second polypeptide is covalently linked to a Cterminus of the second linker polypeptide; andan N-terminus of the second linker polypeptide is conjugated to a cysteine residue at position 275 of the second heavy chain of the antibody.

46. A molecule comprising:a first polypeptide and a second polypeptide that agonize a glucagon receptor (“GCGR”), wherein the first polypeptide and the second polypeptide each comprise the amino acid sequence of SEQ ID NO: 1587;a first linker polypeptide and a second linker polypeptide, wherein the first linker polypeptide and the second linker polypeptide each comprise the amino acid sequence of SEQ ID NO: 1630; andan antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), wherein the antibody comprises a first light chain and a second light chain, wherein the first light chain and the second light chain each comprise the amino acid sequence of SEQ ID NO: 388, and a first heavy chain and a second heavy chain, wherein the first heavy chain and the second heavy chain each comprise the amino acid sequence of SEQ ID NO: 1571, wherein:an εamino group of a lysine residue at position 28 of the first polypeptide is covalently linked to a Cterminus of the first linker polypeptide; an N-terminus of the first linker polypeptide is conjugated to a cysteine residue at position 275 of the first heavy chain of the antibody;an εamino group of a lysine residue at position 28 of the second polypeptide is covalently linked to a Cterminus of the second linker polypeptide; andan N-terminus of the second linker polypeptide is conjugated to a cysteine residue at position 275 of the second heavy chain of the antibody.

47. A pharmaceutical composition comprising: a polypeptide of any one of claims 115 or a molecule of any one of claims 1646; and a pharmaceutically acceptable excipient.

48. A method of reducing body weight and / or food intake in a subject in need thereof, the method comprising administering a polypeptide of any one of claims 115, a molecule of any one of claims 1646, or a pharmaceutical composition of claim 47 to the subject.

49. A method of reducing body weight and / or food intake in a subject in need thereof, the method comprising administering a molecule of any one of claims 2246 to the subject in combination with a GLP-1 agonist.

50. The method of claim 49, wherein the subject is overweight or obese and the GLP1 agonist is semaglutide. 

Images